var title_f11_20_11584="Characteristics of SCA types";
var content_f11_20_11584=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74269%7EPEDS%2F72307%7EPEDS%2F56567%7EPEDS%2F52324&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74269%7EPEDS%2F72307%7EPEDS%2F56567%7EPEDS%2F52324&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Characteristics of the autosomal dominant spinocerebellar ataxias",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disorder",
"       </td>",
"       <td class=\"subtitle1\">",
"        Distinguishing features",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Gene locus and protein",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA1",
"       </td>",
"       <td>",
"        Pyramidal signs, peripheral neuropathy",
"       </td>",
"       <td>",
"        ATXN1",
"       </td>",
"       <td>",
"        CAG repeat, ataxin-1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA2",
"       </td>",
"       <td>",
"        Slow saccades; less often myoclonus, areflexia",
"       </td>",
"       <td>",
"        ATXN2",
"       </td>",
"       <td>",
"        CAG repeat, ataxin-2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA3 (MJD)",
"       </td>",
"       <td>",
"        Slow saccades, persistent stare, extrapyramidal signs, peripheral neuropathy",
"       </td>",
"       <td>",
"        ATXN3",
"       </td>",
"       <td>",
"        CAG repeat, ataxin-3 (MJD1)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA4",
"       </td>",
"       <td>",
"        Sensory neuropathy",
"       </td>",
"       <td>",
"        16q22.1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA5",
"       </td>",
"       <td>",
"        Early onset but slow progression",
"       </td>",
"       <td>",
"        SPTBN2",
"       </td>",
"       <td>",
"        Beta III spectrin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA6",
"       </td>",
"       <td>",
"        May have very late onset, mild, may lack family history, nystagmus",
"       </td>",
"       <td>",
"        CACNA1A",
"       </td>",
"       <td>",
"        CAG repeat, alpha 1A P/Q calcium channel subunit",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA7",
"       </td>",
"       <td>",
"        Macular degeneration",
"       </td>",
"       <td>",
"        ATXN7",
"       </td>",
"       <td>",
"        CAG repeat, ataxin-7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA8",
"       </td>",
"       <td>",
"        Mild disease",
"       </td>",
"       <td>",
"        <p>",
"         ATXN8",
"        </p>",
"        <p>",
"         ATXN8OS",
"        </p>",
"       </td>",
"       <td>",
"        CTG*CAG repeat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA9",
"       </td>",
"       <td>",
"        Not assigned",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA10",
"       </td>",
"       <td>",
"        Generalized or complex partial seizures",
"       </td>",
"       <td>",
"        ATXN10",
"       </td>",
"       <td>",
"        ATTCT repeat, ataxin-10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA11",
"       </td>",
"       <td>",
"        Mild disease",
"       </td>",
"       <td>",
"        TTBK2",
"       </td>",
"       <td>",
"        Tau tubulin kinase-2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA12",
"       </td>",
"       <td>",
"        Tremor, dementia",
"       </td>",
"       <td>",
"        PPP2R2B",
"       </td>",
"       <td>",
"        CAG repeat in 5' region, protein phosphatase 2A",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA13",
"       </td>",
"       <td>",
"        Mental retardation",
"       </td>",
"       <td>",
"        KCNC3",
"       </td>",
"       <td>",
"        Voltage gated potassium channel KCNC3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA14",
"       </td>",
"       <td>",
"        Intermittent myoclonus with early onset disease",
"       </td>",
"       <td>",
"        PRKCG",
"       </td>",
"       <td>",
"        Protein kinase C gamma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA15/16",
"       </td>",
"       <td>",
"        Slowly progressive",
"       </td>",
"       <td>",
"        ITPR1",
"       </td>",
"       <td>",
"        Inositol 1,4,5-triphosphate receptor 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA17",
"       </td>",
"       <td>",
"        Gait ataxia, dementia",
"       </td>",
"       <td>",
"        TBP",
"       </td>",
"       <td>",
"        CAG repeats, TATA binding protein",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA18",
"       </td>",
"       <td>",
"        Pyramidal signs, weakness, sensory axonal neuropathy",
"       </td>",
"       <td>",
"        7q22-q32",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA19/22",
"       </td>",
"       <td>",
"        Predominantly cerebellar syndrome, sometimes with cognitive impairment or myoclonus",
"       </td>",
"       <td>",
"        KCND3 gene",
"       </td>",
"       <td>",
"        Voltage-gated potassium channel Kv4.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA20",
"       </td>",
"       <td>",
"        Palatal tremor and dysphonia",
"       </td>",
"       <td>",
"        11q12",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA21",
"       </td>",
"       <td>",
"        Extrapyramidal signs",
"       </td>",
"       <td>",
"        7p21.3-p15.1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA23",
"       </td>",
"       <td>",
"        Distal sensory deficits",
"       </td>",
"       <td>",
"        PDYN",
"       </td>",
"       <td>",
"        Prodynorphin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA24",
"       </td>",
"       <td>",
"        Recessive inheritance; redesignated as SCAR4",
"       </td>",
"       <td>",
"        1p36",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA25",
"       </td>",
"       <td>",
"        Sensory neuropathy, facial tics, gastrointestinal symptoms",
"       </td>",
"       <td>",
"        2p21-p13",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA26",
"       </td>",
"       <td>",
"        Pure cerebellar ataxia",
"       </td>",
"       <td>",
"        19p13.3",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA27",
"       </td>",
"       <td>",
"        Cognitive impairment",
"       </td>",
"       <td>",
"        FGF14",
"       </td>",
"       <td>",
"        Fibroblast growth factor 14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA28",
"       </td>",
"       <td>",
"        Ophthalmoparesis and ptosis",
"       </td>",
"       <td>",
"        AFG3L2",
"       </td>",
"       <td>",
"        Catalytic subunit of the mitochondrial AAA protease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA29",
"       </td>",
"       <td>",
"        Early onset, nonprogressive ataxia; may be an allelic variant of SCA15",
"       </td>",
"       <td>",
"        3p26",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA30",
"       </td>",
"       <td>",
"        Slowly progressive, relatively pure ataxia",
"       </td>",
"       <td>",
"        4q34.3-q35.1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA31",
"       </td>",
"       <td>",
"        Decreased muscle tone",
"       </td>",
"       <td>",
"        BEAN",
"       </td>",
"       <td>",
"        (TGGAA)n repeat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA32",
"       </td>",
"       <td>",
"        Cognitive impairment, affected males with azoospermia and testicular atrophy",
"       </td>",
"       <td>",
"        7q32-q33",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA33",
"       </td>",
"       <td>",
"        Not assigned",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA34",
"       </td>",
"       <td>",
"        Skin lesions consisting of papulosquamous erythematous ichthyosiform plaques",
"       </td>",
"       <td>",
"        6p12.3-q16.2",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA35",
"       </td>",
"       <td>",
"        Late onset, slowly progressive gait and limb ataxia",
"       </td>",
"       <td>",
"        TGM6",
"       </td>",
"       <td>",
"        Transglutaminase 6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA36",
"       </td>",
"       <td>",
"        Late onset, truncal ataxia, dysarthria, variable motor neuron disease and&nbsp;sensorineural hearing loss",
"       </td>",
"       <td>",
"        NOP56",
"       </td>",
"       <td>",
"        GGCCTG repeat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DRPLA",
"       </td>",
"       <td>",
"        Chorea, seizures, myoclonus, dementia",
"       </td>",
"       <td>",
"        ATN1",
"       </td>",
"       <td>",
"        CAG repeat, atrophin-1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     DRPLA: dentatorubral pallidoluysian atrophy; MJD: Machado-Joseph disease; SCA: spinocerebellar ataxia.",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <a href=\"file://www.ncbi.nlm.nih.gov/sites/entrez?db=omim\" target=\"_blank\">",
"      Online Mendelian Inheritance in Man",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical features of hereditary peripheral neuropathies associated with other disorders-I",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"20%\">",
"     </colgroup>",
"     <colgroup width=\"40%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disorder",
"       </td>",
"       <td class=\"subtitle1\">",
"        Inheritance",
"       </td>",
"       <td class=\"subtitle1\">",
"        Chromosome (gene)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical features",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Friedreich ataxia",
"       </td>",
"       <td>",
"        AR",
"       </td>",
"       <td>",
"        9q13 (frataxin)",
"       </td>",
"       <td>",
"        Usual onset before age 25 years, progressive ataxia of all limbs, optic atrophy, pyramidal signs, early loss of position and vibration sense, bladder dysfunction, distal muscle atrophy, kyphoscoliosis, cardiomyopathy, diabetes mellitus",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Infantile neuroaxonal dystrophy (PLA2G6-associated neurodegeneration)",
"       </td>",
"       <td>",
"        AR",
"       </td>",
"       <td>",
"        22q13.1 (PLA2G6)",
"       </td>",
"       <td>",
"        Usual onset at age 1 to 3 years, motor and cognitive regression, spasticity, muscle atrophy, hypotonia, cerebellar ataxia, dystonia, optic atrophy, distal sensory loss",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Tangier disease",
"       </td>",
"       <td>",
"        AC",
"       </td>",
"       <td>",
"        9q31 (ABC1)",
"       </td>",
"       <td>",
"        Orange tonsils, hepatosplenomegaly, premature coronary disease, neuropathy, absent (homozygotes) or 50 percent normal (heterozygotes) HDL cholesterol",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Abetalipoproteinemia",
"       </td>",
"       <td>",
"        A",
"       </td>",
"       <td>",
"        (MTP)",
"       </td>",
"       <td>",
"        Acanthocytes, fat malabsorption, retinitis pigmentosa, peripheral neuropathy, ataxia, sensory motor neuropathy, absent tendon reflexes, low serum cholesterol and VLDL, absent serum beta lipoprotein",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Classic Refsum disease",
"       </td>",
"       <td>",
"        A",
"       </td>",
"       <td>",
"        PHYH",
"       </td>",
"       <td>",
"        Retinitis pigmentosa, peripheral polyneuropathy, cerebellar ataxia, elevated CSF protein, sensorineural deafness, ichthyosis, anosmia, abnormal accumulation of phytanic acid",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Infantile Refsum disease",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         (PEX1)",
"        </p>",
"        <p>",
"         (PEX6)",
"        </p>",
"       </td>",
"       <td>",
"        Abnormal accumulation of phytanic acid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chediak-Higashi syndrome",
"       </td>",
"       <td>",
"        AR",
"       </td>",
"       <td>",
"        (LYST)",
"       </td>",
"       <td>",
"        Recurrent infections, partial albinism, hepatosplenomegaly, increased risk of lymphoreticular malignancy, nystagmus, seizures, mental retardation, generalized weakness, spinocerebellar degeneration, and parkinsonism",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AR: autosomal recessive; AC: autosomal codominant; A: autosomal; ABC: ATP-binding casette recorder; MTP: microsomal triglyceride transfer protein; PHYH: phytanoyl-CoA hydroxylase.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical features of hereditary peripheral neuropathies associated with lysosomal storage diseases",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disorder",
"       </td>",
"       <td class=\"subtitle1\">",
"        Inheritance",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gene",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fabry disease",
"       </td>",
"       <td>",
"        XLR",
"       </td>",
"       <td>",
"        GLA",
"       </td>",
"       <td>",
"        Onset by 10 years of age, angiokeratomas, peripheral neuropathy, burning of palms and soles, hypohidrosis or anhidrosis, asymptomatic corneal dystrophy, cardiac involvement with disease progression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Krabbe disease",
"       </td>",
"       <td>",
"        AR",
"       </td>",
"       <td>",
"        GALC",
"       </td>",
"       <td>",
"        Usual onset in first six months of life, peripheral motor sensory neuropathy, developmental delay, hypotonia, limb stiffness, optic atrophy, microcephaly, irritability",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Metachromatic leukodystrophy",
"       </td>",
"       <td rowspan=\"3\">",
"        AR",
"       </td>",
"       <td rowspan=\"3\">",
"        <p>",
"         ARSA",
"        </p>",
"        <p>",
"         PSAP",
"        </p>",
"       </td>",
"       <td>",
"        Late infant onset: usual onset at age 6 to 24 months, regression of motor skills, gait difficulty, ataxia, hypotonia, optic atrophy, peripheral neuropathy, absent or diminished deep tendon reflexes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Juvenile onset: onset between 4 to 8 years, gait disturbance, intellectual impairment, ataxia, upper motor neuron signs, peripheral neuropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adult onset: dementia between age 16 and late adulthood, slow progressive motor dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Niemann-Pick Disease",
"       </td>",
"       <td class=\"sublist_other_start\">",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Type A",
"       </td>",
"       <td class=\"sublist_other\">",
"        AR",
"       </td>",
"       <td class=\"sublist_other\">",
"        SMPD1",
"       </td>",
"       <td class=\"sublist_other\">",
"        Hepatosplenomegaly, feeding difficulties, loss of early motor skills, rapidly progressive loss of neurologic function, peripheral neuropathy, macular cherry red spots",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Type B",
"       </td>",
"       <td class=\"sublist_other\">",
"        AR",
"       </td>",
"       <td class=\"sublist_other\">",
"        SMPD1",
"       </td>",
"       <td class=\"sublist_other\">",
"        Onset of hepatomegaly in infancy or childhood, thrombocytopenia, interstitial lung disease, lipid abnormalities, rare peripheral neuropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Type C",
"       </td>",
"       <td class=\"sublist_other\">",
"        AR",
"       </td>",
"       <td class=\"sublist_other\">",
"        <p>",
"         NPC1",
"        </p>",
"        <p>",
"         NPC2",
"        </p>",
"       </td>",
"       <td class=\"sublist_other\">",
"        Can present from the perinatal period until late adulthood (most often in middle to late childhood), typically with cerebellar symptoms, slow cognitive deterioration, vertical supranuclear gaze palsy, and progressive dystonia, dysarthria, and dysphagia",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AR: autosomal recessive; ARSA: arylsulfatase A gene; GALC: galactocerebrosidase gene; GLA: alpha galactosidase A gene; NPC1: Niemann-Pick C1 gene; NPC2: Niemann-Pick C2 gene; PSAP: prosaposin gene; SMPD1: sphingomyelin phosphodiesterase 1 gene; XLR: X-linked recessive.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical features of hereditary peripheral neuropathies associated with other disorders-II",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"20%\">",
"     </colgroup>",
"     <colgroup width=\"40%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disorder",
"       </td>",
"       <td class=\"subtitle1\">",
"        Inheritance",
"       </td>",
"       <td class=\"subtitle1\">",
"        Chromosome (gene)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Mitochondrial disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Leigh's syndrome",
"       </td>",
"       <td>",
"        AR",
"       </td>",
"       <td>",
"        9q34 (SURF1)",
"       </td>",
"       <td>",
"        Onset in infancy or childhood, developmental delay, psychomotor regression, brainstem dysfunction, ataxia, dystonia, external ophthalmoplegia, seizures, weakness, lactic acidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Leber's hereditary optic neuropathy",
"       </td>",
"       <td>",
"        mtDNA",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Affects young adult males, usual onset in late teens, severe permanent visual loss, tremor, multiple sclerosis-like illness, extrapyramidal syndrome, seizures, ataxia, spasticity, mental retardation, peripheral neuropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        DNA repair disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Xeroderma pigmentosa",
"       </td>",
"       <td>",
"        AR",
"       </td>",
"       <td>",
"        (XPA-XPG) (XPV)",
"       </td>",
"       <td>",
"        Peripheral neuropathy, photosensitivity, cutaneous malignancy, skin atrophy and telangiectasia, keratitis, opacification of the cornea, iritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cockayne syndrome",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        (CS-A) (CS-B)",
"       </td>",
"       <td>",
"        Progressive dementia, large ears and sunken eyes, physical and mental retardation, short stature, microcephaly, progressive neurologic dysfunction, optic atrophy, photosensitivity without increased frequency of cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ataxia telangiectasia",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        11q22.3 (ATM)",
"       </td>",
"       <td>",
"        Progressive cerebellar ataxia, oculocutaneous telangiectasias, immune deficiency, increased risk of malignancy, radiation sensitivity, diabetes mellitus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Hereditary tyrosinemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Type I",
"       </td>",
"       <td>",
"        AR",
"       </td>",
"       <td>",
"        (FAH)",
"       </td>",
"       <td>",
"        Severe progressive liver disease, renal tubular dysfunction, peripheral neuropathy, extensor hypertonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Type II",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Keratitis, palmoplantar hyperkeratosis, mental retardation, elevated blood tyrosine concentrations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Type III",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Hypertyrosinemia, mental retardation",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AR: autosomal recessive; mtDNA: mitochondrial DNA; XPA-XPG: xeroderma pigmentosa A-G; XPV: xeroderma pigmentosa variant; ATM: ataxia telangiectasia mutated; FAH: fumarylacetoacetate hydrolase.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_20_11584=[""].join("\n");
var outline_f11_20_11584=null;
var title_f11_20_11585="Water sol vit DRI";
var content_f11_20_11585=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F69963&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F69963&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Dietary Reference Index (DRIs) of water soluble vitamins",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"30%\">",
"     </colgroup>",
"     <colgroup span=\"14\" width=\"5%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Life stage group",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Thiamin",
"        <br/>",
"        (mg/d)",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Riboflavin",
"        <br/>",
"        (mg/d)",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Niacin*",
"        <br/>",
"        (mg/d)",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Pantothenic acid",
"        <br/>",
"        (mg/d)",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Vitamin B",
"        <sub>",
"         6",
"        </sub>",
"        <br/>",
"        (mg/d)",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Biotin",
"        <br/>",
"        (&micro;g/d)",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Vitamin C",
"        <br/>",
"        (mg/d)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        <span class=\"red\">",
"         RDA*",
"        </span>",
"        /",
"        <span class=\"green\">",
"         AI",
"         <sup>",
"          &bull;",
"         </sup>",
"        </span>",
"       </td>",
"       <td class=\"subtitle2\">",
"        UL",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td class=\"subtitle2\">",
"        <span class=\"red\">",
"         RDA",
"        </span>",
"        /",
"        <span class=\"green\">",
"         AI",
"        </span>",
"       </td>",
"       <td class=\"subtitle2\">",
"        UL",
"       </td>",
"       <td class=\"subtitle2\">",
"        <span class=\"red\">",
"         RDA",
"        </span>",
"        /",
"        <span class=\"green\">",
"         AI",
"        </span>",
"       </td>",
"       <td class=\"subtitle2\">",
"        UL",
"       </td>",
"       <td class=\"subtitle2\">",
"        <span class=\"red\">",
"         RDA",
"        </span>",
"        /",
"        <span class=\"green\">",
"         AI",
"        </span>",
"       </td>",
"       <td class=\"subtitle2\">",
"        UL",
"       </td>",
"       <td class=\"subtitle2\">",
"        <span class=\"red\">",
"         RDA",
"        </span>",
"        /",
"        <span class=\"green\">",
"         AI",
"        </span>",
"       </td>",
"       <td class=\"subtitle2\">",
"        UL",
"       </td>",
"       <td class=\"subtitle2\">",
"        <span class=\"red\">",
"         RDA",
"        </span>",
"        /",
"        <span class=\"green\">",
"         AI",
"        </span>",
"       </td>",
"       <td class=\"subtitle2\">",
"        UL",
"       </td>",
"       <td class=\"subtitle2\">",
"        <span class=\"red\">",
"         RDA",
"        </span>",
"        /",
"        <span class=\"green\">",
"         AI",
"        </span>",
"       </td>",
"       <td class=\"subtitle2\">",
"        UL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"15\">",
"        Infants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0-6 mo",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         0.2",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         0.3",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         2",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         1.7",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         0.1",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         5",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         40",
"        </span>",
"       </td>",
"       <td>",
"        ND&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        7-12 mo",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         0.3",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         0.4",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         4",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         1.8",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         0.3",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         6",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         50",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"15\">",
"        Children",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1-3 y",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         0.5",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         0.5",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         6",
"        </span>",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         2",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         0.5",
"        </span>",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         8",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         15",
"        </span>",
"       </td>",
"       <td>",
"        400",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4-8 y",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         0.6",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         0.6",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         8",
"        </span>",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         3",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         0.6",
"        </span>",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         12",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         25",
"        </span>",
"       </td>",
"       <td>",
"        650",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"15\">",
"        Males",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        9-13 y",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         0.9",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         0.9",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         12",
"        </span>",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         4",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         1.0",
"        </span>",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         20",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         45",
"        </span>",
"       </td>",
"       <td>",
"        1200",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        14-18 y",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         1.2",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         1.3",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         16",
"        </span>",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         5",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         1.3",
"        </span>",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         25",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         75",
"        </span>",
"       </td>",
"       <td>",
"        1800",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        19-30 y",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         1.2",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         1.3",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         16",
"        </span>",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         5",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         1.3",
"        </span>",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         30",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         90",
"        </span>",
"       </td>",
"       <td>",
"        2000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        31-50 y",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         1.2",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         1.3",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         16",
"        </span>",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         5",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         1.3",
"        </span>",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         30",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         90",
"        </span>",
"       </td>",
"       <td>",
"        2000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        51-70 y",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         1.2",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         1.3",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         16",
"        </span>",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         5",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         1.7",
"        </span>",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         30",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         90",
"        </span>",
"       </td>",
"       <td>",
"        2000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &gt;70 y",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         1.2",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         1.3",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         16",
"        </span>",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         5",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         1.7",
"        </span>",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         30",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         90",
"        </span>",
"       </td>",
"       <td>",
"        2000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"15\">",
"        Females",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        9-13 y",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         0.9",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         0.9",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         12",
"        </span>",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         4",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         1.0",
"        </span>",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         20",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         45",
"        </span>",
"       </td>",
"       <td>",
"        1200",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        14-18 y",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         1.0",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         1.0",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         14",
"        </span>",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         5",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         1.2",
"        </span>",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         25",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         65",
"        </span>",
"       </td>",
"       <td>",
"        1800",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        19-30 y",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         1.1",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         1.1",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         14",
"        </span>",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         5",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         1.3",
"        </span>",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         30",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         75",
"        </span>",
"       </td>",
"       <td>",
"        2000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        31-50 y",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         1.1",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         1.1",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         14",
"        </span>",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         5",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         1.3",
"        </span>",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         30",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         75",
"        </span>",
"       </td>",
"       <td>",
"        2000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        51-70 y",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         1.1",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         1.1",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         14",
"        </span>",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         5",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         1.5",
"        </span>",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         30",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         75",
"        </span>",
"       </td>",
"       <td>",
"        2000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &gt;70 y",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         1.1",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         1.1",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         14",
"        </span>",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         5",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         1.5",
"        </span>",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         30",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         75",
"        </span>",
"       </td>",
"       <td>",
"        2000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"15\">",
"        Pregnancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        14-18 y",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         1.4",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         1.4",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         18",
"        </span>",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         6",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         1.9",
"        </span>",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         30",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         80",
"        </span>",
"       </td>",
"       <td>",
"        1800",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        19-30 y",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         1.4",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         1.4",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         18",
"        </span>",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         6",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         1.9",
"        </span>",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         30",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         85",
"        </span>",
"       </td>",
"       <td>",
"        2000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        31-50 y",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         1.4",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         1.4",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         18",
"        </span>",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         6",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         1.9",
"        </span>",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         30",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         85",
"        </span>",
"       </td>",
"       <td>",
"        2000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"15\">",
"        Lactation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        14-18 y",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         1.4",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         1.6",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         17",
"        </span>",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         7",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         2.0",
"        </span>",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         35",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         115",
"        </span>",
"       </td>",
"       <td>",
"        1800",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        19-30 y",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         1.4",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         1.6",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         17",
"        </span>",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         7",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         2.0",
"        </span>",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         35",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         120",
"        </span>",
"       </td>",
"       <td>",
"        2000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        31-50 y",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         1.4",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         1.6",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         17",
"        </span>",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         7",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         2.0",
"        </span>",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        <span class=\"green\">",
"         35",
"        </span>",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        <span class=\"red\">",
"         120",
"        </span>",
"       </td>",
"       <td>",
"        2000",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     <span style=\"color: #ff0000;\">",
"      RDA: recommended dietary allowance;",
"     </span>",
"     <span style=\"color: #008000;\">",
"      AI: adequate intake;",
"     </span>",
"     UL: upper tolerable level.",
"     <br/>",
"     * The RDA is the level of dietary intake that is sufficient to meet the daily nutrient requirements of 97 percent of the individuals in a specific life stage group.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     The AI represents an approximation of the average nutrient intake that sustains a defined nutritional state, based on observed or experimentally determined values in a defined population.",
"     <br/>",
"     &Delta; The UL is the maximum level of daily nutrient intake that is likely to pose no risk of adverse health effects in almost all individuals in the specified life-stage or gender group.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dietary Reference Intakes: The Essential Guide to Nutrient Requirements. Otten JJ, Hellwig JP, Meyers LD (Eds), The National Academies Press, Washington, DC 2006. pp.530-541. Copyright &copy; 2006, National Academy of Sciences.",
"     <br/>",
"     Sources: Dietary reference intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Panthothenic acid, Biotin, and Choline (1998); Dietary reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids (2000). These reports may be accessed via www.nap.edu.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_20_11585=[""].join("\n");
var outline_f11_20_11585=null;
var title_f11_20_11586="Patient information: Febrile seizures (The Basics)";
var content_f11_20_11586=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16118\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/33/6675\">",
"         Measuring rectal temperature",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?39/40/40578\">",
"         Patient information: Fever in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/56/28546\">",
"         Patient information: Seizures (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?38/35/39473\">",
"         Patient information: Febrile seizures (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/23/37235\">",
"         Patient information: Fever in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?0/26/419\">",
"         Patient information: Seizures in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?19/5/19540\">",
"         Patient information: Treatment of seizures in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Febrile seizures (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/febrile-seizures-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H17481629\">",
"      <span class=\"h1\">",
"       What are febrile seizures?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Seizures are waves of abnormal electrical activity in the brain. They can make you pass out, or move or behave strangely. &ldquo;Febrile&rdquo; means that the seizure is caused by a fever. Febrile seizures occur in children ages 6 months to 6 years old.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H17481636\">",
"      <span class=\"h1\">",
"       How do I know if my child has a fever?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To find out if your child has a fever, take his or her temperature. The most accurate way is to take a rectal temperature (",
"      <a class=\"graphic graphic_figure graphicRef74460 \" href=\"UTD.htm?6/33/6675\">",
"       figure 1",
"      </a>",
"      ). A rectal temperature higher than 100.4&deg;F (38&deg;C) is a fever.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H17481643\">",
"      <span class=\"h1\">",
"       What are the symptoms of a febrile seizure?",
"      </span>",
"      &nbsp;&mdash;&nbsp;During a febrile seizure, a child usually passes out and has jerking movements of the arms, legs, or face. Most febrile seizures last less than 1 or 2 minutes. After a seizure, a child can be confused or sleepy.",
"     </p>",
"     <p>",
"      Although not as common, some febrile seizures last more than 15 minutes. After a longer seizure, a child can have short-term weakness in his or her arm or leg.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H17481650\">",
"      <span class=\"h1\">",
"       How can I help my child during a seizure?",
"      </span>",
"      &nbsp;&mdash;&nbsp;During a seizure, you should:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Put your child on his or her side",
"       </li>",
"       <li>",
"        Not put anything in your child&rsquo;s mouth or try to stop the jerking movements",
"       </li>",
"       <li>",
"        Keep track of how long the seizure lasts &mdash; If it lasts more than 5 minutes, call 9-1-1.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H17481657\">",
"      <span class=\"h1\">",
"       Does my child need to see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Take your child to the doctor or nurse as soon as possible. He or she will want to make sure that your child&rsquo;s fever isn&rsquo;t caused by a serious infection. To do this, your doctor or nurse might need to do tests.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H17481664\">",
"      <span class=\"h1\">",
"       How are febrile seizures treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If a febrile seizure stops on its own, it does not need to be treated. If a febrile seizure lasts more than 15 minutes, a doctor will use anti-seizure medicines to stop it.",
"     </p>",
"     <p>",
"      Your child might also get other treatments, such as:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Medicines to bring down his or her fever",
"       </li>",
"       <li>",
"        Medicines to treat the infection that is causing the fever (if the fever is caused by an infection)",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H17481671\">",
"      <span class=\"h1\">",
"       Will my child have more febrile seizures?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It&rsquo;s possible. Children who have one febrile seizure have a higher chance of having another one. Talk with your doctor or nurse about how to treat any fevers that your child gets in the future.",
"     </p>",
"     <p>",
"      If your child keeps having febrile seizures, your doctor might prescribe medicine so that you can treat your child&rsquo;s seizures at home.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H17481678\">",
"      <span class=\"h1\">",
"       Does a febrile seizure cause brain damage?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. A febrile seizure does not cause brain damage. It also does not mean that your child will have a life-long seizure condition.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H17481685\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/56/28546?source=see_link\">",
"       Patient information: Seizures (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/40/40578?source=see_link\">",
"       Patient information: Fever in children (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/35/39473?source=see_link\">",
"       Patient information: Febrile seizures (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?0/26/419?source=see_link\">",
"       Patient information: Seizures in children (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/5/19540?source=see_link\">",
"       Patient information: Treatment of seizures in children (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/23/37235?source=see_link\">",
"       Patient information: Fever in children (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?11/20/11586?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16118 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-203.80.222.8-5CA963D2D9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_20_11586=[""].join("\n");
var outline_f11_20_11586=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17481629\">",
"      What are febrile seizures?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17481636\">",
"      How do I know if my child has a fever?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17481643\">",
"      What are the symptoms of a febrile seizure?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17481650\">",
"      How can I help my child during a seizure?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17481657\">",
"      Does my child need to see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17481664\">",
"      How are febrile seizures treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17481671\">",
"      Will my child have more febrile seizures?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17481678\">",
"      Does a febrile seizure cause brain damage?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17481685\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16118\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/33/6675\">",
"      Measuring rectal temperature",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/35/39473?source=related_link\">",
"      Patient information: Febrile seizures (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/23/37235?source=related_link\">",
"      Patient information: Fever in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/40/40578?source=related_link\">",
"      Patient information: Fever in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/56/28546?source=related_link\">",
"      Patient information: Seizures (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/26/419?source=related_link\">",
"      Patient information: Seizures in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/5/19540?source=related_link\">",
"      Patient information: Treatment of seizures in children (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_20_11587="Alopecia areata ophiasis";
var content_f11_20_11587=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F52784&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F52784&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Alopecia areata - ophiasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 319px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A band-like distribution of hair loss extends along the occipital scalp.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_20_11587=[""].join("\n");
var outline_f11_20_11587=null;
var title_f11_20_11588="Sodium phenylbutyrate: Pediatric drug information";
var content_f11_20_11588=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"10\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sodium phenylbutyrate: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?9/39/9845?source=see_link\">",
"    see \"Sodium phenylbutyrate: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?21/59/22452?source=see_link\">",
"    see \"Sodium phenylbutyrate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F221871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Buphenyl&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1062225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Ammonium Detoxicant",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Hyperammonemia Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Urea Cycle Disorder (UCD) Treatment Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11445046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: 300-600 mg/kg/day divided 4-6 times daily dependent upon deficiency type (Berry, 2001)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Arginase deficiency: 300-600 mg/kg/day divided 4 times daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Argininosuccinic acid lyase (ASL), argininosuccinic synthetase (ASS), carbamyl phosphate synthetase I (CPS), or ornithine transcarbamylase (OTC) deficiency: 450-600 mg/kg/day divided 4 times daily",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1062218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?9/39/9845?source=see_link\">",
"      see \"Sodium phenylbutyrate: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants and Children &lt;20 kg: 300-600 mg/kg/day divided 4-6 times daily dependent upon on deficiency type; maximum daily dose: 20 g/day (Berry, 2001)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Arginase deficiency: 300-600 mg/kg/day divided 4 times daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Argininosuccinic acid lyase (ASL), argininosuccinic synthetase (ASS), carbamyl phosphate synthetase I (CPS), or ornithine transcarbamylase (OTC) deficiency: 450-600 mg/kg/day divided 4 times daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &gt;20 kg and Adults: 9.9-13 g/m",
"     <sup>",
"      2",
"     </sup>",
"     /day, divided 4-6 times daily; maximum daily dose: 20 g/day (Berry, 2001)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F221862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for solution, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Buphenyl&reg;:  (250 g) [contains sodium 125 mg/g]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Buphenyl&reg;: 500 mg [contains sodium 62 mg/tablet]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F221850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1062228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with meals or feedings; mix powder with food or drink; avoid mixing with acidic beverages (eg, most fruit juices or colas)",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1062221\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature (59&deg;F to 86&deg;F); after opening, containers should be kept tightly closed",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1062227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunctive therapy in the chronic management of patients with urea cycle disorder involving deficiencies of carbamoylphosphate synthetase, ornithine transcarbamylase, or argininosuccinic acid synthetase; provides an alternative pathway for waste nitrogen excretion",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F221887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Syncope",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Depression, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Acidosis, alkalosis, amenorrhea/menstrual dysfunction, hyperbilirubinemia, hyperchloremia, hyper-/hypophosphatemia, hypernatremia, hyperuricemia, hypokalemia, total protein decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, abnormal taste, anorexia, gastritis, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, leukocytosis, leukopenia, thrombocytopenia, thrombocytosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Renal tubular acidosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Offensive body odor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Aplastic anemia, arrhythmia, bruising, constipation, edema, fatigue, lightheadedness, memory impairment, neuropathy (exacerbation), pancreatitis, peptic ulcer disease, rectal bleeding, somnolence",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1062231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to phenylbutyrate, or any component; patients with severe hypertension, heart failure or renal dysfunction;",
"     <b>",
"      phenylbutyrate is not indicated in the treatment of acute hyperammonemia",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1062217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use cautiously in patients with renal or hepatic dysfunction and in patients who must maintain a low sodium diet as each gram of drug contains 125 mg sodium",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F5673907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1062234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid mixing with acidic-type beverages (eg, colas, lemonade, grape juice) since drug may precipitate",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F221859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5673904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1062224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Plasma ammonia and glutamine concentrations, serum electrolytes, proteins, hepatic and renal function tests, physical signs/symptoms of hyperammonemia (ie, lethargy, ataxia, confusion, vomiting, seizures, and memory impairment)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1062216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sodium phenylbutyrate is a prodrug that, when given orally, is rapidly converted to phenylacetate. Phenylacetate is conjugated with glutamine to form the active compound phenylacetyglutamine. Phenylacetyglutamine serves as a substitute for urea and is excreted in the urine carrying with it 2 moles nitrogen (equivalent to urea) per mole of phenylacetyglutamine thus assisting in the clearance of nitrogenous waste in patients with urea cycle disorders.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1062230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.2 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: conjugation to phenylacetylglutamine (active form); undergoes nonlinear Michaelis-Menten elimination kinetics",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 0.8 hours (parent compound); 1.2 hours (phenylacetate)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Powder: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tablet: 1.35 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 80% of metabolite excreted in urine in 24 hours",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1062223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?21/59/22452?source=see_link\">",
"      see \"Sodium phenylbutyrate: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is important to follow the dietary restrictions required when treating this disorder, the medication must be taken in strict accordance with the prescribed regimen; avoid altering the dosage without the prescriber's knowledge; the powder formulation has a very salty taste",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1062232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teaspoon and tablespoon measuring devices are provided with the powder; each 1 g powder contains 0.94 g sodium phenylbutyrate = 125 mg sodium; each tablet contains 0.5 g sodium phenylbutyrate = 62 mg sodium",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F12817092\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     A 200 mg/mL oral suspension may be prepared with sodium phenylbutyrate powder, USP; Ora-Plus&reg;; and either Ora-Sweet&reg; or Ora-Sweet&reg; SF. Place 12 g of sodium phenylbutyrate in a glass mortar and reduce to a fine powder. Separately, mix 30 mL Ora-Plus&reg; and 30 mL of either Ora-Sweet&reg; or Ora-Sweet&reg; SF for a total volume of 60 mL. Add 30 mL of the vehicle mixture to the powder and mix to a uniform smooth suspension. Transfer the mixture into a 2 oz amber prescription bottle; rinse mortar with vehicle, and add quantity of vehicle sufficient to make 60 mL. Label &ldquo;shake well&rdquo;. Stable for 90 days at room temperature.",
"     <b>",
"      Note:",
"     </b>",
"     Authors recommend administering a masking agent such as chocolate syrup or peanut butter, before and after medication administration, to mask the bitter taste.",
"    </p>",
"    <div class=\"reference\">",
"     Caruthers RL and Johnson CE, \"Stability of Extemporaneously Prepared Sodium Phenylbutyrate Oral Suspensions,\"",
"     <i>",
"      Am J Health Syst Pharm",
"     </i>",
"     , 2007, 64(14):1513-5.",
"     <span class=\"pubmed-id\">",
"      17617502",
"     </span>",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Batshaw ML, MacArthur RB, and Tuchman M, &ldquo;Alternative Pathway Therapy for Urea Cycle Disorders: Twenty Years Later,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2001, 138(1 Suppl):S46-S55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/20/11588/abstract-text/11148549 /pubmed\" id=\"11148549 \" target=\"_blank\">",
"        11148549",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berry GT and Steiner RD, &ldquo;Long-Term Management of Patients With Urea Cycle Disorders,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2001, 138(1 Suppl):S56-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/20/11588/abstract-text/11148550/pubmed\" id=\"11148550\" target=\"_blank\">",
"        11148550",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brusilow SW, &ldquo;Phenylacetylglutamine May Replace Urea as a Vehicle for Waste Nitrogen Excretion,&rdquo;",
"      <i>",
"       Pediatr Res",
"      </i>",
"      , 1991, 29(2):147-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/20/11588/abstract-text/2014149 /pubmed\" id=\"2014149 \" target=\"_blank\">",
"        2014149",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Maestri NE, Brusilow SW, Clissold DB, et al, &ldquo;Long-Term Treatment of Girls With Ornithine Transcarbamylase Deficiency,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1996, 335(12):855-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/20/11588/abstract-text/8778603/pubmed\" id=\"8778603\" target=\"_blank\">",
"        8778603",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12798 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-B32189B1BC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_20_11588=[""].join("\n");
var outline_f11_20_11588=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221871\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062225\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11445046\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062218\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221862\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221850\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062228\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062221\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062227\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221887\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062231\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062217\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300066\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5673907\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062234\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221859\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5673904\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062224\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062216\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062230\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062223\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062232\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12817092\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12798\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12798|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?9/39/9845?source=related_link\">",
"      Sodium phenylbutyrate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?21/59/22452?source=related_link\">",
"      Sodium phenylbutyrate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_20_11589="Implantable cardioverter-defibrillators";
var content_f11_20_11589=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Implantable cardioverter-defibrillators (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?11/20/11589/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/20/11589/contributors\" id=\"au6340\">",
"       Bradley P Knight, MD, FACC",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?11/20/11589/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/20/11589/contributors\" id=\"se214\">",
"       Samuel L&eacute;vy, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?11/20/11589/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/20/11589/contributors\" id=\"de7537\">",
"       Brian C Downey, MD, FACC",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?11/20/11589?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     It is estimated that 200,000 to 400,000 people die suddenly every year in the United States; the majority die as a result of heart rhythm abnormalities known as ventricular tachycardia (VT) or ventricular fibrillation (VF). An implantable cardioverter-defibrillator (ICD) is a battery-powered device that significantly improves the chances of survival in people at high risk for these arrhythmias.",
"    </p>",
"    <p>",
"     Cardiac arrest, also known as sudden cardiac death, occurs when an abnormal heart rhythm prevents the heart from working normally to deliver blood to the brain and other vital organs. A heart attack occurs when a blood vessel is partially or completely blocked, preventing blood flow to the heart, causing heart muscle to die. Cardiac arrest is not the same as a heart attack, although a person can be at a higher risk for cardiac arrest during or after a heart attack.",
"    </p>",
"    <p>",
"     These dangerous arrhythmias often occur without warning and can be fatal within minutes, making them difficult or impossible to treat with conventional methods. Having an ICD does not prevent the abnormal rhythm from occurring, but it rapidly detects and treats the abnormality, restoring a normal heart rhythm before the event becomes life-threatening.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      WHAT DOES AN ICD DO?",
"     </span>",
"    </p>",
"    <p>",
"     Modern ICDs are sophisticated devices that are able to perform three general functions: treat dangerous ventricular arrhythmias, record the heart's activity, and work as a pacemaker should marked slowing of heart rate occur, or if VT requires antitachycardia pacing (detailed below).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Treat ventricular arrhythmias",
"     </span>",
"     &nbsp;&mdash;&nbsp;The primary purpose of an ICD is to treat potentially fatal ventricular arrhythmias (VT and VF). The ICD is highly effective in the treatment of these arrhythmias, and studies have demonstrated that people who have or who are at risk for these arrhythmias survive longer with an ICD. The ICD does not prevent arrhythmias from occurring, but the ICD can stop an arrhythmia that develops, often saving the patient's life.",
"    </p>",
"    <p>",
"     The ICD treats an arrhythmia in one of three ways:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Cardioversion",
"      </li>",
"      <li>",
"       Defibrillation",
"      </li>",
"      <li>",
"       Anti-tachycardia pacing",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Cardioversion and defibrillation are both forms of high-energy shocks that stop dangerous arrhythmias and restore a normal heart rhythm. If the patient is conscious (awake) at the time of the shock, it is painful and usually described as feeling like a kick in the chest. Most of the time, however, a shock for a dangerous arrhythmia is delivered after the patient has lost consciousness, and is therefore unable to feel the shock.",
"    </p>",
"    <p>",
"     Anti-tachycardia pacing is an alternative method of stopping ventricular arrhythmias. It involves delivering a short series (eg, 5 to 10) of paced beats. This is not painful and may be unnoticed by the patient, although some patients may feel a brief burst of palpitations. Anti-tachycardia pacing can be very effective for some slower ventricular arrhythmias (eg, 150 to 200 beats per minute), and is often programmed as the initial therapy for these arrhythmias. High-energy shocks are often programmed as the initial therapy for very fast rhythms (eg, more than 200 to 220 beats per minute), or as a rescue therapy if anti-tachycardia pacing fails.",
"    </p>",
"    <p>",
"     ICDs can usually distinguish between different arrhythmias, such as atrial fibrillation and VT. This is important because atrial fibrillation causes a rapid heart rate, but rarely requires a shock. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/16/261?source=see_link\">",
"      \"Patient information: Atrial fibrillation (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Record the heart's activity",
"     </span>",
"     &nbsp;&mdash;&nbsp;A record of the heart's activity is kept by the ICD. The record can be retrieved during an office visit, enabling the healthcare provider to monitor any underlying conditions causing abnormal heart rhythms. This allows the provider to make adjustments to ICD programming and recommend or change other treatment measures (eg, antiarrhythmic medications).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Pacemaker",
"     </span>",
"     &nbsp;&mdash;&nbsp;In addition to treating dangerous rapid arrhythmias, all modern ICDs also have the ability to function as a standard cardiac pacemaker. However, standard pacemakers do not perform the functions of an ICD. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/16/20741?source=see_link\">",
"      \"Patient information: Pacemakers (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Combination therapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;A healthcare provider may recommend the use of an additional treatment for some people with ICDs, depending upon the frequency of the arrhythmia, the underlying cause, the type of device used, and other factors.",
"    </p>",
"    <p>",
"     Additional therapies may include antiarrhythmic drugs, lipid lowering medications, and catheter ablation. However, antiarrhythmic drugs provide incomplete protection from VT, VF, and sudden death so they are generally used together with an ICD. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?42/6/43108?source=see_link\">",
"      \"Patient information: High cholesterol treatment options (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/31/14834?source=see_link\">",
"      \"Patient information: Radiofrequency catheter ablation for the heart (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      WHO SHOULD CONSIDER AN ICD?",
"     </span>",
"    </p>",
"    <p>",
"     Specific recommendations have been established regarding the use of ICD therapy. The reasons for using an ICD have expanded as more groups of patients have been shown to benefit from ICD therapy. Categories of patients in whom an ICD is recommended include the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Patients who have experienced one or more episodes of spontaneous, sustained VT or VF (if it is not due to a transient or reversible cause).",
"      </li>",
"      <li>",
"       Certain patients who have not had prior episodes of VT or VF, but are at high risk for one of these arrhythmias. The estimated risk for these arrhythmias is based upon a combination of several risk factors (for example, prior heart attacks, severely reduced heart function,",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       advanced heart failure).",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     People who have a combination of risk factors may be referred for an additional test, called an electrophysiology study, to determine if an ICD is necessary.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      PARTS OF AN ICD",
"     </span>",
"    </p>",
"    <p>",
"     An ICD is approximately the size of a pager. The main parts include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The ICD &mdash; The ICD is powered by a battery and generates an electrical shock. It is also called the battery, device, or pulse generator. It is a single unit that is usually inserted into a \"pocket\" created under the skin (or muscle) in the chest below the collarbone (in the pectoral region). The longevity of the ICD is defined by the length of life of the battery (usually three to five years).",
"      </li>",
"      <li>",
"       The leads &mdash; Flexible, insulated wires, or leads, monitor the electrical impulses and report the heart's electrical activity back to the ICD. These leads deliver electrical charges from the generator to the heart muscle when needed. During implantation, the ICD leads are passed through a vein into the heart.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The leads are connected to the ICD. When the ICD reaches the end of battery life and is replaced, the original leads are usually left in place and connected to the new device. The leads may last for 20 years or more.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      PROCEDURE",
"     </span>",
"    </p>",
"    <p>",
"     In most cases, an ICD is inserted after the person is given a sedative and a local anesthetic (numbing medication) is injected into the skin. Some patients will be given general anesthesia, which is used to induce sleep while the procedure is performed.",
"    </p>",
"    <p>",
"     The surgery involves making an incision below one of the collarbones. The leads will be placed into the heart through the vein that runs next to the collarbone. Up to two leads will be placed inside the heart (",
"     <a class=\"graphic graphic_figure graphicRef67053 \" href=\"UTD.htm?16/32/16899\">",
"      figure 1",
"     </a>",
"     ). One lead will be placed in the ventricle (bottom chamber) and one may be placed in the atrium (top chamber), on the right side of heart.",
"    </p>",
"    <p>",
"     During the operation, routine electrical measurements of the heart will be made to be sure that the leads are positioned correctly. After the leads are in place, they are connected to the ICD. The device will be placed under the skin in the upper chest. The physician may trigger the heart to beat rapidly, and then use the ICD to deliver a shock to the heart and stop the rapid beating; this is usually done one to five times to make sure the ICD functions properly. The procedure takes about 15 to 25 minutes to complete. A chest x-ray is performed after the procedure to be sure the leads are in the proper position.",
"    </p>",
"    <p>",
"     Patients will usually need to stay in the hospital overnight. The first follow-up appointment to check the incision is usually one to two weeks after the surgery.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Cardiac resynchronization",
"     </span>",
"     &nbsp;&mdash;&nbsp;An increasingly common therapy that is being used in conjunction with ICD implantation is cardiac resynchronization therapy (CRT). This treatment may be recommended for certain people with advanced heart failure and a widened QRS interval on electrocardiogram (ECG). CRT can relieve heart failure symptoms by synchronizing the contraction of the left ventricle so that the heart functions more efficiently. To deliver CRT, a third lead is placed in the heart and positioned to pace the left ventricle.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      COMPLICATIONS",
"     </span>",
"    </p>",
"    <p>",
"     As with any therapy, complications can occur with the placement or use of an ICD. Before the ICD is placed, the surgeon will discuss the possible complications and specific risks.",
"    </p>",
"    <p>",
"     Complications can be divided into those that can occur around the time of surgery, and those that can occur well after surgery. The following list describes the most common complications.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Surgical risks",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Collapse of the lung (pneumothorax) occurs in about 1 percent of cases and can usually be treated by inserting a chest tube.",
"      </li>",
"      <li>",
"       Perforation of the heart, causing a collection of blood to develop within the sac around the heart (pericardial effusion or tamponade). This occurs in less than 1 percent of cases and can usually be treated by placing a drain in the sac around the heart.",
"      </li>",
"      <li>",
"       Bleeding can occur under the skin around the defibrillator and can require drainage. The risk of this complication is higher for patients who take blood thinners (eg, warfarin or aspirin) or have a tendency to bleed easily.",
"      </li>",
"      <li>",
"       The risk of infection is about 1 percent. Because the defibrillator is a foreign material, the entire system must usually be removed if an infection occurs. Removal is relatively easy if the device was recently implanted. If an infection occurs several months or years after implantation, there can be significant risk of removal of the device because the leads can become scarred to the blood vessels and the heart.",
"      </li>",
"      <li>",
"       Lead displacement occurs in about 1 percent of patients, and is usually managed by repositioning the lead within the heart.",
"      </li>",
"      <li>",
"       The risk of death from implantation of a modern defibrillator is less than 1 in 500.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Long-term risks",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Infection or erosion of the device. In most cases, the entire system must be removed.",
"      </li>",
"      <li>",
"       Lead failure. The leads are the weakest part of the ICD system, and the mechanical stresses on the leads can lead to breakage of the wires within the leads or in the insulation surrounding the leads.",
"      </li>",
"      <li>",
"       Inappropriate detection and subsequent delivery of a shock (see",
"       <a class=\"local\" href=\"#H16\">",
"        'After a shock is delivered'",
"       </a>",
"       below).",
"      </li>",
"      <li>",
"       Premature battery depletion or device failure. Although ICD systems are extremely reliable, they are like any other piece of electronic equipment and can occasionally fail without warning.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     There has been an increase in the number of devices found to have significant problems after manufacturing and placement. In many cases, the problem is too rare to justify replacing every single device. However, in some cases, the device must be replaced. The primary risk of replacement is infection.",
"    </p>",
"    <p>",
"     The decision to replace the device depends on many factors, including the type and likelihood of device failure, the risk to the individual patient if failure were to occur, the risk of replacement, and the patient's preference. Manufacturers, doctor groups, and the federal government are paying increased attention to surveillance of ICDs after implantation as a result of the numbers of device failures.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      LIVING WITH AN ICD",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Monitoring",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with ICDs require monitoring throughout their lifetime, generally every three to six months. The device can be painlessly examined with a programmer that is placed on the area of the chest where the ICD is located. ICD manufacturers have developed technology to allow patients to have this evaluation from their home using the internet or over the telephone. Information stored on the device can be reviewed to determine the remaining battery life, lead stability and function, programmed settings, assess pacing and shocks provided, and obtain data concerning the type of rhythm disturbances treated.",
"    </p>",
"    <p>",
"     Monitoring of the battery life allows time for the device to be replaced before it stops functioning. The ICD is usually powered by lithium batteries, which last approximately three to five years. Replacing the ICD usually requires a simple procedure in which a repeat incision is made, the older ICD is removed, and a new ICD is implanted and joined with existing leads.",
"    </p>",
"    <p>",
"     Modern ICDs are able to continuously record the electrical activity of heart muscle and record the date and time of each episode and store graphs from such events. This data helps the provider to monitor and diagnose underlying conditions responsible for arrhythmias and to make programming changes if needed.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      After a shock is delivered",
"     </span>",
"     &nbsp;&mdash;&nbsp;If a person experiences a shock from their ICD, they are advised to immediately notify their doctor. Also, because most arrhythmias require only one shock to return the heart rhythm to normal, anyone who has frequent or clusters of shocks must be urgently evaluated, usually at the hospital, to investigate the cause. In some cases, programming",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     medications may need to be adjusted; less commonly, a malfunctioning lead may be detected.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Fear of the ICD",
"     </span>",
"     &nbsp;&mdash;&nbsp;Many patients describe the shocks from an ICD as severe and painful; however, most patients are willing to tolerate them because they are lifesaving. Some people feel anxious or depressed because they fear ICD shock or device failure. Supportive therapies (eg, relaxation and cognitive behavioral therapies) and support groups may be helpful in reducing anxiety.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Driving restrictions",
"     </span>",
"     &nbsp;&mdash;&nbsp;After placement of an ICD, or after the ICD administers a shock, many states require the person to stop driving for a period of time. Because VT and VF usually cause the person to pass out and lose control of the car if driving, it is important to follow your heart specialist's recommendation as well as the law. These laws are intended to protect the patient as well as others on the road.",
"    </p>",
"    <p>",
"     Although the laws vary within the United States and other countries, most experts recommend the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Driving is not recommended for one week after the ICD is implanted.",
"      </li>",
"      <li>",
"       Driving is not recommended for six months after an ICD administers a shock. Commercial drivers who have experienced an ICD shock may be prohibited from driving for a lifetime.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Avoiding electromagnetic interference",
"     </span>",
"     &nbsp;&mdash;&nbsp;Since reliable ICD functioning depends upon proper sensing of the electrical activity of the heart, it is important to avoid electromagnetic interference from external sources.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h3\">",
"      Telephones",
"     </span>",
"     &nbsp;&mdash;&nbsp;It is unlikely that wireless communication devices, such as cellular telephones or wireless home telephones, will interfere with ICD functioning. However, patients are usually advised to use a cell phone on the opposite side from the ICD.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h3\">",
"      Household appliances",
"     </span>",
"     &nbsp;&mdash;&nbsp;Manufacturers do not recommend any special precautions when using common household appliances, such as televisions, radios, toasters, microwave ovens, and electric blankets.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h3\">",
"      Security systems",
"     </span>",
"     &nbsp;&mdash;&nbsp;Electromagnetic security systems can be located in the workplace, airports, courthouses, or other high-security areas. Exposure to this type of security system has been shown to cause interference in some cases. Interference may be related to the duration of exposure",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     the distance between the ICD and the security device.",
"    </p>",
"    <p>",
"     Experts advise that people with ICDs be aware of the location of security systems, move through them at a normal pace, and avoid standing too close. In other words, \"Don't linger, don't lean.\"",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h3\">",
"      External electrical equipment",
"     </span>",
"     &nbsp;&mdash;&nbsp;The use of ICDs in certain workplaces, such as near welding equipment or motor-generator systems, has not been shown to cause problems in the functioning of the ICD. However, because interference remains a concern, experts recommend that patients remain at least two feet from external electrical equipment, verify that the equipment is properly grounded, and wear insulated gloves when using electrical devices.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24\">",
"     <span class=\"h3\">",
"      During medical tests or procedures",
"     </span>",
"     &nbsp;&mdash;&nbsp;Although standard x-rays, computed tomography (CT) scans, and fluoroscopy do not interfere with the ICD, certain other procedures may interfere. This includes magnetic resonance imaging (MRI), which should be avoided. Extracorporeal shock wave lithotripsy, often performed as a treatment for kidney stones, can damage an ICD, and the device should be turned off during this procedure. ICD function may also be altered during transcutaneous muscle or nerve stimulation (TENS), sometimes used for pain management.",
"    </p>",
"    <p>",
"     Thus, patients should inform all doctors, dentists, and other healthcare team members about their ICD to discuss the benefits, risks, and alternatives of any planned procedure. Patients should carry or wear a medical identification bracelet or necklace in case of an emergency situation in which the patient cannot speak.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H25\">",
"     <span class=\"h2\">",
"      Pregnancy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Women who have an ICD placed are generally able to become pregnant and carry the pregnancy to term without any increased risk of shocks or harm to the fetus. However, if the woman has underlying heart disease or other health problems, she should speak with her healthcare provider before becoming pregnant to discuss the risks, possible need to change medications, and plans for care during pregnancy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H26\">",
"     <span class=\"h2\">",
"      End of life",
"     </span>",
"     &nbsp;&mdash;&nbsp;If a person with an ICD is near death, either due to heart failure or another condition, he or she may choose to have the ICD turned off so that it does not deliver a shock. This decision should be discussed in advance, if possible, and should include the patient, family, and physician.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H27\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10150279\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10150287\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/60/38850?source=see_link\">",
"      Patient information: Implantable cardioverter-defibrillators (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/49/6931?source=see_link\">",
"      Patient information: Pacemakers (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/56/23427?source=see_link\">",
"      Patient information: Wolff-Parkinson-White syndrome (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/34/37410?source=see_link\">",
"      Patient information: Cardiac resynchronization therapy (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/39/34419?source=see_link\">",
"      Patient information: Sudden cardiac arrest (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/12/25795?source=see_link\">",
"      Patient information: Ventricular fibrillation (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/24/36226?source=see_link\">",
"      Patient information: Hypertrophic cardiomyopathy in children (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/24/1411?source=see_link\">",
"      Patient information: Time to stop driving? (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/25/19859?source=see_link\">",
"      Patient information: Long QT syndrome (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10150337\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/16/261?source=see_link\">",
"      Patient information: Atrial fibrillation (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/16/20741?source=see_link\">",
"      Patient information: Pacemakers (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?42/6/43108?source=see_link\">",
"      Patient information: High cholesterol treatment options (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/31/14834?source=see_link\">",
"      Patient information: Radiofrequency catheter ablation for the heart (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H28\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28250?source=see_link\">",
"      Brugada syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/56/11142?source=see_link\">",
"      Cardiac device interactions with electromagnetic fields",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/20/30024?source=see_link\">",
"      Driving restrictions in patients with an implantable cardioverter-defibrillator",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/50/24362?source=see_link\">",
"      General principles of the implantable cardioverter-defibrillator",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19657?source=see_link\">",
"      Implantable cardioverter-defibrillators: Clinical trials of primary prevention of sudden cardiac death",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/56/30599?source=see_link\">",
"      Implantable cardioverter-defibrillators: Clinical trials of secondary prevention of sudden cardiac death",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5434?source=see_link\">",
"      Implantable cardioverter-defibrillators: Complications",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39672?source=see_link\">",
"      Implantable cardioverter-defibrillators: Patient follow-up",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44345?source=see_link\">",
"      Infections involving cardiac implantable electronic devices",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15338?source=see_link\">",
"      Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=see_link\">",
"      Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/47/21241?source=see_link\">",
"      Ventricular arrhythmias in heart failure and cardiomyopathy",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/pacemakersandimplantabledefibrillators.html\">",
"      www.nlm.nih.gov/medlineplus/pacemakersandimplantabledefibrillators.html",
"     </a>",
"     , available in Spanish)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Heart, Lung, and Blood Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nhlbi.nih.gov/health/dci/Diseases/icd/icd_whatis.html\">",
"      www.nhlbi.nih.gov/health/dci/Diseases/icd/icd_whatis.html",
"     </a>",
"     , available in Spanish)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Heart Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.americanheart.org/\">",
"      www.americanheart.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Heart Rhythm Society",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.hrsonline.org/\">",
"      www.hrsonline.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?11/20/11589/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 3, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?11/20/11589?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11589/abstract/1\">",
"      Gregoratos G, Abrams J, Epstein AE, et al. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). Circulation 2002; 106:2145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11589/abstract/2\">",
"      Hauer RN, Aliot E, Block M, et al. Indications for implantable cardioverter defibrillator (ICD) therapy. Study Group on Guidelines on ICDs of the Working Group on Arrhythmias and the Working Group on Cardiac Pacing of the European Society of Cardiology. Eur Heart J 2001; 22:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11589/abstract/3\">",
"      Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study. Eur Heart J 2000; 21:2071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11589/abstract/4\">",
"      European Heart Rhythm Association, Heart Rhythm Society, Zipes DP, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 2006; 48:e247.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f11_20_11589=[""].join("\n");
var outline_f11_20_11589=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           WHAT DOES AN ICD DO?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           WHO SHOULD CONSIDER AN ICD?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           PARTS OF AN ICD",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           PROCEDURE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           COMPLICATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           LIVING WITH AN ICD",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H27\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/32/16899\" title=\"figure 1\">",
"           ICD PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f11_20_11590="Electroanatomic mapping ARVD";
var content_f11_20_11590=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F54163&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F54163&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 473px\">",
"   <div class=\"ttl\">",
"    Echocardiographic and electroanatomic mapping of the right ventricle in arrhythmogenic right ventricular dysplasia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 453px; height: 451px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Two-dimensional echocardiographic apical view of a patient with arrhythmogenic right ventricular dysplasia show severe enlargement of the right ventricle (RV) and right atrium (RA) (panel A). (B) The RV unipolar voltage maps, generated by electroanatomic mapping, are seen in the anteroposterior (panel B) and left anterior oblique views (panel C). There is extensive area of low voltage (red indicates &lt;2 mV) in the apex and anterolateral free wall of the RV, with the septum being spared (purple indicates &gt;5 mV).",
"    <div class=\"footnotes\">",
"     LA: left atrium; RVOT: RV outflow tract.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Boulos, M, Lashevsky, I, Reisner, S, Gepstein, L. J Am Coll Cardiol 2001; 38:2020. Copyright &copy; 2001 American College of Cardiology",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.elsevier.com/locate/jacc\">",
"      file://www.elsevier.com/locate/jacc",
"     </a>",
"     <br/>",
"     <a href=\" file://www.sciencedirect.com\">",
"      file://www.sciencedirect.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_20_11590=[""].join("\n");
var outline_f11_20_11590=null;
var title_f11_20_11591="Glycopyrrolate (glycopyrronium): Drug information";
var content_f11_20_11591=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Glycopyrrolate (glycopyrronium): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?43/0/44036?source=see_link\">",
"    see \"Glycopyrrolate (glycopyrronium): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/4/43078?source=see_link\">",
"    see \"Glycopyrrolate (glycopyrronium): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F176915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cuvposa&trade;;",
"     </li>",
"     <li>",
"      Robinul&reg;;",
"     </li>",
"     <li>",
"      Robinul&reg; Forte",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2969522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Glycopyrrolate Injection, USP;",
"     </li>",
"     <li>",
"      Seebri&reg; Breezhaler&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F176943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anticholinergic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F176917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chronic obstructive pulmonary disease (COPD):",
"     </b>",
"     Oral powder for inhalation: Seebri&reg; Breezhaler&reg; (Canadian availability; not available in the U.S.): 50 mcg (contents of one capsule) once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Reduction of secretions:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Preoperative:",
"     </i>",
"     I.M.: 4 mcg/kg 30-60 minutes before procedure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Intraoperative:",
"     </i>",
"     I.V.: 0.1 mg repeated as needed at 2- to 3-minute intervals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Reversal of neuromuscular blockade:",
"     </b>",
"     I.V.: 0.2 mg for each 1 mg of neostigmine or 5 mg of pyridostigmine administered or 5-15 mcg/kg glycopyrrolate with 25-70 mcg/kg of neostigmine or 0.1-0.3 mg/kg of pyridostigmine (agents usually administered simultaneously, but glycopyrrolate may be administered first if bradycardia is present)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F176932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/4/43078?source=see_link\">",
"      see \"Glycopyrrolate (glycopyrronium): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Reduction of secretions:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Preoperative:",
"     </i>",
"     I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &lt;2 years: 4-9 mcg/kg 30-60 minutes before procedure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;2 years: 4 mcg/kg 30-60 minutes before procedure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Intraoperative:",
"     </i>",
"     I.V.: 4 mcg/kg not to exceed 0.1 mg; repeat at 2- to 3-minute intervals as needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Chronic (unlabeled):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: 40-100 mcg/kg/dose 3-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M., I.V.: 4-10 mcg/kg/dose every 3-4 hours; maximum: 0.2 mg/dose or 0.8 mg/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Drooling, chronic:",
"     </b>",
"     Children 3-16 years: Oral solution (Cuvposa&trade;): 0.02 mg/kg 3 times/day; titrate in increments of 0.02 mg/kg every 5-7 days as tolerated, up to a maximum dose of  0.1 mg/kg 3 times/day, not to exceed 1.5-3 mg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Reversal of neuromuscular blockade:",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F176918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15896378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling. However, data suggest renal impairment reduces glycopyrrolate elimination; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15896379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F176894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 0.2 mg/mL (1 mL, 2 mL, 5 mL, 20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Robinul&reg;: 0.2 mg/mL (1 mL, 2 mL, 5 mL, 20 mL) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cuvposa&trade;: 1 mg/5 mL (473 mL) [contains propylene glycol; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 1 mg, 2 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Robinul&reg;: 1 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Robinul&reg; Forte: 2 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F16138301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, for oral inhalation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Seebri&reg; Breezhaler&reg;: 50 mcg/capsule (30s) [contains lactose]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F176879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes: Oral solution; Inhaler (Canadian availability; not available in U.S.)",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F176897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Administer I.V. at a rate of 0.2 mg over 1-2 minutes. May be administered I.M. or I.V. without dilution. May also be administered via the tubing of a running I.V. infusion of a compatible solution. May be administered I.V. in the same syringe with neostigmine or pyridostigmine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Administer oral solution on an empty stomach, 1 hour before or 2 hours after meals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral inhalation (Canadian availability; not available in the U.S.): Administer once daily preferably at the same time each day using the Seebri&reg; Breezhaler&reg; only. Remove capsule from foil blister immediately before use. Do not swallow capsule. Avoid getting powder into eyes. Place capsule in the capsule-chamber in the base of the Seebri&reg; Breezhaler&reg;. A click is heard as it fully closes. Hold inhaler with mouthpiece in upright position and pierce capsule within chamber by simultaneously pressing piercing buttons on base of inhaler (click is heard as capsule is pierced). Release buttons. Exhale fully. Do not exhale into inhaler. Tilt head slightly back and place mouthpiece in mouth with piercing buttons on base of inhaler in horizontal position and not up and down. Do not press piercing buttons. Inhale (rapidly, steadily and deeply); the capsule vibration should be heard within the device. Hold breath for at least 5-10 seconds or as long as possible. Remove mouthpiece prior to exhalation. Patient should not breathe out through the mouthpiece. If any powder remains in capsule, exhale and inhale again. Repeat until capsule is empty. Throw away empty capsule; do not leave in inhaler. Always keep capsules and inhaler dry.",
"     <b>",
"      Note:",
"     </b>",
"     If a dose is missed, take as soon as possible on that day; do not take 2 doses on the same day.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F176949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, NS, R;",
"     <b>",
"      incompatible",
"     </b>",
"     in LR",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Palonosetron, propofol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Atropine, buprenorphine with haloperidol, butorphanol, chlorpromazine, cimetidine, codeine, diphenhydramine, droperidol, droperidol and fentanyl, hydromorphone, hydroxyzine, lidocaine, meperidine, midazolam, morphine, nalbuphine, neostigmine, ondansetron, oxymorphone, palonosetron, physostigmine, prochlorperazine edisylate, promethazine, pyridostigmine, ranitidine, scopolamine, trimethobenzamide.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Chloramphenicol, dexamethasone sodium phosphate, diazepam, dimenhydrinate, methohexital, pentazocine, pentobarbital, secobarbital, sodium bicarbonate, thiopental.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F176896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibit salivation and excessive secretions of the respiratory tract preoperatively; control of upper airway secretions; intraoperatively to counteract drug-induced or vagal mediated bradyarrhythmias; adjunct in treatment of peptic ulcer (indication listed in product labeling but currently has no place in management of peptic ulcer disease)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Cuvposa&trade;: Reduce chronic, severe drooling in those with neurologic conditions (eg, cerebral palsy) associated with drooling",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Seebri&reg; Breezhaler&reg; (Canadian availability; not available in U.S.): Maintenance treatment of chronic obstructive pulmonary disease (COPD) including chronic bronchitis and emphysema",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F7823805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct with acetylcholinesterase inhibitors (eg, neostigmine, edrophonium, pyridostigmine) to antagonize cholinergic effects",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7913945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Robinul [U.S. and multiple international markets] may be confused with Reminyl brand name for galantamine [Canada and multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F176941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10% (as reported with Cuvposa&trade;):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Flushing (30%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Vomiting (40%), xerostomia (40%), constipation (35%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Urinary retention (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Nasal congestion (30%), sinusitis (15%), upper respiratory tract infection (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     &lt;10% (frequency not always defined):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Pallor (&le;2%), arrhythmias, cardiac arrest, heart block, hyper-/hypotension, malignant hyperthermia, palpitation, QT",
"     <sub>",
"      c",
"     </sub>",
"     -interval prolongation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Aggressiveness (&le;2%), agitation (&le;2%), crying (abnormal;  &le;2%), irritability (&le;2%), mood changes (&le;2%), pain(&le;2%), restlessness(&le;2%), confusion, dizziness, drowsiness, excitement, insomnia, nervousness,  seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Dry skin (&le;2%), pruritus (&le;2%), rash (&le;2%), urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dehydration (&le;2%), lactation suppression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal distention (&le;2%), abdominal pain (&le;2%), flatulence (&le;2%), retching (&le;2%), bloated feeling, intestinal obstruction, loss of taste, nausea, pseudo-obstruction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (&le;2%), impotence, urinary hesitancy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site reactions (edema, erythema, pain)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Nystagmus (&le;2%), blurred vision, cycloplegia, mydriasis, ocular tension increased, photophobia, sensitivity to light increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchial secretion (thickening; &le;2%), nasal dryness (&le;2%), pneumonia (&le;2%), respiratory depression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylactoid reactions, diaphoresis decreased, hypersensitivity reactions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     As reported with Seebri&reg; Breezhaler&reg; (Canadian availability; not available in U.S.):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Central nervous system: Headache (elderly: 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Gastrointestinal: Xerostomia (2% to 3%), gastroenteritis (1% to 3%), dyspepsia (1%), vomiting (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Genitourinary: Urinary tract infection (elderly: 3%), dysuria (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Neuromuscular &amp; skeletal: Musculoskeletal pain (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Respiratory: Nasopharyngitis (9%), rhinitis (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     &lt;1% (Limited to important or life-threatening): Cough, cystitis, dental caries, diabetes mellitus, epistaxis, fatigue, hypoesthesia, palpitations, rash, throat irritation, urinary retention, weakness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F176900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to glycopyrrolate or any component of the formulation; medical conditions that preclude use of anticholinergic medication; severe ulcerative colitis, toxic megacolon complicating ulcerative colitis, paralytic ileus, obstructive disease of GI tract (eg, pyloric stenosis), intestinal atony in the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; narrow-angle glaucoma; acute hemorrhage; tachycardia; obstructive uropathy; myasthenia gravis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Oral solution: Additional contraindication: Concomitant use of potassium chloride in a solid oral dosage form",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Seebri&reg; Breezhaler&reg; (Canadian availability; not available in U.S.): Hypersensitivity to glycopyrronium bromide or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F176883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bronchospasm: Rarely, paradoxical bronchospasm may occur with use of inhaled bronchodilating agents; discontinue use of inhaler and consider other therapy if bronchospasm occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: May cause drowsiness and/or blurred vision, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diarrhea: May be a sign of incomplete intestinal obstruction, treatment should be discontinued if this occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; GI transit: Slowing of GI muscular action can occur resulting in constipation or intestinal pseudo-obstruction.  Constipation is a common dose-limiting adverse event. Intestinal pseudo-obstruction can result in abdominal distention, pain, nausea, or vomiting.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heat prostration: May occur in the presence of increased environmental temperature; use caution in hot weather and/or exercise.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Mechanical obstruction (incomplete): Diarrhea may be a sign of incomplete intestinal obstruction, especially in patients with an ileostomy or colostomy. Discontinue treatment if this occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pigment effects: Caution should be used in individuals demonstrating decreased pigmentation (skin and iris coloration, dark versus light) since there has been some evidence that these individuals have an enhanced sensitivity to the anticholinergic response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with coronary artery disease, tachyarrhythmias, heart failure, or hypertension; evaluate tachycardia prior to administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hiatal hernia: Use with caution in patients with hiatal hernia with reflux.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperthyroidism: Use with caution in patients with hyperthyroidism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Narrow-angle glaucoma: Use with caution in patients with narrow-angle glaucoma; patients using Seebri&reg; Breezhaler&reg; (Canadian availability; not available in U.S.) should avoid getting powder in eyes. Monitor for signs/symptoms of glaucoma and instruct patient to contact healthcare provider immediately with onset of symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuropathy: Use with caution in patients with autonomic neuropathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/bladder neck obstruction: Glycopyrrolate may worsen the symptoms (eg, urinary retention) of prostatic hyperplasia and/or bladder neck obstruction; use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Elimination is severely impaired in renal failure; dosage adjustment may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ulcerative colitis: Use with caution as large doses suppress intestinal motility; may precipitate/exacerbate an ileus or toxic megacolon.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; increased risk for anticholinergic effects, confusion, and hallucinations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Benzyl alcohol: Injection contains benzyl alcohol which has been associated with \"gasping syndrome\" in neonates.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Oral inhaler (Canadian availability; not available in U.S.): Not indicated for the initial (rescue) treatment of acute episodes of bronchospasm or with acutely deteriorating COPD; after initiation of therapy, patients should use short-acting bronchodilators only on an as needed basis for acute symptoms.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F176888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amantadine: May enhance the anticholinergic effect of Glycopyrrolate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atenolol: Glycopyrrolate may increase the serum concentration of Atenolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoids.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Glycopyrrolate may increase the serum concentration of Digoxin. This effect is specific to digoxin administered as slow dissolution oral tablets.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Haloperidol: Glycopyrrolate may decrease the serum concentration of Haloperidol.  Management: Monitor patients closely for signs/symptoms of reduced clinical response to haloperidol if concurrent use with glycopyrrolate is required.  When possible, consider avoiding concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levodopa: Glycopyrrolate may decrease the serum concentration of Levodopa.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetFORMIN: Glycopyrrolate may increase the serum concentration of MetFORMIN.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: Anticholinergic Agents may enhance the therapeutic effect of Mirabegron. This may result in acute urinary retention.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Chloride: Glycopyrrolate may enhance the adverse/toxic effect of Potassium Chloride. This is specific to solid oral dosage forms of potassium chloride.  Management: Concurrent use of solid oral dosage forms of potassium chloride are contraindicated with glycopyrrolate.  Consider using a non-solid oral dosage form or another alternative therapy as appropriate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. Specifically, the risk of oligohidrosis and hyperthermia may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F12747184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Administration with a high-fat meal significantly reduced absorption; administer on an empty stomach.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F176890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (injection) / C (oral solution) (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F744542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. Small amounts of glycopyrrolate cross the human placenta.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F176921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F744543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     May suppress lactation",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F176902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Glycopyrrolate Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.2 mg/mL (1 mL): $1.56",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Robinul Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.2 mg/mL (1 mL): $1.54",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Glycopyrrolate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (100): $131.29",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (100): $219.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Robinul Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (100): $708.58",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Robinul-Forte Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (100): $1081.74",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F176892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Heart rate; anticholinergic effects; bowel sounds; bowel movements; effects on drooling",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral inhalation:  FEV",
"     <sub>",
"      1",
"     </sub>",
"     , peak flow (or other pulmonary function studies)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Acpan (AR);",
"     </li>",
"     <li>",
"      Glyco-P (IN);",
"     </li>",
"     <li>",
"      Glycopyrodyn (TW);",
"     </li>",
"     <li>",
"      Glycopyrrola (KP);",
"     </li>",
"     <li>",
"      Mobinul (KP);",
"     </li>",
"     <li>",
"      Pyrolate (PK);",
"     </li>",
"     <li>",
"      Robinul (JP);",
"     </li>",
"     <li>",
"      Robinul Inj. (AT, AU, BE, CH, DE, DK, FI, GB, GR, IE, NL, NO, NZ, SE);",
"     </li>",
"     <li>",
"      Strodin (KP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F176882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blocks the action of acetylcholine at parasympathetic sites in smooth muscle, secretory glands, and the CNS; indirectly reduces the rate of salivation by preventing the stimulation of acetylcholine receptors",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     In COPD, competitively and reversibly inhibits the action of acetylcholine at muscarinic receptor subtypes 1-3 (greater affinity for subtypes 1 and 3) in bronchial smooth muscle thereby causing bronchodilation",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F176899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Oral powder for inhalation is not available in the U.S.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Oral: 50 minutes; I.M.: 15-30 minutes; I.V.: ~1 minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: Oral: ~1 hour; I.M.: 30-45 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Vagal effect: 2-3 hours; Inhibition of salivation: Up to 7 hours; Anticholinergic: Oral: 8-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral tablet: Poor and erratic; Oral solution: 23% lower compared to tablet; Oral powder for inhalation: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Children: 1.3-1.8 L/kg; Adults: 0.2-0.62 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic (minimal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Tablet: ~1% to 13%; Oral powder for inhalation: ~40%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Infants: 22-130 minutes; Children 19-99 minutes;  Adults: ~60-75 minutes; Oral solution: Adults: 3 hours; Oral powder for inhalation: 13-22 hours (Sechaud, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: Oral powder for inhalation: 5 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (as unchanged drug, I.M.: 80%, I.V.: 85%); bile (as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      D'Urzo A, Ferguson GT, van Noord JA, et al, &ldquo;Efficacy and Safety of Once-Daily NVA237 in Patients With Moderate-to-Severe COPD: The GLOW1 Trial,&rdquo;",
"      <i>",
"       Respir Res",
"      </i>",
"      , 2011, 12:156.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/20/11591/abstract-text/22151296/pubmed\" id=\"22151296\" target=\"_blank\">",
"        22151296",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kerwin E, H&eacute;bert J, Gallagher N, et al, &ldquo;Efficacy and Safety of NVA237 versus Placebo and Tiotropium in Patients With COPD: The GLOW2 Study,&rdquo;",
"      <i>",
"       Eur Respir J",
"      </i>",
"      , 2012, 40(5):1106-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/20/11591/abstract-text/23060624/pubmed\" id=\"23060624\" target=\"_blank\">",
"        23060624",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sechaud R, Renard D, Zhang-Auberson L, et al, &ldquo;Pharmacokinetics of Multiple Inhaled NVA237 Doses in Patients With Chronic Obstructive Pulmonary Disease (COPD),&rdquo;",
"      <i>",
"       Int J Clin Pharmacol Ther",
"      </i>",
"      , 2012, 50(2):118-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/20/11591/abstract-text/22257577/pubmed\" id=\"22257577\" target=\"_blank\">",
"        22257577",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8496 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-D438A33F91-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_20_11591=[""].join("\n");
var outline_f11_20_11591=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176915\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2969522\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176943\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176917\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176932\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176918\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15896378\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15896379\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176894\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16138301\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176879\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176897\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176949\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176896\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7823805\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7913945\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176941\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176900\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176883\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299415\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176888\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12747184\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176890\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F744542\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176921\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F744543\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176902\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176892\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038647\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176882\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176899\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8496\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8496|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?43/0/44036?source=related_link\">",
"      Glycopyrrolate (glycopyrronium): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/4/43078?source=related_link\">",
"      Glycopyrrolate (glycopyrronium): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_20_11592="Role of endothelin in heart failure";
var content_f11_20_11592=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Role of endothelin in heart failure",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/20/11592/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/20/11592/contributors\">",
"     Flora Sam, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/20/11592/contributors\">",
"     Michael M Givertz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/20/11592/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/20/11592/contributors\">",
"     Wilson S Colucci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/20/11592/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/20/11592/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/20/11592/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathophysiology of heart failure (HF) remains incompletely understood. Reduced myocardial contractility and systemic and pulmonary vasoconstriction induced by neurohumoral activation (eg, increased angiotensin II, aldosterone, and norepinephrine) play important roles in the progression of disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32455?source=see_link\">",
"     \"Pathophysiology of heart failure: Neurohumoral adaptations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The improvement in patient survival associated with the use of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers, beta blockers, and aldosterone antagonists provides direct evidence of the long-term deleterious effect of these neurohumoral changes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Circulating levels of endothelin also are increased in patients with HF and may contribute to the progression of left ventricular dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/1\">",
"     1",
"    </a>",
"    ] and the development of secondary pulmonary hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The possible role of endothelin in HF and studies of anti-endothelin therapies will be reviewed here. Unfortunately, while the pathophysiology of HF strongly implicates endothelin in the progression of disease, the promise of endothelin inhibition as a novel therapeutic strategy has not been realized in clinical trials.",
"   </p>",
"   <p>",
"    The role of endothelin receptor antagonists in treatment of pulmonary arterial hypertension is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35210?source=see_link&amp;anchor=H25#H25\">",
"     \"Treatment of pulmonary hypertension in adults\", section on 'Endothelin receptor antagonists'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BIOLOGY AND PHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endothelin (ET) is a 21 amino acid, vasoconstrictor peptide first isolated in 1988 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/4\">",
"     4",
"    </a>",
"    ]. In addition to its direct vasoconstrictor properties, ET can exert long-term effects on vascular smooth muscle cell proliferation and phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Endothelin is synthesized as a large preprohormone (big ET-1) that is cleaved to pro-ET and then undergoes further modification by one of several endothelin converting enzymes to yield mature ET. Three isoforms have been cloned and sequenced: ET-1, ET-2, and ET-3.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ET-1, the predominant isoform synthesized in the human vasculature, is the most potent vasoconstrictor.",
"     </li>",
"     <li>",
"      ET-2 is not found in human plasma but is present in the kidney and intestine where it has vasoconstrictor properties similar to ET-1.",
"     </li>",
"     <li>",
"      ET-3 has minimal vasoconstrictor properties; its major source is unclear, although high concentrations have been found in the developing central nervous system.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Endothelins are rapidly cleared from the circulation by the lung, liver and kidneys [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Endothelin receptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two major endothelin receptors: ET-A and ET-B. Both receptors are expressed on several cells in the cardiovascular system including endothelial cells, vascular smooth muscle cells, cardiac myocytes, and fibroblasts [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/7\">",
"     7",
"    </a>",
"    ]. A third receptor, ET-C, has not yet been isolated in mammals or humans [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/8\">",
"     8",
"    </a>",
"    ]. Polymorphisms of genes encoding the ET receptors may increase the risk of development of cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Understanding the physiologic importance of ET-1 has been greatly aided by the development of ET receptor antagonists [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/10\">",
"     10",
"    </a>",
"    ]. Some of these antagonists are subtype selective (eg, BQ123 for the ET-A receptor) while others are nonselective (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/16/40200?source=see_link\">",
"     bosentan",
"    </a>",
"    ), also referred to as dual-receptor antagonists. Selective ET receptor agonists (eg, sarafotoxin S6c for the ET-B receptor) are also available. As described below, some of these antagonists have undergone clinical investigation as therapy for heart failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Cardiovascular actions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Activation of the ET-A and ET-B receptors appears to produce different hemodynamic effects. In vascular beds, ET-A receptors are located on vascular smooth muscle cells where they mediate both vasoconstriction and smooth muscle cell proliferation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/11\">",
"     11",
"    </a>",
"    ]. In comparison, ET-B receptors are found primarily on vascular endothelial cells and mediate vasodilation via the release of endothelium-derived nitric oxide [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/12\">",
"     12",
"    </a>",
"    ]. ET-B receptors are also located on vascular smooth muscle cells where they mediate vasoconstriction.",
"   </p>",
"   <p>",
"    In humans, the vasoconstrictor actions of ET-1 predominate, resulting in concentration-dependent contraction of systemic and pulmonary arteries. In one study in healthy subjects, for example, selective antagonism of the ET-A receptor caused vasodilation associated with an increase in nitric oxide generation; this response was attenuated by inhibition of nitric oxide synthesis or antagonism of the ET-B receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/13\">",
"     13",
"    </a>",
"    ]. In contrast, stimulation of both ET-A and ET-B receptors mediates vasoconstriction in patients with left ventricular dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/14\">",
"     14",
"    </a>",
"    ]. ET-1 may also play a role in inflammation by increasing vascular permeability, inducing cytokine release, and stimulating production of vascular adhesion molecules [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Effects on myocardium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endothelin is expressed in the myocardium [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/16-18\">",
"     16-18",
"    </a>",
"    ] where it has potent inotropic activity [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. The latter effect is mediated in part by increased sensitivity of the myofilaments to calcium [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. On the other hand, there is some evidence that endothelin may have a negative inotropic effect in the failing heart [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/19\">",
"     19",
"    </a>",
"    ]. In addition, ET-1 may be proarrhythmic in the setting of heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ET-1 is the predominant isoform in the human heart and is largely synthesized by vascular endothelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/18\">",
"     18",
"    </a>",
"    ]; in addition, synthesis can occur in ventricular myocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/24\">",
"     24",
"    </a>",
"    ] and fibroblasts [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/25\">",
"     25",
"    </a>",
"    ]. In normal myocardium, ET-A receptors predominate on cardiac myocytes, whereas ET-B receptors are located primarily on fibroblasts. The density of ET receptors is 1.5 to 2 fold higher in atrial tissue than in ventricular myocardium [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In failing human myocardium, chronic stimulation of ET-A receptors by elevated plasma and myocardial endothelin (see below) results in myocyte hypertrophy and fibroblast proliferation. Receptor density is unchanged or slightly increased [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/22,26\">",
"     22,26",
"    </a>",
"    ], but the functional effects of ET-1 are attenuated [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Myocardial ET-1 synthesis can be stimulated in vitro by hypoxia, ischemia, neurohormones (eg, norepinephrine, angiotensin II, and arginine vasopressin) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/27,28\">",
"     27,28",
"    </a>",
"    ], and inflammatory cytokines (eg, interleukin [IL]-1b) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/29\">",
"     29",
"    </a>",
"    ]. Many of these stimuli are increased in failing human myocardium and may contribute to ventricular remodeling. In a mouse model, cardiac overexpression of ET-1 was associated with increased expression of inflammatory cytokines and the development of a dilated cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By analogy to the tissue renin-angiotensin system, it has been hypothesized that the expression of ET-1 in the myocardium results in high local concentrations of ET-1, which could in turn alter the structure and function of cardiomyocytes and fibroblasts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/43/14008?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in heart failure: Mechanisms of action\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In support of this hypothesis are observations suggesting that ET-1 plays an important role in the cardiac hypertrophic response to pressure or volume overload. This effect appears to be mediated by stress-activated protein kinases (SAPK), as inhibition of the SAPK pathway markedly attenuates the ET-1-induced increase in protein synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Other effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to its actions on the vasculature and myocardium, circulating ET-1 modulates renal function and the activity of the renin-angiotensin and sympathetic nervous systems. In normal humans, ET-1 helps to maintain volume homeostasis, whereas in heart failure, increased circulating levels of ET-1 may contribute to renal vasoconstriction and sodium retention [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/32\">",
"     32",
"    </a>",
"    ]. ET-1 stimulates the secretion of norepinephrine, angiotensin II, and vasopressin [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PLASMA ET IN HEART FAILURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma ET-1 concentrations are generally increased in patients with HF [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/27,34-36\">",
"     27,34-36",
"    </a>",
"    ]. Animal studies suggest that at least part of this increase is mediated by angiotensin II [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/28\">",
"     28",
"    </a>",
"    ]. If this occurs in humans, then part of the beneficial action of ACE inhibitors in HF may be mediated by diminished release of endothelin.",
"   </p>",
"   <p>",
"    In symptomatic patients, resting plasma ET-1 is often two to three times higher than in control subjects. The elevation in plasma big ET-1 and ET-1 in HF is primarily due to increased production, rather than decreased clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/37\">",
"     37",
"    </a>",
"    ]. The increase in production includes enhanced release from the lungs [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/38-40\">",
"     38-40",
"    </a>",
"    ] and myocardial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Plasma ET-1 may also correlate with pulmonary artery pressures and pulmonary vascular resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/34,39\">",
"     34,39",
"    </a>",
"    ]. Whether ET-1 contributes to the development of pulmonary hypertension or is a marker for its presence is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Plasma ET-1 appears to be related to the severity of the heart failure, correlating positively with NYHA class [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/43\">",
"     43",
"    </a>",
"    ] and plasma angiotensin II [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/35\">",
"     35",
"    </a>",
"    ], and negatively with left ventricular ejection fraction and exercise capacity [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Short-term and intermittent outpatient vasodilator therapy (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/16/33029?source=see_link\">",
"     nesiritide",
"    </a>",
"    ) reduces plasma ET-1 levels [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/38,45\">",
"     38,45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Role in prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;To the degree that plasma ET-1 reflects the severity of HF, it might be expected to have some predictive prognostic value. In one series of 120 patients with an ischemic or nonischemic cardiomyopathy, elevated plasma ET-1 (&gt;5",
"    <span class=\"nowrap\">",
"     pg/mL)",
"    </span>",
"    was the most important prognostic marker in patients with left ventricular dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/46\">",
"     46",
"    </a>",
"    ]. Patients with increased plasma ET-1 had a significantly higher one-year mortality than those with normal values (21 versus 4 percent, p = 0.001).",
"   </p>",
"   <p>",
"    Plasma big ET-1 also has predictive value and may improve the short-term prognostic accuracy of VO2max measured during exercise testing. This was illustrated in a report of 226 patients with chronic HF who were stable on oral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/47\">",
"     47",
"    </a>",
"    ]. The one year survival free of death or prioritization for urgent transplant was significantly lower in patients with a serum big ET-1 concentration &ge;4.3",
"    <span class=\"nowrap\">",
"     fmol/mL",
"    </span>",
"    compared with those with lower levels (",
"    <a class=\"graphic graphic_figure graphicRef58488 \" href=\"UTD.htm?14/52/15181\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/47\">",
"     47",
"    </a>",
"    ]. In a multivariate stepwise regression analysis, serum big ET-1 was independently predictive of outcome. In a more recent study that analyzed a panel of neurohormones in patients with severe HF, big ET-1 and ET-1 were found to be superior to natriuretic peptides in predicting long-term survival [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33546?source=see_link\">",
"     \"Predictors of survival in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Plasma ET-1 also may have predictive value in patients with an acute myocardial infarction. In a report of 142 such patients, plasma ET-1 concentrations measured on day three were inversely related to one-year survival [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ET RECEPTOR ANTAGONISTS IN EXPERIMENTAL HF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Animal studies in which endothelin receptor antagonists have been administered after a myocardial infarction and during the development of heart failure provide support for the hypothesis that ET, like angiotensin II, contributes to the progression of HF.",
"   </p>",
"   <p>",
"    In a rat model of chronic HF, for example, the administration of an ET-A receptor antagonist prolonged survival in association with amelioration of left ventricular dysfunction and prevention of remodeling [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/42\">",
"     42",
"    </a>",
"    ]. Other studies have shown similar benefits with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/16/40200?source=see_link\">",
"     bosentan",
"    </a>",
"    or tezosentan, which are dual-receptor (ET-A and ET-B) antagonists [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/42,50-53\">",
"     42,50-53",
"    </a>",
"    ]. The improvement in survival has ranged from 85 versus 43 percent at 12 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/42\">",
"     42",
"    </a>",
"    ] to 65 versus 47 percent at nine months [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These benefits appear to require blockade of the ET-A receptor. As noted above, activation of the ET-B receptors results in vasodilation via the release of nitric oxide [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/12\">",
"     12",
"    </a>",
"    ]. Thus, selective inhibition of the ET-B receptor may have adverse effects on cardiac and renal hemodynamics due to vasoconstriction [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/13,54\">",
"     13,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Animal models also suggest that adverse effects can occur with ET receptor blockade. Early therapy, begun within 24 hours of an infarction had a favorable hemodynamic effect, reducing pulmonary artery pressure, but impaired scar healing and was associated with left ventricular dilatation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/55\">",
"     55",
"    </a>",
"    ]. In dogs with pacing-induced heart failure, early administration of an ET-A receptor antagonist caused further activation of the renin-angiotensin and endothelin systems and sustained sodium and water retention [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ET RECEPTOR ANTAGONISTS IN HUMAN HF",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preceding experimental observations provided the rationale for the administration of endothelin receptor antagonists to patients with HF [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/57\">",
"     57",
"    </a>",
"    ]. A number of uncontrolled and smaller phase II studies showed acute beneficial hemodynamic effects with dual-receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/58-60\">",
"     58-60",
"    </a>",
"    ] and ET-A selective antagonists [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/61-63\">",
"     61-63",
"    </a>",
"    ] in patients with HF. However, a large phase III study testing the effects of intravenous tezosentan (a dual-receptor antagonist) on morbidity and mortality in patients with acute decompensated heart failure was stopped because of lack of efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/64\">",
"     64",
"    </a>",
"    ]. In addition, three large, randomized controlled trials (ENABLE, ENCOR, and EARTH), two of which have only been presented at American College of Cardiology meetings, have shown no benefit of chronic ET receptor blockade in ambulatory patients with heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/65-67\">",
"     65-67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ENABLE trial randomly assigned 1613 patients with NYHA class IIIB or IV heart failure and an EF less than 35 percent who were receiving optimal therapy with diuretics, beta blockers, and ACE inhibitors to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/16/40200?source=see_link\">",
"     bosentan",
"    </a>",
"    (125 mg twice per day), a dual",
"    <span class=\"nowrap\">",
"     (ET-A/ET-B)",
"    </span>",
"    receptor antagonist, or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/65,68\">",
"     65,68",
"    </a>",
"    ]. At one-year follow-up, there was no difference in the primary end point of death and hospitalization for heart failure (39 versus 40 percent for placebo) or all-cause mortality (20 versus 21 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/65\">",
"     65",
"    </a>",
"    ]. These findings were consistent across subgroups. In addition, bosentan increased the risk of excess fluid retention and an adverse event (primarily an increase in hospitalizations for heart failure) during the first four weeks of therapy. Increases in liver transaminases to at least three times the upper limit of normal occurred in 2.7 percent of the placebo group and 9.5 percent of the bosentan-treated patients.",
"   </p>",
"   <p>",
"    A similar lack of clinical benefit was noted in the ENCOR trial in which the dual-receptor antagonist enrasentan was administered for nine months to 419 patients with NYHA class II or III heart failure and an EF less than 35 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/68\">",
"     68",
"    </a>",
"    ]. Enrasentan therapy was associated with a higher rate of adverse effects requiring drug discontinuation (21 versus 8 percent for placebo) and a trend toward increased mortality. There was also a threefold increase in hospitalizations with enrasentan. In patients with asymptomatic LV dysfunction, six-month therapy with enrasentan caused adverse ventricular remodeling despite an increase in cardiac index [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effect of selective ET-A receptor blockade was evaluated in the EARTH trial, in which 642 patients with HF (79 percent NYHA class III) and an EF less than or equal to 35 percent were randomly assigned to one of five doses of darusentan or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/67\">",
"     67",
"    </a>",
"    ]. At 24 weeks, the primary end point (magnetic resonance measured left ventricular end systolic volume) did not change significantly with any dose of darusentan compared to placebo. There were also no significant changes in symptoms, neurohormone concentrations, or clinical outcomes with darusentan. The withdrawal rate due to an adverse effect was 10.5 percent in the darusentan group versus 2.7 percent in placebo-treated patients.",
"   </p>",
"   <p>",
"    In summary, clinical trials of endothelin receptor blockade in heart failure patients have demonstrated no benefit and some evidence of harm. This is in contrast to the role of endothelin receptor antagonists as one class of advanced therapy for patients with group 1 pulmonary arterial hypertension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35210?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment of pulmonary hypertension in adults\", section on 'Advanced therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A potential benefit limited to patients with end-stage heart failure was suggested by a later retrospective study of endothelin receptor antagonist therapy in patients with end-stage heart failure with pulmonary hypertension awaiting cardiac transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ET CONVERTING ENZYME INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative strategy for anti-ET therapy is to block the conversion of pro-ET-1 (big ET-1) to ET-1 with specific endothelin converting enzyme (ECE) inhibitors. Preliminary data in dogs with pacing-induced heart failure suggest that, while selective ET-A receptor antagonism produces a greater degree of systemic and renal vasodilation, ECE inhibition reduces the secretion of neurohumoral factors, including renin, angiotensin II and aldosterone [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data are limited in humans. ECE therapy (alone or in combination with a neutral endopeptidase (NEP) inhibitor) appears to improve hemodynamics, but outcomes have not been evaluated [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. Based on pre-clinical data suggesting benefits of combining an ACE inhibitor with an ECE-NEP inhibitor in heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/74\">",
"     74",
"    </a>",
"    ], triple inhibitors of ECE, ACE, and NEP are also under development [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11592/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2925081\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Circulating levels of endothelin (isoform ET-1) are increased in patients with heart failure and may contribute to the progression of left ventricular dysfunction and the development of secondary pulmonary hypertension. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Biology and physiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Plasma ET in heart failure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ET-A receptors on vascular smooth muscle cells mediate vasoconstriction and smooth muscle cell proliferation. ET-B receptors are found primarily on vascular endothelial cells and mediate vasodilation via the release of endothelium-derived nitric oxide; they are also located on vascular smooth muscle cells where they mediate vasoconstriction. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Cardiovascular actions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The level of plasma ET-1 appears to be a negative prognostic indicator in patients with heart failure. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Role in prognosis'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Studies of endothelin receptor antagonists in animal models of heart failure suggested mortality benefit, although adverse effects were also seen. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'ET receptor antagonists in experimental HF'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical trials have found no benefit from endothelin receptor antagonist administration in patients with NYHA Class II to IV heart failure and reduced ejection fraction, and some evidence of harm including fluid retention and LFT abnormalities. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'ET receptor antagonists in human HF'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/1\">",
"      Rich S, McLaughlin VV. Endothelin receptor blockers in cardiovascular disease. Circulation 2003; 108:2184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/2\">",
"      Moraes DL, Colucci WS, Givertz MM. Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management. Circulation 2000; 102:1718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/3\">",
"      Fang JC, DeMarco T, Givertz MM, et al. World Health Organization Pulmonary Hypertension group 2: pulmonary hypertension due to left heart disease in the adult--a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2012; 31:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/4\">",
"      Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/5\">",
"      Komuro I, Kurihara H, Sugiyama T, et al. Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells. FEBS Lett 1988; 238:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/6\">",
"      Fukuroda T, Fujikawa T, Ozaki S, et al. Clearance of circulating endothelin-1 by ETB receptors in rats. Biochem Biophys Res Commun 1994; 199:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/7\">",
"      Colucci WS. Myocardial endothelin. Does it play a role in myocardial failure? Circulation 1996; 93:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/8\">",
"      Karne S, Jayawickreme CK, Lerner MR. Cloning and characterization of an endothelin-3 specific receptor (ETC receptor) from Xenopus laevis dermal melanophores. J Biol Chem 1993; 268:19126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/9\">",
"      Charron P, Tesson F, Poirier O, et al. Identification of a genetic risk factor for idiopathic dilated cardiomyopathy. Involvement of a polymorphism in the endothelin receptor type A gene. CARDIGENE group. Eur Heart J 1999; 20:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/10\">",
"      L&uuml;scher TF, Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 2000; 102:2434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/11\">",
"      Bialecki RA, Fisher CS, Murdoch WW, et al. Functional comparison of endothelin receptors in human and rat pulmonary artery smooth muscle. Am J Physiol 1997; 272:L211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/12\">",
"      de Nucci G, Thomas R, D'Orleans-Juste P, et al. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci U S A 1988; 85:9797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/13\">",
"      Verhaar MC, Strachan FE, Newby DE, et al. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 1998; 97:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/14\">",
"      Cowburn PJ, Cleland JG, McArthur JD, et al. Endothelin B receptors are functionally important in mediating vasoconstriction in the systemic circulation in patients with left ventricular systolic dysfunction. J Am Coll Cardiol 1999; 33:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/15\">",
"      Teerlink JR. Endothelins: pathophysiology and treatment implications in chronic heart failure. Curr Heart Fail Rep 2005; 2:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/16\">",
"      Nunez DJ, Brown MJ, Davenport AP, et al. Endothelin-1 mRNA is widely expressed in porcine and human tissues. J Clin Invest 1990; 85:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/17\">",
"      Plumpton C, Ashby MJ, Kuc RE, et al. Expression of endothelin peptides and mRNA in the human heart. Clin Sci (Lond) 1996; 90:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/18\">",
"      Ito H, Hirata Y, Hiroe M, et al. Endothelin-1 induces hypertrophy with enhanced expression of muscle-specific genes in cultured neonatal rat cardiomyocytes. Circ Res 1991; 69:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/19\">",
"      MacCarthy PA, Grocott-Mason R, Prendergast BD, Shah AM. Contrasting inotropic effects of endogenous endothelin in the normal and failing human heart: studies with an intracoronary ET(A) receptor antagonist. Circulation 2000; 101:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/20\">",
"      Kr&auml;mer BK, Smith TW, Kelly RA. Endothelin and increased contractility in adult rat ventricular myocytes. Role of intracellular alkalosis induced by activation of the protein kinase C-dependent Na(+)-H+ exchanger. Circ Res 1991; 68:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/21\">",
"      Kelly RA, Eid H, Kr&auml;mer BK, et al. Endothelin enhances the contractile responsiveness of adult rat ventricular myocytes to calcium by a pertussis toxin-sensitive pathway. J Clin Invest 1990; 86:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/22\">",
"      Pieske B, Beyermann B, Breu V, et al. Functional effects of endothelin and regulation of endothelin receptors in isolated human nonfailing and failing myocardium. Circulation 1999; 99:1802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/23\">",
"      Aronson D, Burger AJ. Neurohumoral activation and ventricular arrhythmias in patients with decompensated congestive heart failure: role of endothelin. Pacing Clin Electrophysiol 2003; 26:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/24\">",
"      Thomas PB, Liu EC, Webb ML, et al. Exogenous effects and endogenous production of endothelin in cardiac myocytes: potential significance in heart failure. Am J Physiol 1996; 271:H2629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/25\">",
"      Fujisaki H, Ito H, Hirata Y, et al. Natriuretic peptides inhibit angiotensin II-induced proliferation of rat cardiac fibroblasts by blocking endothelin-1 gene expression. J Clin Invest 1995; 96:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/26\">",
"      P&ouml;nicke K, Vogelsang M, Heinroth M, et al. Endothelin receptors in the failing and nonfailing human heart. Circulation 1998; 97:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/27\">",
"      McMurray JJ, Ray SG, Abdullah I, et al. Plasma endothelin in chronic heart failure. Circulation 1992; 85:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/28\">",
"      Clavell AL, Mattingly MT, Stevens TL, et al. Angiotensin converting enzyme inhibition modulates endogenous endothelin in chronic canine thoracic inferior vena caval constriction. J Clin Invest 1996; 97:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/29\">",
"      Noll G, Wenzel RR, L&uuml;scher TF. Endothelin and endothelin antagonists: potential role in cardiovascular and renal disease. Mol Cell Biochem 1996; 157:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/30\">",
"      Yang LL, Gros R, Kabir MG, et al. Conditional cardiac overexpression of endothelin-1 induces inflammation and dilated cardiomyopathy in mice. Circulation 2004; 109:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/31\">",
"      Choukroun G, Hajjar R, Kyriakis JM, et al. Role of the stress-activated protein kinases in endothelin-induced cardiomyocyte hypertrophy. J Clin Invest 1998; 102:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/32\">",
"      Ding SS, Qiu C, Hess P, et al. Chronic endothelin receptor blockade prevents renal vasoconstriction and sodium retention in rats with chronic heart failure. Cardiovasc Res 2002; 53:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/33\">",
"      Wong NL, Sonntag M, Tsui JK. Attenuation of renal vasopressin V2 receptor upregulation by bosentan, an ETA/ETB receptor antagonist. Metabolism 2003; 52:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/34\">",
"      Cody RJ, Haas GJ, Binkley PF, et al. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 1992; 85:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/35\">",
"      Good JM, Nihoyannopoulos P, Ghatei MA, et al. Elevated plasma endothelin concentrations in heart failure; an effect of angiotensin II? Eur Heart J 1994; 15:1634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/36\">",
"      Lerman A, Kubo SH, Tschumperlin LK, Burnett JC Jr. Plasma endothelin concentrations in humans with end-stage heart failure and after heart transplantation. J Am Coll Cardiol 1992; 20:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/37\">",
"      Parker JD, Thiessen JJ. Increased endothelin-1 production in patients with chronic heart failure. Am J Physiol Heart Circ Physiol 2004; 286:H1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/38\">",
"      Stangl K, Dschietzig T, Richter C, et al. Pulmonary release and coronary and peripheral consumption of big endothelin and endothelin-1 in severe heart failure: acute effects of vasodilator therapy. Circulation 2000; 102:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/39\">",
"      Tsutamoto T, Wada A, Maeda Y, et al. Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure. J Am Coll Cardiol 1994; 23:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/40\">",
"      Dupuis J, Stewart DJ, Cernacek P, Gosselin G. Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation 1996; 94:1578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/41\">",
"      Sakai S, Miyauchi T, Sakurai T, et al. Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure. Marked increase in endothelin-1 production in the failing heart. Circulation 1996; 93:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/42\">",
"      Sakai S, Miyauchi T, Kobayashi M, et al. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 1996; 384:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/43\">",
"      Wei CM, Lerman A, Rodeheffer RJ, et al. Endothelin in human congestive heart failure. Circulation 1994; 89:1580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/44\">",
"      Krum H, Goldsmith R, Wilshire-Clement M, et al. Role of endothelin in the exercise intolerance of chronic heart failure. Am J Cardiol 1995; 75:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/45\">",
"      Yancy CW, Saltzberg MT, Berkowitz RL, et al. Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting (from the FUSION I trial). Am J Cardiol 2004; 94:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/46\">",
"      Pousset F, Isnard R, Lechat P, et al. Prognostic value of plasma endothelin-1 in patients with chronic heart failure. Eur Heart J 1997; 18:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/47\">",
"      H&uuml;lsmann M, Stanek B, Frey B, et al. Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure. J Am Coll Cardiol 1998; 32:1695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/48\">",
"      Van Beneden R, Gurn&eacute; O, Selvais PL, et al. Superiority of big endothelin-1 and endothelin-1 over natriuretic peptides in predicting survival in severe congestive heart failure: a 7-year follow-up study. J Card Fail 2004; 10:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/49\">",
"      Omland T, Lie RT, Aakvaag A, et al. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 1994; 89:1573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/50\">",
"      Mulder P, Richard V, Derumeaux G, et al. Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation 1997; 96:1976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/51\">",
"      Fraccarollo D, Hu K, Galuppo P, et al. Chronic endothelin receptor blockade attenuates progressive ventricular dilation and improves cardiac function in rats with myocardial infarction: possible involvement of myocardial endothelin system in ventricular remodeling. Circulation 1997; 96:3963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/52\">",
"      Mishima T, Tanimura M, Suzuki G, et al. Effects of long-term therapy with bosentan on the progression of left ventricular dysfunction and remodeling in dogs with heart failure. J Am Coll Cardiol 2000; 35:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/53\">",
"      Clozel M, Qiu C, Qiu CS, et al. Short-term endothelin receptor blockade with tezosentan has both immediate and long-term beneficial effects in rats with myocardial infarction. J Am Coll Cardiol 2002; 39:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/54\">",
"      Wada A, Tsutamoto T, Fukai D, et al. Comparison of the effects of selective endothelin ETA and ETB receptor antagonists in congestive heart failure. J Am Coll Cardiol 1997; 30:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/55\">",
"      Nguyen QT, Cernacek P, Calderoni A, et al. Endothelin A receptor blockade causes adverse left ventricular remodeling but improves pulmonary artery pressure after infarction in the rat. Circulation 1998; 98:2323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/56\">",
"      Schirger JA, Chen HH, Jougasaki M, et al. Endothelin A receptor antagonism in experimental congestive heart failure results in augmentation of the renin-angiotensin system and sustained sodium retention. Circulation 2004; 109:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/57\">",
"      Spieker LE, Noll G, Ruschitzka FT, L&uuml;scher TF. Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future? J Am Coll Cardiol 2001; 37:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/58\">",
"      Kiowski W, S&uuml;tsch G, Hunziker P, et al. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet 1995; 346:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/59\">",
"      Torre-Amione G, Young JB, Colucci WS, et al. Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2003; 42:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/60\">",
"      S&uuml;tsch G, Kiowski W, Yan XW, et al. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation 1998; 98:2262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/61\">",
"      Givertz MM, Colucci WS, LeJemtel TH, et al. Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure. Circulation 2000; 101:2922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/62\">",
"      L&uuml;scher TF, Enseleit F, Pacher R, et al. Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT). Circulation 2002; 106:2666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/63\">",
"      Bergler-Klein J, Pacher R, Berger R, et al. Neurohumoral and hemodynamic effects of the selective endothelin antagonist darusentan in advanced chronic heart failure. J Heart Lung Transplant 2004; 23:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/64\">",
"      McMurray JJ, Teerlink JR, Cotter G, et al. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA 2007; 298:2009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/65\">",
"      Cleland JG, Coletta AP, Freemantle N, et al. Clinical trials update from the American College of Cardiology meeting: CARE-HF and the remission of heart failure, Women's Health Study, TNT, COMPASS-HF, VERITAS, CANPAP, PEECH and PREMIER. Eur J Heart Fail 2005; 7:931.",
"     </a>",
"    </li>",
"    <li>",
"     Data presented at American College of Cardiology 51st Annual Session, Atlanta, Georgia, 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/67\">",
"      Anand I, McMurray J, Cohn JN, et al. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/68\">",
"      Teerlink JR. Recent heart failure trials of neurohormonal modulation (OVERTURE and ENABLE): approaching the asymptote of efficacy? J Card Fail 2002; 8:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/69\">",
"      Prasad SK, Dargie HJ, Smith GC, et al. Comparison of the dual receptor endothelin antagonist enrasentan with enalapril in asymptomatic left ventricular systolic dysfunction: a cardiovascular magnetic resonance study. Heart 2006; 92:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/70\">",
"      Hefke T, Zittermann A, Fuchs U, et al. Bosentan effects on hemodynamics and clinical outcome in heart failure patients with pulmonary hypertension awaiting cardiac transplantation. Thorac Cardiovasc Surg 2012; 60:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/71\">",
"      Wada A, Tsutamoto T, Ohnishi M, et al. Effects of a specific endothelin-converting enzyme inhibitor on cardiac, renal, and neurohumoral functions in congestive heart failure: comparison of effects with those of endothelin A receptor antagonism. Circulation 1999; 99:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/72\">",
"      Love MP, Haynes WG, Gray GA, et al. Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors. Circulation 1996; 94:2131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/73\">",
"      Dickstein K, De Voogd HJ, Miric MP, et al. Effect of single doses of SLV306, an inhibitor of both neutral endopeptidase and endothelin-converting enzyme, on pulmonary pressures in congestive heart failure. Am J Cardiol 2004; 94:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/74\">",
"      Mellin V, Jeng AY, Monteil C, et al. Triple ACE-ECE-NEP inhibition in heart failure: a comparison with ACE and dual ECE-NEP inhibition. J Cardiovasc Pharmacol 2005; 46:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11592/abstract/75\">",
"      Battistini B, Daull P, Jeng AY. CGS 35601, a triple inhibitor of angiotensin converting enzyme, neutral endopeptidase and endothelin converting enzyme. Cardiovasc Drug Rev 2005; 23:317.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3469 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-1.234.2.38-C3DAD56939-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_20_11592=[""].join("\n");
var outline_f11_20_11592=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2925081\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BIOLOGY AND PHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Endothelin receptors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Cardiovascular actions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Effects on myocardium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Other effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PLASMA ET IN HEART FAILURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Role in prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ET RECEPTOR ANTAGONISTS IN EXPERIMENTAL HF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ET RECEPTOR ANTAGONISTS IN HUMAN HF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ET CONVERTING ENZYME INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2925081\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3469\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3469|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/52/15181\" title=\"figure 1\">",
"      Big endothelin outcome HF",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/43/14008?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in heart failure: Mechanisms of action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32455?source=related_link\">",
"      Pathophysiology of heart failure: Neurohumoral adaptations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33546?source=related_link\">",
"      Predictors of survival in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35210?source=related_link\">",
"      Treatment of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_20_11593="Causes of acute abdominal pain in children and adolescents";
var content_f11_20_11593=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Causes of acute abdominal pain in children and adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/20/11593/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/20/11593/contributors\">",
"     George D Ferry, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/20/11593/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/20/11593/contributors\">",
"     Gary R Fleisher, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/20/11593/contributors\">",
"     Jan E Drutz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/20/11593/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/20/11593/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/20/11593/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal pain is one of the most common complaints in childhood and one that frequently requires urgent evaluation in the office or emergency department. The cause is typically a self-limited minor condition, such as constipation, gastroenteritis, or viral syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11593/abstract/1\">",
"     1",
"    </a>",
"    ]. The challenge for the clinician is to identify those patients with abdominal pain who have either serious, potentially life-threatening conditions, such as appendicitis or bowel obstruction (as can occur from volvulus, intussusception, or adhesions), or infections that require specific treatment (ie, streptococcal pharyngitis or pneumonia) (",
"    <a class=\"graphic graphic_table graphicRef65488 \" href=\"UTD.htm?28/20/29005\">",
"     table 1",
"    </a>",
"    ). The likely diagnosis is often suggested by the child's age and clinical features (ie, associated symptoms, past medical history, and physical examination).",
"   </p>",
"   <p>",
"    The causes of acute abdominal pain in children will be discussed in this review. The emergent evaluation of children with acute abdominal pain and the evaluation and management of children with chronic abdominal pain are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/61/22490?source=see_link\">",
"     \"Emergent evaluation of the child with acute abdominal pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/17/1306?source=see_link\">",
"     \"Evaluation of the child and adolescent with chronic abdominal pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NEUROLOGIC BASIS OF ABDOMINAL PAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain receptors in the abdomen include visceral receptors (located on serosal surfaces, within the mesentery, and within the walls of hollow viscera) and mucosal receptors. Visceral receptors respond to mechanical and chemical stimuli whereas mucosal receptors respond primarily to chemical stimuli.",
"   </p>",
"   <p>",
"    Visceral pain is usually poorly localized. Most visceral digestive tract pain is perceived in the midline because of bilaterally symmetric innervation. In some conditions, such as appendicitis, precise localization of the pain may develop once the overlying parietal peritoneum (which is somatically innervated) becomes inflamed.",
"   </p>",
"   <p>",
"    Pain originating in the viscera may sometimes be perceived as originating from a site distant from the affected organ. Referred pain usually is located in the cutaneous dermatomes sharing the same spinal cord level as the visceral inputs.",
"   </p>",
"   <p>",
"    The neurologic basis of abdominal pain is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/30/16874?source=see_link&amp;anchor=H2#H2\">",
"     \"Differential diagnosis of abdominal pain in adults\", section on 'Neurologic basis of abdominal pain'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     LIFE-THREATENING CAUSES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with abdominal pain who have sustained trauma must be carefully evaluated for intraabdominal injuries. Mechanisms typically associated with significant injury (ie, solid organ laceration or perforated viscus) include motor vehicle collisions, motor vehicle pedestrian collisions, falls, and child abuse. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33768?source=see_link\">",
"     \"Overview of blunt abdominal trauma in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Appendicitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The three most predictive clinical features of appendicitis are pain in the right lower quadrant, abdominal wall rigidity, and migration of periumbilical pain to the right lower quadrant. However, at least one of these manifestations is frequently absent, particularly in younger children. Clinicians should therefore consider the diagnosis of appendicitis in all cases of previously healthy children who have a history of abdominal pain and vomiting, with or without fever or focal abdominal tenderness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/3/32826?source=see_link&amp;anchor=H5#H5\">",
"     \"Acute appendicitis in children: Clinical manifestations and diagnosis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Intussusception",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with intussusception (invagination of a part of the intestine into itself, causing obstruction) are typically two months to two years of age and present with characteristic pain that develops suddenly, is intermittent, severe, and classically accompanied by inconsolable crying with drawing up of the legs toward the abdomen. Bilious emesis may develop as the obstruction progresses.",
"   </p>",
"   <p>",
"    Between the painful episodes, the child may behave normally. Initial symptoms can be confused with gastroenteritis. Lethargy or altered consciousness can be the primary symptom of intussusception, especially in infants. Most children have gross or occult blood in the stool. Presentations may be variable, however, with some children having no apparent pain or blood in the stool. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35145?source=see_link&amp;anchor=H9#H9\">",
"     \"Intussusception in children\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Malrotation with midgut volvulus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonates may have emesis (bilious or nonbilious) with apparent abdominal discomfort as the result of midgut volvulus (",
"    <a class=\"graphic graphic_figure graphicRef78111 \" href=\"UTD.htm?28/19/28977\">",
"     figure 1",
"    </a>",
"    ). Over 50 percent of children with malrotation present before one month of age with this life-threatening complication. Among older children with volvulus from malrotation, the onset of symptoms is usually acute, but some children present with more chronic patterns of episodic vomiting and abdominal pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/48/20232?source=see_link&amp;anchor=H8#H8\">",
"     \"Intestinal malrotation\", section on 'Volvulus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Incarcerated inguinal hernia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants with incarcerated inguinal hernias are usually irritable and crying. Vomiting and abdominal distention may develop, depending on the duration of incarceration and whether or not intestinal obstruction has occurred. On physical examination, a firm, discrete inguinal mass, which may extend to the scrotum or labia majora, can be palpated in the groin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/3/21561?source=see_link&amp;anchor=H18#H18\">",
"     \"Overview of inguinal hernia in children\", section on 'Incarcerated mass'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Adhesions with intestinal obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with abdominal pain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vomiting who have had previous abdominal surgery may have small bowel obstruction (SBO) as the result of adhesions. Shock (from hypovolemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sepsis) can develop as the result of ischemic bowel injury.",
"   </p>",
"   <p>",
"    In retrospective series describing children who had abdominal surgery, 1 to 2 percent developed adhesions within five years of surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11593/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Excluding children who underwent appendectomy increased the frequency of adhesions to 5.3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11593/abstract/3\">",
"     3",
"    </a>",
"    ]. Factors associated with the development of adhesions in these series included multiple procedures, peritonitis, and surgery on the ileum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Necrotizing enterocolitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Newborns who develop necrotizing enterocolitis (NEC), a syndrome of intestinal necrosis, typically have vomiting, abdominal distention, and tenderness. Systemic signs include apnea, respiratory failure, lethargy, poor feeding, temperature instability, or hypotension resulting from septic shock in the most severe cases. Although the majority of affected infants are born prematurely, rarely normal term infants, and slightly more often those with conditions, such as congenital heart disease or protracted diarrhea, may develop NEC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/39/41591?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical features and diagnosis of necrotizing enterocolitis in newborns\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Peptic ulcer disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peptic ulcer disease (PUD) that is complicated by severe hemorrhage or perforation is an uncommon cause of life-threatening abdominal pain among children. The clinical manifestations vary by age. Vomiting, hemorrhage, and perforation are more commonly seen in young children, while older children and teens have a presentation similar to adults. PUD related to Helicobacter pylori is relatively uncommon in children compared with adults [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11593/abstract/4\">",
"     4",
"    </a>",
"    ]. In children younger than 6 to 10 years of age, peptic ulcers are often due to medications (corticosteroids or NSAIDs) or major stresses.",
"   </p>",
"   <p>",
"    Idiopathic PUD (caused by neither H. pylori infection nor medications) appears to be more common than previously thought, at least in some populations. In children with PUD in China and Italy, about half were determined to be idiopathic [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11593/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. These findings are similar to those reported in adult populations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Ectopic pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ectopic pregnancy must be considered in the diagnosis of abdominal pain for postmenarchal girls. Abdominal pain, amenorrhea, and vaginal bleeding are the classic symptoms, with or without rupture. Life-threatening hemorrhage can occur with rupture. Symptoms typically appear six to eight weeks after a missed menstrual period. Risk factors include previous genital infection and previous ectopic pregnancy (",
"    <a class=\"graphic graphic_table graphicRef82282 \" href=\"UTD.htm?10/38/10860\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1178?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and management of ectopic pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Uncommon life-threatening causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following unusual life-threatening causes of abdominal pain generally have other distinguishing clinical features:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diabetic ketoacidosis (DKA) is a life-threatening condition that usually presents with polyuria, polydipsia, and glycosuria, but may also present with abdominal pain and vomiting, especially in young children. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/32/41480?source=see_link&amp;anchor=H9#H9\">",
"       \"Clinical features and diagnosis of diabetic ketoacidosis in children\", section on 'Signs and symptoms'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hirschsprung associated enterocolitis (HAEC) is an uncommon, fulminant complication of Hirschsprung disease. Children typically have explosive diarrhea, fever, and abdominal pain. HAEC can occur prior to surgical intervention, in the immediate postoperative period, or more than two years after definitive repair. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/8/34950?source=see_link&amp;anchor=H5#H5\">",
"       \"Emergency complications of Hirschsprung disease\", section on 'Enterocolitis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hemolytic uremic syndrome (HUS) typically develops after an infection with Shiga toxin-producing enterohemorrhagic E. coli (EHEC) or Shigella (",
"      <a class=\"graphic graphic_figure graphicRef75352 \" href=\"UTD.htm?28/53/29534\">",
"       figure 2",
"      </a>",
"      ). HUS has also been associated with pneumococcal infection, HIV, and genetic factors. Clinical and laboratory features of HUS include bloody diarrhea, hemolytic anemia, thrombocytopenia, and acute renal injury manifested by elevated blood urea nitrogen. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35704?source=see_link\">",
"       \"Clinical manifestations and diagnosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/52/43849?source=see_link\">",
"       \"Atypical hemolytic uremic syndrome in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Primary bacterial peritonitis, usually caused by Streptococcus pneumoniae or E. coli, is a life-threatening infectious complication of nephrotic syndrome and occasionally other conditions that cause ascites (eg, cirrhosis of the liver). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25974?source=see_link&amp;anchor=H3#H3\">",
"       \"Complications of idiopathic nephrotic syndrome in children\", section on 'Bacterial infection'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Myocarditis may cause abdominal pain as the result of passive hepatic congestion from heart failure. Pericarditis may cause referred abdominal pain. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34647?source=see_link\">",
"       \"Clinical manifestations and diagnosis of myocarditis in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Case reports have described children who have developed volvulus and bowel perforation following ingestion of small rare-earth magnets. Injury occurs when objects become magnetically attached to each other across bowel wall. Symptoms are nonspecific and typically include abdominal pain. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/22/1386?source=see_link&amp;anchor=H20#H20\">",
"       \"Foreign bodies of the esophagus and gastrointestinal tract in children\", section on 'Magnets'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     COMMON CAUSES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Constipation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with constipation can present with rectal impaction and, at times, severe lower, colicky abdominal pain. In a series of 83 children presenting to primary care providers or an emergency department with acute abdominal pain, acute or chronic constipation was the most common underlying cause, occurring in 48 percent of subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11593/abstract/7\">",
"     7",
"    </a>",
"    ]. In many cases, rectal examination was a key step in establishing the diagnosis.",
"   </p>",
"   <p>",
"    Constipation is likely in children with at least two of the following characteristics: fewer than three stools weekly, fecal incontinence (usually related to encopresis), large stools palpable in the rectum or through the abdominal wall, retentive posturing, or painful defecation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11593/abstract/7\">",
"     7",
"    </a>",
"    ]. Parents may not recognize the relationship of constipation to the child's abdominal pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/63/15354?source=see_link\">",
"     \"Constipation in children: Etiology and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/9/44182?source=see_link\">",
"     \"Definition, clinical manifestations, and evaluation of functional fecal incontinence in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Gastrointestinal infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with acute gastroenteritis may develop fever, severe cramping abdominal pain, and diffuse abdominal tenderness before diarrhea begins [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11593/abstract/8\">",
"     8",
"    </a>",
"    ]. While the severity of the pain can mimic other more serious conditions (ie, appendicitis), the onset of diarrhea generally clarifies the etiology. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/13/13529?source=see_link\">",
"     \"Evaluation of diarrhea in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/56/14216?source=see_link\">",
"     \"Epidemiology, pathogenesis, clinical presentation and diagnosis of viral gastroenteritis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Yersinia enterocolitica gastroenteritis can cause focal right lower quadrant pain and peritoneal signs that are clinically indistinguishable from appendicitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/63/41974?source=see_link&amp;anchor=H89479916#H89479916\">",
"     \"Clinical manifestations and diagnosis of Yersinia infections\", section on 'Pseudoappendicitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Other infections",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Urinary tract infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal pain and fever are the most common presenting symptoms of urinary tract infection for children two to five years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11593/abstract/9\">",
"     9",
"    </a>",
"    ]. Infants may also have vomiting or anorexia, while children &gt;5 years of age are more likely to have classic symptoms, such as dysuria, frequency,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    flank discomfort. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21129?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical features and diagnosis of urinary tract infections in infants and children older than one month\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Streptococcal pharyngitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with group A beta hemolytic streptococcal (GABHS) pharyngitis may have abdominal pain in addition to fever and exudative pharyngitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41417?source=see_link&amp;anchor=H18#H18\">",
"     \"Approach to diagnosis of acute infectious pharyngitis in children and adolescents\", section on 'Clinical predictors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with pharyngitis from causes other than GABHS can also have abdominal pain. This was demonstrated in one observational series describing children presenting to an emergency department with suspected GABHS pharyngitis in which 25 percent of those with throat cultures positive for GABHS and 34 percent of those with negative throat cultures had abdominal pain [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11593/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with pneumonia, particularly in the lower lobes, may complain of abdominal pain [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11593/abstract/11\">",
"     11",
"    </a>",
"    ]. Associated symptoms usually include fever, tachypnea,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cough. Auscultation of the lungs may demonstrate focal abnormalities (ie, decreased breath sounds or crackles), although some children with pneumonia may have normal breath sounds on examination. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical features and diagnosis of community-acquired pneumonia in children\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Viral illnesses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viral illnesses other than gastroenteritis (ie, viral pharyngitis and upper respiratory tract infection) are also associated with abdominal pain [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11593/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. History of fever, cough, sore throat,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    rhinorrhea may also be reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Pelvic inflammatory disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pelvic inflammatory disease (PID), an acute infection of the upper female genital tract, may be the cause of lower abdominal pain in sexually active girls. Pain often begins during or shortly after menses. There may be vaginal discharge. Rarely, sepsis and tuboovarian abscess are life-threatening complications of PID. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/0/1032?source=see_link\">",
"     \"Clinical features and diagnosis of pelvic inflammatory disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36823?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of tuboovarian abscess\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Mesenteric lymphadenitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mesenteric lymphadenitis is an inflammatory condition of the mesenteric lymph nodes that can present with acute or chronic abdominal pain. Because the nodes are usually in the right lower quadrant, mesenteric lymphadenitis sometimes mimics appendicitis. In one series of 70 children with clinically suspected acute appendicitis, 16 percent had a final diagnosis of mesenteric lymphadenitis established by ultrasound, clinical course, or surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11593/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mesenteric lymphadenitis is diagnosed by an ultrasound that shows abdominal lymph nodes greater than 10 mm. The presence of enlarged lymph nodes on diagnostic imaging does not, by itself, exclude a diagnosis of appendicitis; it is necessary to demonstrate a normal appendix as well [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11593/abstract/15\">",
"     15",
"    </a>",
"    ]. Etiologies of mesenteric lymphadenitis include viral and bacterial gastroenteritis (eg, Yersinia enterocolitica), Group A Streptococcal pharyngitis, inflammatory bowel disease, and lymphoma; viral infection is most common. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/63/41974?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Yersinia infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/3/32826?source=see_link&amp;anchor=H26#H26\">",
"     \"Acute appendicitis in children: Clinical manifestations and diagnosis\", section on 'Other nonsurgical diagnoses'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Ruptured ovarian cyst",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute severe pain simulating appendicitis or peritonitis may result from rupture of an ovarian cyst. Usually, the patient is stable. Rarely, life-threatening hemorrhage develops. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/34/21033?source=see_link\">",
"     \"Ovarian cysts and neoplasms in infants, children, and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Foreign body ingestion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Young children commonly ingest small, smooth, nonfood objects that are usually eliminated without difficulty once they have passed through the pylorus. Abdominal pain in children who have ingested foreign bodies, particularly objects that are sharp (which may perforate the bowel) or &gt;5 cm in length (which may cause obstruction), multiple magnets (which may lead to entrapment of a piece of bowel wall between two magnets that are attracted to each other), or button batteries (which may release caustic material) warrant emergent evaluation for obstruction or perforation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15337?source=see_link\">",
"     \"Button and cylindrical battery ingestion\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/22/1386?source=see_link\">",
"     \"Foreign bodies of the esophagus and gastrointestinal tract in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Colic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants with colic, particularly those with hypertonic characteristics, may appear to have abdominal pain (",
"    <a class=\"graphic graphic_table graphicRef78133 \" href=\"UTD.htm?4/13/4315\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/27/10680?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical features and etiology of colic\", section on 'Colic'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other clinical features that suggest the diagnosis of colic include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A typical pattern of paroxysmal crying",
"     </li>",
"     <li>",
"      Crying usually in the evening",
"     </li>",
"     <li>",
"      Crying relieved with the passage of flatus or stool",
"     </li>",
"     <li>",
"      Normal feeding",
"     </li>",
"     <li>",
"      No associated symptoms",
"     </li>",
"     <li>",
"      Normal physical examination",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     OTHER CAUSES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Gastrointestinal",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inflammatory bowel disease (more often Crohn disease than ulcerative colitis) can present with intermittent abdominal pain. Associated features may include diarrhea and weight loss. Although the onset of symptoms for children with ulcerative colitis is usually subacute, a fulminant presentation with severe abdominal pain, bloody diarrhea, tenesmus, and fever can occur. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/7/24693?source=see_link&amp;anchor=H2#H2\">",
"       \"Clinical manifestations of Crohn's disease in children and adolescents\", section on 'Overview'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4650?source=see_link&amp;anchor=H2#H2\">",
"       \"Treatment of ulcerative colitis in children and adolescents\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pancreatitis generally causes acute upper abdominal pain (usually in the mid-epigastrium or right upper quadrant) at the onset, which may radiate to the back. Vomiting (that may be bilious) and fever also occur commonly. Causes of pancreatitis among children include trauma, infection, structural anomalies, and some medications (ie,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/38/28262?source=see_link\">",
"       tetracycline",
"      </a>",
"      , L-asparaginase, valproic acid, and steroids) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/20/11593/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/5/20569?source=see_link\">",
"       \"Clinical manifestations and diagnosis of acute pancreatitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acute cholecystitis typically causes pain in the right upper quadrant or epigastrium. Pain may radiate to the right shoulder or back. Associated complaints include nausea, vomiting, and anorexia. Cholecystitis is uncommon among children, and most have predisposing conditions, such as hemoglobinopathies or cystic fibrosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29208?source=see_link\">",
"       \"Pathogenesis, clinical features, and diagnosis of acute cholecystitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Intraabdominal abscess can cause abdominal pain. Children are typically febrile and may have histories of prior intraabdominal disease or abdominal surgery. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38905?source=see_link&amp;anchor=H17#H17\">",
"       \"Etiologies of fever of unknown origin in children\", section on 'Intraabdominal abscess'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Dietary protein allergy can be associated with irritability that parents may interpret as abdominal pain. Infants typically pass blood-tinged stools and mucus, but do not have diarrhea. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34631?source=see_link&amp;anchor=H2#H2\">",
"       \"Food protein-induced proctitis/colitis and enteropathy of infancy\", section on 'Food protein-induced proctitis/proctocolitis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Malabsorption (such as occurs with celiac disease and carbohydrate malabsorption) may cause recurrent abdominal pain. Children with celiac disease typically have chronic diarrhea, anorexia, and weight loss. Some may also have vomiting. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37946?source=see_link&amp;anchor=H15#H15\">",
"       \"Clinical manifestations and diagnosis of celiac disease in children\", section on 'Gastrointestinal symptoms'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/17/1306?source=see_link&amp;anchor=H11#H11\">",
"       \"Evaluation of the child and adolescent with chronic abdominal pain\", section on 'Organic disorders'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Meckel's diverticulum usually presents with painless rectal bleeding. Abdominal pain may develop as the result of mucosal ulceration (from ectopic gastric tissue) with perforation or from bowel obstruction [",
"      <a class=\"abstract\" href=\"UTD.htm?11/20/11593/abstract/18\">",
"       18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29513?source=see_link&amp;anchor=H19#H19\">",
"       \"Diagnostic approach to lower gastrointestinal bleeding in children\", section on 'Meckel's diverticulum'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Abdominal migraine (included in childhood periodic syndromes) often presents with acute onset of abdominal pain that is periumbilical (78 percent), or occasionally more diffuse (16 percent). It is more common after age seven years. The pain is often incapacitating, with or without vomiting and headache. A family history of migraine is common. Since this condition is a recurrent problem, there may be a history of similar presentations. The first episode must be differentiated from gastrointestinal and other non-gastrointestinal causes of acute onset abdominal pain. Physical examination may be normal or reveal mild abdominal discomfort. Blood work and imaging studies are usually normal. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/21/42327?source=see_link&amp;anchor=H12#H12\">",
"       \"Classification of migraine in children\", section on 'Abdominal migraine'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Wandering spleen refers to acquired laxity or congenital underdevelopment or absence of the primary ligamentous attachments of the spleen in the left upper quadrant [",
"      <a class=\"abstract\" href=\"UTD.htm?11/20/11593/abstract/19\">",
"       19",
"      </a>",
"      ]. As a result, patients are at increased risk of splenic torsion and infarction. Wandering spleen is most commonly seen in children and is associated with congenital diaphragmatic hernia, prune-belly syndrome, renal agenesis, and gastric volvulus. It typically presents with acute, diffuse, severe abdominal pain. Patients may also have an abdominal mass which is mobile to the left upper quadrant and may have a crenated border. Ultrasound is most helpful in establishing a preoperative diagnosis and can assess adequacy of splenic perfusion. According to case series, approximately two-thirds of patients require splenectomy. Early diagnosis allows for splenopexy and preservation of splenic function.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Nongastrointestinal",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Henoch-Sch&ouml;nlein purpura (HSP [IgA vasculitis (IgAV)] ) is a systemic vasculitis affecting small vessels in skin, gut, and glomeruli that may present with colicky abdominal pain (presumably due to local vasculitis). Pain typically develops after the appearance of a characteristic purpuric rash involving predominantly the lower extremities and buttocks (",
"      <a class=\"graphic graphic_picture graphicRef63367 graphicRef72094 \" href=\"UTD.htm?26/46/27367\">",
"       picture 1A-B",
"      </a>",
"      ). Stool often contains gross or occult blood. Rare complications of HSP (IgAV) that can cause abdominal pain include intussusception (typically in the ileum), pancreatitis, and cholecystitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40729?source=see_link\">",
"       \"Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hepatitis typically causes jaundice, mild abdominal pain, and fever, but young children in particular may be afebrile",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      anicteric. The incidence of hepatitis A and B infections among children has declined since the introduction of effective vaccines. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16295?source=see_link\">",
"       \"Overview of hepatitis A virus infection in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/41/31386?source=see_link\">",
"       \"Overview of hepatitis B virus infection in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/18/34090?source=see_link\">",
"       \"Approach to the patient with abnormal liver biochemical and function tests\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Sickle cell syndromes are typically associated with acute painful episodes that may manifest as abdominal pain. Patients must always be carefully evaluated for other causes of abdominal pain. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=see_link&amp;anchor=H14#H14\">",
"       \"Overview of the clinical manifestations of sickle cell disease\", section on 'Acute painful episodes'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/5/5209?source=see_link\">",
"       \"Variant sickle cell syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Malignant solid tumors may present with abdominal pain and abdominal mass. Wilms' tumor and neuroblastoma occur more commonly in infants, whereas leukemic or lymphomatous involvement of the liver, spleen, or retroperitoneal lymph nodes occurs more often in older children. Other causes include hepatic tumors, ovarian tumors, Burkitt lymphoma, and soft tissue sarcomas. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/47/5882?source=see_link&amp;anchor=H17#H17\">",
"       \"Clinical assessment of the child with suspected cancer\", section on 'Abdominal masses'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Urolithiasis &ndash; Nonspecific abdominal pain is typical as a presenting feature of urolithiasis among young children. In comparison, adolescents are more likely to experience colicky flank pain [",
"      <a class=\"abstract\" href=\"UTD.htm?11/20/11593/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]. Hematuria and urinary tract infection are other frequent manifestations of urolithiasis among children.",
"     </li>",
"     <li>",
"      Testicular torsion causes scrotal pain that may radiate to the abdomen. Patients may have associated nausea, vomiting, and fever. The affected testis usually is tender, swollen, and slightly elevated because of shortening of the cord from twisting. It may be lying horizontally, displacing the epididymis from its normal posterolateral position. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/39/32376?source=see_link&amp;anchor=H2#H2\">",
"       \"Causes of scrotal pain in children and adolescents\", section on 'Testicular torsion'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ovarian torsion typically develops as the result of an ovarian mass or cyst, but can develop in normal ovaries. Nausea and vomiting frequently occur. Partial or intermittent ovarian torsion may present as intermittent abdominal pain. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/8/23690?source=see_link\">",
"       \"Ovarian and fallopian tube torsion\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Toxins that are associated with abdominal pain include lead and iron. Lead poisoning is usually the result of chronic ingestion and causes intermittent abdominal pain. In comparison, iron poisoning is typically an acute ingestion with other gastrointestinal symptoms, such as vomiting and diarrhea. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/24/394?source=see_link\">",
"       \"Childhood lead poisoning: Clinical manifestations and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/57/2970?source=see_link\">",
"       \"Acute iron poisoning\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acute porphyrias present with a variety of nonspecific neurovisceral symptoms (eg, abdominal pain, psychiatric disorders, neurologic symptoms), the most common of which is abdominal pain. These can include potentially life-threatening neurological effects (eg, seizures, coma, bulbar paralysis) and are associated with elevations in the porphyrin precursors delta-aminolevulinic acid (ALA) and porphobilinogen (PBG). Symptoms usually occur as acute attacks, but are sometimes chronic. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10439?source=see_link&amp;anchor=H2#H2\">",
"       \"Clinical manifestations and diagnosis of acute intermittent porphyria\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Familial Mediterranean fever is characterized by episodic attacks of fever lasting one to three days and accompanied in most cases by abdominal pain, pleurisy, and arthralgias or arthritis, the result of accompanying serositis and synovitis. Attacks are accompanied by an elevation in peripheral white blood cell count and acute phase markers, while fluid from inflamed joints exhibits a neutrophil-predominant leukocytosis. Persistent inflammation can lead to secondary (AA) amyloidosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15494?source=see_link\">",
"       \"Periodic fever syndromes and other autoinflammatory diseases: An overview\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/48/8962?source=see_link\">",
"       \"Patient information: Acute abdomen (belly pain) (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/33/34321?source=see_link\">",
"       \"Patient information: Intussusception (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal pain is one of the most common complaints in childhood and one that frequently requires urgent evaluation in the office or emergency department. Although the cause is typically a self-limited, minor condition, such as constipation, gastroenteritis, or viral syndrome, potentially life-threatening causes that require urgent treatment, such as appendicitis or bowel obstruction, must be promptly identified (",
"    <a class=\"graphic graphic_table graphicRef65488 \" href=\"UTD.htm?28/20/29005\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Visceral abdominal pain is generally poorly localized. Once the parietal peritoneum becomes irritated (as occurs in appendicitis when the serosal surface becomes inflamed), pain may become more localized. Referred pain usually is located in the cutaneous dermatomes sharing the same spinal cord level as the visceral inputs. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/30/16874?source=see_link&amp;anchor=H2#H2\">",
"       \"Differential diagnosis of abdominal pain in adults\", section on 'Neurologic basis of abdominal pain'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Life-threatening causes of abdominal pain often result in hemorrhage, obstruction,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      perforation (such as occurs with trauma, intussusception, volvulus, or appendicitis). Extraabdominal causes (ie, hemolytic uremic syndrome and myocarditis) usually have other distinguishing clinical features. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Life-threatening causes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Common causes of abdominal pain include constipation, gastrointestinal (GI) infections, infections outside of the GI tract, and colic. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Common causes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Less common GI conditions (ie, inflammatory bowel disease, pancreatitis, cholecystitis, intraabdominal abscess, dietary milk protein allergy, malabsorption, and Meckel's diverticulum) and conditions outside of the GI tract (ie, diabetic ketoacidosis, painful crisis with sickle syndromes, Henoch Sch&ouml;nlein purpura (IgA vasculitis), tumors, urolithiasis, testicular torsion, and some toxic ingestions) can present with abdominal pain. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Other causes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11593/abstract/1\">",
"      D'Agostino J. Common abdominal emergencies in children. Emerg Med Clin North Am 2002; 20:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11593/abstract/2\">",
"      Festen C. Postoperative small bowel obstruction in infants and children. Ann Surg 1982; 196:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11593/abstract/3\">",
"      Grant HW, Parker MC, Wilson MS, et al. Adhesions after abdominal surgery in children. J Pediatr Surg 2008; 43:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11593/abstract/4\">",
"      Sherman P, Czinn S, Drumm B, et al. Helicobacter pylori infection in children and adolescents: Working Group Report of the First World Congress of Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr 2002; 35 Suppl 2:S128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11593/abstract/5\">",
"      Tam YH, Lee KH, To KF, et al. Helicobacter pylori-positive versus Helicobacter pylori-negative idiopathic peptic ulcers in children with their long-term outcomes. J Pediatr Gastroenterol Nutr 2009; 48:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11593/abstract/6\">",
"      Oderda G, Mura S, Valori A, Brustia R. Idiopathic peptic ulcers in children. J Pediatr Gastroenterol Nutr 2009; 48:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11593/abstract/7\">",
"      Loening-Baucke V, Swidsinski A. Constipation as cause of acute abdominal pain in children. J Pediatr 2007; 151:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11593/abstract/8\">",
"      Carty HM. Paediatric emergencies: non-traumatic abdominal emergencies. Eur Radiol 2002; 12:2835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11593/abstract/9\">",
"      Chang SL, Shortliffe LD. Pediatric urinary tract infections. Pediatr Clin North Am 2006; 53:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11593/abstract/10\">",
"      Attia M, Zaoutis T, Eppes S, et al. Multivariate predictive models for group A beta-hemolytic streptococcal pharyngitis in children. Acad Emerg Med 1999; 6:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11593/abstract/11\">",
"      Kanegaye JT, Harley JR. Pneumonia in unexpected locations: an occult cause of pediatric abdominal pain. J Emerg Med 1995; 13:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11593/abstract/12\">",
"      Reynolds SL, Jaffe DM. Diagnosing abdominal pain in a pediatric emergency department. Pediatr Emerg Care 1992; 8:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11593/abstract/13\">",
"      Scholer SJ, Pituch K, Orr DP, Dittus RS. Clinical outcomes of children with acute abdominal pain. Pediatrics 1996; 98:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11593/abstract/14\">",
"      Vignault F, Filiatrault D, Brandt ML, et al. Acute appendicitis in children: evaluation with US. Radiology 1990; 176:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11593/abstract/15\">",
"      Simanovsky N, Hiller N. Importance of sonographic detection of enlarged abdominal lymph nodes in children. J Ultrasound Med 2007; 26:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11593/abstract/16\">",
"      Benifla M, Weizman Z. Acute pancreatitis in childhood: analysis of literature data. J Clin Gastroenterol 2003; 37:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11593/abstract/17\">",
"      Chen CF, Kong MS, Lai MW, Wang CJ. Acute pancreatitis in children: 10-year experience in a medical center. Acta Paediatr Taiwan 2006; 47:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11593/abstract/18\">",
"      Sai Prasad TR, Chui CH, Singaporewalla FR, et al. Meckel's diverticular complications in children: is laparoscopy the order of the day? Pediatr Surg Int 2007; 23:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11593/abstract/19\">",
"      Brown CV, Virgilio GR, Vazquez WD. Wandering spleen and its complications in children: a case series and review of the literature. J Pediatr Surg 2003; 38:1676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11593/abstract/20\">",
"      Milliner DS, Murphy ME. Urolithiasis in pediatric patients. Mayo Clin Proc 1993; 68:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11593/abstract/21\">",
"      Gillespie RS, Stapleton FB. Nephrolithiasis in children. Pediatr Rev 2004; 25:131.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6454 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.111.122.2-14B9D587E9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_20_11593=[""].join("\n");
var outline_f11_20_11593=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NEUROLOGIC BASIS OF ABDOMINAL PAIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      LIFE-THREATENING CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Trauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Appendicitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Intussusception",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Malrotation with midgut volvulus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Incarcerated inguinal hernia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Adhesions with intestinal obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Necrotizing enterocolitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Uncommon life-threatening causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      COMMON CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Constipation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Gastrointestinal infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Other infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Urinary tract infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Streptococcal pharyngitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Pneumonia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Viral illnesses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Mesenteric lymphadenitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Ruptured ovarian cyst",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Foreign body ingestion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Colic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      OTHER CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Gastrointestinal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Nongastrointestinal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6454\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6454|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/19/28977\" title=\"figure 1\">",
"      Midgut volvulus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/53/29534\" title=\"figure 2\">",
"      Timeline course HUS in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6454|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/32/33282\" title=\"picture 1A\">",
"      Rash - Henoch Schonlein purpura IgA vasculitis A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/46/42721\" title=\"picture 1B\">",
"      Rash - Henoch Schonlein purpura IgA vasculitis B",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6454|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/20/29005\" title=\"table 1\">",
"      Acute abdominal pain in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/38/10860\" title=\"table 2\">",
"      Risk factors ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/13/4315\" title=\"table 3\">",
"      Hypertonia in infantile colic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/3/32826?source=related_link\">",
"      Acute appendicitis in children: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/57/2970?source=related_link\">",
"      Acute iron poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41417?source=related_link\">",
"      Approach to diagnosis of acute infectious pharyngitis in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/18/34090?source=related_link\">",
"      Approach to the patient with abnormal liver biochemical and function tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/52/43849?source=related_link\">",
"      Atypical hemolytic uremic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15337?source=related_link\">",
"      Button and cylindrical battery ingestion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/39/32376?source=related_link\">",
"      Causes of scrotal pain in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/24/394?source=related_link\">",
"      Childhood lead poisoning: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/21/42327?source=related_link\">",
"      Classification of migraine in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/47/5882?source=related_link\">",
"      Clinical assessment of the child with suspected cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=related_link\">",
"      Clinical features and diagnosis of community-acquired pneumonia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/32/41480?source=related_link\">",
"      Clinical features and diagnosis of diabetic ketoacidosis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/39/41591?source=related_link\">",
"      Clinical features and diagnosis of necrotizing enterocolitis in newborns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/0/1032?source=related_link\">",
"      Clinical features and diagnosis of pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21129?source=related_link\">",
"      Clinical features and diagnosis of urinary tract infections in infants and children older than one month",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/27/10680?source=related_link\">",
"      Clinical features and etiology of colic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40729?source=related_link\">",
"      Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35704?source=related_link\">",
"      Clinical manifestations and diagnosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/63/41974?source=related_link\">",
"      Clinical manifestations and diagnosis of Yersinia infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10439?source=related_link\">",
"      Clinical manifestations and diagnosis of acute intermittent porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/5/20569?source=related_link\">",
"      Clinical manifestations and diagnosis of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37946?source=related_link\">",
"      Clinical manifestations and diagnosis of celiac disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34647?source=related_link\">",
"      Clinical manifestations and diagnosis of myocarditis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/7/24693?source=related_link\">",
"      Clinical manifestations of Crohn's disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1178?source=related_link\">",
"      Clinical manifestations, diagnosis, and management of ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25974?source=related_link\">",
"      Complications of idiopathic nephrotic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/63/15354?source=related_link\">",
"      Constipation in children: Etiology and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/9/44182?source=related_link\">",
"      Definition, clinical manifestations, and evaluation of functional fecal incontinence in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29513?source=related_link\">",
"      Diagnostic approach to lower gastrointestinal bleeding in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/30/16874?source=related_link\">",
"      Differential diagnosis of abdominal pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/8/34950?source=related_link\">",
"      Emergency complications of Hirschsprung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/61/22490?source=related_link\">",
"      Emergent evaluation of the child with acute abdominal pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36823?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of tuboovarian abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/56/14216?source=related_link\">",
"      Epidemiology, pathogenesis, clinical presentation and diagnosis of viral gastroenteritis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38905?source=related_link\">",
"      Etiologies of fever of unknown origin in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/13/13529?source=related_link\">",
"      Evaluation of diarrhea in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/17/1306?source=related_link\">",
"      Evaluation of the child and adolescent with chronic abdominal pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34631?source=related_link\">",
"      Food protein-induced proctitis/colitis and enteropathy of infancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/22/1386?source=related_link\">",
"      Foreign bodies of the esophagus and gastrointestinal tract in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/48/20232?source=related_link\">",
"      Intestinal malrotation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35145?source=related_link\">",
"      Intussusception in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/8/23690?source=related_link\">",
"      Ovarian and fallopian tube torsion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/34/21033?source=related_link\">",
"      Ovarian cysts and neoplasms in infants, children, and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33768?source=related_link\">",
"      Overview of blunt abdominal trauma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16295?source=related_link\">",
"      Overview of hepatitis A virus infection in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/41/31386?source=related_link\">",
"      Overview of hepatitis B virus infection in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/3/21561?source=related_link\">",
"      Overview of inguinal hernia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=related_link\">",
"      Overview of the clinical manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29208?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of acute cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/48/8962?source=related_link\">",
"      Patient information: Acute abdomen (belly pain) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/33/34321?source=related_link\">",
"      Patient information: Intussusception (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15494?source=related_link\">",
"      Periodic fever syndromes and other autoinflammatory diseases: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4650?source=related_link\">",
"      Treatment of ulcerative colitis in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/5/5209?source=related_link\">",
"      Variant sickle cell syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_20_11594="Exertional heat illness in adolescents and adults: Management and prevention";
var content_f11_20_11594=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Exertional heat illness in adolescents and adults: Management and prevention",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/20/11594/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/20/11594/contributors\">",
"     Francis G O'Connor, MD, MPH, FACSM",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/20/11594/contributors\">",
"     Douglas J Casa, PhD, ATC, FACSM, FNATA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/20/11594/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/20/11594/contributors\">",
"     Daniel F Danzl, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/20/11594/contributors\">",
"     Karl B Fields, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/20/11594/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/20/11594/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/20/11594/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H12885668\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exertional heat illness (EHI) is among the leading causes of death in young athletes each year [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11594/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. A report by the United States Centers for Disease Control found that EHI occurs both during practice and competition and noted a disturbing trend of increasing incidence [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11594/abstract/3\">",
"     3",
"    </a>",
"    ]. Clinicians who care for athletes, both young and old, and for others who exert themselves in the heat (eg, firefighters, soldiers, construction workers) need to be aware of the basic physiologic principles of thermoregulation, the spectrum of heat illness, strategies for prevention and treatment, and current guidelines for determining safe return to play or work.",
"   </p>",
"   <p>",
"    The management and prevention of exertional heat illness are reviewed here. Thermoregulation and the clinical presentation and diagnosis of exertional heat illness are discussed separately, as are exercise-associated hyponatremia, nonexertional heat stroke, malignant hyperthermia, and heat illness in children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/58/39849?source=see_link\">",
"     \"Exertional heat illness in adolescents and adults: Epidemiology, thermoregulation, risk factors, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/42/1706?source=see_link\">",
"     \"Exercise-associated hyponatremia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16007?source=see_link\">",
"     \"Severe hyperthermia (heat stroke) in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32984?source=see_link\">",
"     \"Malignant hyperthermia: Clinical diagnosis and management of acute crisis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20553?source=see_link\">",
"     \"Neuroleptic malignant syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10234?source=see_link\">",
"     \"Heat stroke in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21878?source=see_link\">",
"     \"Heat illness (other than heat stroke) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12884448\">",
"    <span class=\"h1\">",
"     GUIDING PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two critical observations inform the management of exertional heat stroke (EHS) and all types of severe heat illness [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11594/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The severity of a heat illness may not be apparent during the initial presentation.",
"     </li>",
"     <li>",
"      Morbidity and mortality are directly related to the duration of core temperature elevation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Accordingly, effective management of any severe heat illness requires careful evaluation at the field and hospital, and treatment of EHS with rapid cooling is paramount. It may help to think of EHS as a &ldquo;heat attack&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11594/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinicians caring for patients with severe heat illness must remain vigilant for late developing complications, possibly including rhabdomyolysis, acute kidney injury, disseminated intravascular coagulation, and acute liver failure. For patients with high rectal temperatures (&ge;105&deg;F, 40.5&deg;C) and concerning symptoms but no clear signs of end-organ damage, clinical suspicion needs to remain high. In most such cases, it is prudent to observe or admit the patient and reevaluate with serial clinical examinations and laboratory studies. (See",
"    <a class=\"local\" href=\"#H12884506\">",
"     'Complications'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H12884513\">",
"     'Disposition and admission criteria'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H737851\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF EXERTIONAL HEAT STROKE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12884456\">",
"    <span class=\"h2\">",
"     Prehospital",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12884464\">",
"    <span class=\"h3\">",
"     Initial assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resuscitation of the athlete with possible severe heat illness begins by evaluating and securing the airway, breathing, and circulation, in accordance with standard life support protocols. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23079?source=see_link\">",
"     \"Basic airway management in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/25/36248?source=see_link\">",
"     \"Basic life support (BLS) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Measurements of vital signs, including a rectal temperature, blood (ie, fingerstick) glucose, and serum sodium concentration, should be obtained quickly and appropriate treatment initiated rapidly. Treatment tents at major endurance events often have the capacity to measure a serum sodium concentration, but emergency medical services (EMS) units typically do not. Elevated temperature (&ge;105&deg;F, 40.5&deg;C) in the setting of altered mental status is consistent with a diagnosis of exertional heat stroke and is treated with rapid cooling. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/58/39849?source=see_link&amp;anchor=H25338621#H25338621\">",
"     \"Exertional heat illness in adolescents and adults: Epidemiology, thermoregulation, risk factors, and diagnosis\", section on 'Exertional heat stroke'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If appropriate medical staff is available on-site (eg, team physician), materials needed for aggressive cooling are readily available (ie, cold water immersion,",
"    <span class=\"nowrap\">",
"     ice/wet",
"    </span>",
"    towel rotation, high flow cold water dousing), and no other emergency medical treatment is needed other than rapid lowering of the body temperature, it is usually best to follow the &ldquo;cool-first, transport second&rdquo; guideline. Once cooling to a reasonable temperature (eg, 38.9&deg;C or 102&deg;F) is achieved, the patient is rapidly transported to the closest emergency department.",
"   </p>",
"   <p>",
"    If the conditions for on-site cooling are not met, particularly if the patient has additional problems (eg, seizure) requiring medical intervention, the patient should be transferred immediately to the closest emergency department. Cooling can be initiated during transport in the most effective manner possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12884471\">",
"    <span class=\"h3\">",
"     Cooling measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid cooling is the most effective strategy for minimizing morbidity and mortality from exertional heat stroke (EHS) and should be initiated as soon as possible, and within 30 minutes of presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11594/abstract/8-13\">",
"     8-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Key steps in cooling the athlete at the field include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Activate emergency medical system immediately; if appropriate medical staff is on-site and no medical emergencies other than EHS are present, cool first and transport second whenever possible.",
"     </li>",
"     <li>",
"      Remove all equipment and excess clothing.",
"     </li>",
"     <li>",
"      If ice water immersion is to be performed, immerse the athlete in a tub of cold water (the colder the better); water temperature should be between 35 to 60&deg;F (2 to 15&deg;C); ice water is ideal but even tepid water is helpful; maintain an appropriately cool water temperature; stir the water vigorously during cooling.",
"     </li>",
"     <li>",
"      If ice water immersion is not feasible or possible, rapidly initiate an alternative method of cooling. These are described immediately below.",
"     </li>",
"     <li>",
"      Monitor vital signs (rectal temperature, heart rate, respiratory rate, blood pressure) and mental status continually. Maintain patient safety at all times.",
"     </li>",
"     <li>",
"      Cease cooling when rectal temperature reaches 101 to 102&deg;F (38.3 to 38.9&deg;C).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A detailed guide to field-side cooling is provided in the accompanying table (",
"    <a class=\"graphic graphic_table graphicRef54492 \" href=\"UTD.htm?13/57/14237\">",
"     table 1",
"    </a>",
"    ). Note that cooling rates are slower initially, but increase the longer the patient is treated.",
"   </p>",
"   <p>",
"    If immersion is not possible in the field (equipment is unavailable), alternative cooling methods should be used. Such measures include putting the athlete in a cold shower, dousing them with cold water from a hose, or moving them to a cool shaded area and applying cold, wet towels to as much of the body surface as possible. For the last method, towels should be replaced as soon as they are no longer cool or every two to three minutes otherwise. If ice is available but no tub, the patient can be placed in a tarp or sheet, covered with a large amount of ice, and then the tarp or sheet can be wrapped around them. Ice should be replenished as soon as a moderate degree of melting occurs.",
"   </p>",
"   <p>",
"    Few controlled studies are available to determine the best method for achieving rapid cooling of patients with EHS and other forms of severe EHI. Based upon largely low quality evidence, several systematic reviews have concluded that ice water immersion is the most effective method available [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11594/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. When appropriate conditions are met, the authors strongly prefer this approach; however, in some circumstances, treatment with ice water immersion is not feasible, particularly if the patient has complications requiring aggressive medical intervention (eg, compromised airway, seizure). If clinicians are actively managing or anticipate the need to manage such complications, alternative methods of cooling should be used that allow for necessary interventions (eg, tracheal intubation, administration of medication or IV fluid) and close patient monitoring. In the emergency department, one reasonable approach is to undress the patient and apply ice packs to the neck, axillae, and inguinal regions (areas adjacent to large blood vessels), while simultaneously spraying tepid water over the patient&rsquo;s body and using fans to blow air over the moist skin (ie, evaporative cooling). Water should be continually reapplied as needed and fanning performed continuously.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5303831\">",
"    <span class=\"h3\">",
"     Measuring temperature",
"    </span>",
"    &nbsp;&mdash;&nbsp;Do",
"    <strong>",
"     NOT",
"    </strong>",
"    use alternative methods to determine body temperature (eg, oral, tympanic, axillary, temporal, forehead sticker) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11594/abstract/16-19\">",
"     16-19",
"    </a>",
"    ], even if a rectal thermometer is not available. Alternative methods do",
"    <strong>",
"     not",
"    </strong>",
"    provide accurate measurements of core temperature in athletes who have been exercising intensely in the heat. If a rectal temperature is not available when treating EHS, we suggest one of two options:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cool until the patient begins to shiver.",
"      <br/>",
"      <br/>",
"      OR",
"     </li>",
"     <li>",
"      Treat with cold water immersion for 15 to 20 minutes. This would cool most patients 3 to 4&deg;C (5 to 7&deg;F), which would make removal from an ice tub prudent in most cases.",
"      <br/>",
"      <br/>",
"      The latter approach assumes a typical cooling rate with cold water immersion of about 0.21&deg;C per minute (0.37&deg;F per minute), and that nearly all patients are between 41 and 43.5&deg;C at the time of the incident (106 and 110&deg;F). In such cases, the patient would cool 1&deg;C every five minutes or 1&deg;F every three minutes. This approach does",
"      <strong>",
"       not",
"      </strong>",
"      account for patients who are exceptionally hot at the start of treatment or those who cool slower than average. Continuous monitoring with a rectal thermistor (flexible thermometer) remains the best approach.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12884478\">",
"    <span class=\"h2\">",
"     Clinical assessment at the hospital",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment of the patient with exertional heat stroke (EHS) begins with careful evaluation of the patient&rsquo;s airway, breathing, and circulation (ABC&rsquo;s). A protected airway, adequate oxygenation and ventilation, and adequate circulation must be ensured. Regular reassessment of the ABC&rsquo;s is important. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/12/22726?source=see_link\">",
"     \"The decision to intubate\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36068?source=see_link\">",
"     \"Advanced emergency airway management in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16007?source=see_link&amp;anchor=H10#H10\">",
"     \"Severe hyperthermia (heat stroke) in adults\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If rapid cooling was initiated in the field but the temperature has not yet been sufficiently lowered (goal temperature is 101 to 102&deg;F, or 38.3 to 38.9&deg;C), cooling measures are continued in the hospital. Rapid cooling is initiated as quickly as possible for patients diagnosed with EHS who could not be treated in the field. The appropriate method of cooling is discussed above. (See",
"    <a class=\"local\" href=\"#H12884471\">",
"     'Cooling measures'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Frequent vital sign measurements combined with pulse oximetry, cardiac and other monitoring provide immediate insight into respiratory and hemodynamic status. A bladder (eg, Foley&trade;) catheter allows for monitoring of fluid status and renal function. In some cases, in particular when urine output may not be reliable, central venous pressure monitoring may be needed to guide fluid resuscitation.",
"   </p>",
"   <p>",
"    Continuous temperature measurement is invaluable during the initial resuscitation of the patient with EHS. If available, a rectal thermistor (flexible thermometer) that provides continuous temperature readings is preferred to episodic measurements performed with a standard rectal thermometer. If a rectal thermistor is not available during cold water immersion, or evaporative cooling, a rectal temperature should be measured approximately every 10 minutes using a rectal thermometer.",
"   </p>",
"   <p>",
"    The secondary survey must include a careful assessment of mental status, evaluation of muscle compartments for evidence of acute compartment syndrome, and examination of all orifices for possible bleeding. Patients with severe EHS typically demonstrate muscle flaccidity; rigidity should prompt consideration for malignant hyperthermia or neuroleptic malignant syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11594/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32984?source=see_link\">",
"     \"Malignant hyperthermia: Clinical diagnosis and management of acute crisis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8090?source=see_link\">",
"     \"Acute compartment syndrome of the extremities\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinician should inquire about the nature of the precipitating event, interventions at the scene, medical history (eg, sickle cell trait, malignant hyperthermia, cardiovascular disease), medications, supplements, and drugs of abuse.",
"   </p>",
"   <p>",
"    There is evidence that many of the complications of EHS result from the systemic inflammatory response syndrome (SIRS) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11594/abstract/4,22\">",
"     4,22",
"    </a>",
"    ]. Accordingly, SIRS criteria should be followed during the course of the hospitalization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24744?source=see_link&amp;anchor=H5#H5\">",
"     \"Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis\", section on 'Systemic inflammatory response syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12884485\">",
"    <span class=\"h2\">",
"     Laboratory and radiographic assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Targeted laboratory and radiographic studies are important for identifying early and late complications of severe EHI [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11594/abstract/23\">",
"     23",
"    </a>",
"    ]. Initial laboratory studies to be performed include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete blood count (hemoglobin, platelet and white blood cell counts)",
"     </li>",
"     <li>",
"      Basic serum electrolytes (Na, K, Cl, HCO3), including calcium",
"     </li>",
"     <li>",
"      Renal function studies (BUN, creatinine)",
"     </li>",
"     <li>",
"      Urinalysis",
"     </li>",
"     <li>",
"      Creatine kinase (CK)",
"     </li>",
"     <li>",
"      Liver function tests (AST, ALT)",
"     </li>",
"     <li>",
"      Coagulation studies (PT, INR, aPTT)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional studies are obtained based upon the clinical presentation and potential complications, and may include: urine myoglobin, electrocardiogram, cardiac biomarkers, arterial",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    venous blood gas, serum lactate, toxicology screening tests, chest radiograph, CT of the head. (See",
"    <a class=\"local\" href=\"#H12884506\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12884492\">",
"    <span class=\"h2\">",
"     Supportive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aggressive and appropriate supportive care, particularly rapid cooling, is critical for reducing the risk of severe morbidity and mortality associated with EHS [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11594/abstract/24\">",
"     24",
"    </a>",
"    ]. Important interventions early during hospitalization include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Treatment of hyperthermia with rapid cooling (see",
"      <a class=\"local\" href=\"#H12884471\">",
"       'Cooling measures'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Fluid resuscitation, as determined by the patient&rsquo;s volume status, urine output, and cardiopulmonary function",
"     </li>",
"     <li>",
"      Correction of electrolyte abnormalities",
"     </li>",
"     <li>",
"      Diagnosis and treatment of complications (eg, central nervous system dysfunction, rhabdomyolysis, acute kidney injury, acute liver failure, disseminated intravascular coagulation)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with classic (ie, nonexertional) heat stroke can manifest significant cardiac dysfunction. The combination of a hyperdynamic heart and peripheral vasodilation can lead to high output cardiac failure [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11594/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Although generally less common among patients with EHS, clinicians should be aware of this complication and the potential need for aggressive fluid resuscitation with isotonic crystalloid, despite possible signs of pulmonary edema.",
"   </p>",
"   <p>",
"    EHS management in patients who develop complications can be complex and we suggest early consultation with appropriate specialists as needed, including critical care and possibly nephrology, neurology, and gastroenterology. Potential complications and links to topics describing the management of these entities are provided. (See",
"    <a class=\"local\" href=\"#H12884506\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12884499\">",
"    <span class=\"h2\">",
"     Pharmacologic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no specific pharmacologic treatment for EHS. In addition, there is no role for antipyretic therapy, as the pathogenesis of EHS does not involve a change in the hypothalamic set-point, as is seen in patients with fever. Moreover, drugs used to reduce fever, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    and nonsteroidal anti-inflammatory medications (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    ), can exacerbate complications of EHS, such as acute kidney injury, hepatic failure, and disseminated intravascular coagulation.",
"   </p>",
"   <p>",
"    Pharmacologic interventions may be needed to treat complications. Treatment of severe exertional heat illness with immune modulators is a subject of on-going research [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11594/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12884506\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;EHS can lead to a number of complications during resuscitation and subsequent hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11594/abstract/11,27\">",
"     11,27",
"    </a>",
"    ]. These complications can result directly from heat-related injury or from associated conditions, such as fluid and electrolyte abnormalities and a protracted systemic inflammatory response [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11594/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Important complications to look for in patients with EHS include the conditions listed below. Information about the diagnosis and management of these conditions is found in the accompanying UpToDate topics.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Electrolyte and other metabolic abnormalities (eg, hypo- and hyperkalemia, hypo- and hypernatremia, hypoglycemia, hypophosphatemia, hypomagnesemia, and hypocalcemia). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/2/9258?source=see_link\">",
"       \"Clinical manifestations and treatment of hypokalemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17258?source=see_link\">",
"       \"Treatment and prevention of hyperkalemia in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18986?source=see_link\">",
"       \"Overview of the treatment of hyponatremia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/42/1706?source=see_link\">",
"       \"Exercise-associated hyponatremia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2167?source=see_link\">",
"       \"Diagnosis and treatment of hypophosphatemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36646?source=see_link\">",
"       \"Clinical manifestations of hypocalcemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44632?source=see_link\">",
"       \"Treatment of hypocalcemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/63/11254?source=see_link\">",
"       \"Evaluation and treatment of hypomagnesemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Seizure (may be secondary to electrolyte abnormalities that require correction, hypoglycemia, brain trauma, inadequate cerebral perfusion pressure, or other causes). While investigating the underlying cause, clinicians provide initial treatment with benzodiazepines (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      4 mg IV or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"       diazepam",
"      </a>",
"      5 mg IV). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25753?source=see_link&amp;anchor=H2#H2\">",
"       \"Evaluation of the first seizure in adults\", section on 'Etiology'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/42/1706?source=see_link\">",
"       \"Exercise-associated hyponatremia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19642?source=see_link&amp;anchor=H19#H19\">",
"       \"Status epilepticus in adults\", section on 'Benzodiazepines'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Agitated delirium (most often is transient from the effects of hyperthermia, but may be secondary to hypoglycemia, inadequate cerebral perfusion pressure, brain injury, or other causes). Short-acting benzodiazepines can be used for treatment (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"       midazolam",
"      </a>",
"      2.5 to 5 mg IV or IM).",
"     </li>",
"     <li>",
"      Respiratory failure; acute respiratory distress syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23079?source=see_link\">",
"       \"Basic airway management in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36068?source=see_link\">",
"       \"Advanced emergency airway management in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=see_link\">",
"       \"Acute respiratory distress syndrome: Clinical features and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9065?source=see_link\">",
"       \"Supportive care and oxygenation in acute respiratory distress syndrome\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Rhabdomyolysis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=see_link\">",
"       \"Clinical manifestations and diagnosis of rhabdomyolysis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21847?source=see_link\">",
"       \"Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Acute kidney injury (usually associated with rhabdomyolysis; see above; nephrology consultation for renal replacement therapy (eg, hemodialysis) should be obtained as soon as a potential need arises)",
"     </li>",
"     <li>",
"      Hepatic injury (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38538?source=see_link\">",
"       \"Acute liver failure in adults: Management and prognosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Disseminated intravascular coagulation (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=see_link\">",
"       \"Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Gastrointestinal bleeding and ischemic bowel injury (possibly sustained during a period of myocardial depression) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28538?source=see_link\">",
"       \"Approach to acute upper gastrointestinal bleeding in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30841?source=see_link\">",
"       \"Approach to resuscitation and diagnosis of acute lower gastrointestinal bleeding in the adult patient\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Myocardial injury (generally resolves with rapid cooling, fluid resuscitation, and correction of electrolyte abnormalities; cardiology consultation is prudent for patients with persistent hypotension or arrhythmias). Electrical cardioversion and antiarrhythmic medications are generally ineffective in severe hyperthermia, until the patient is sufficiently cooled.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk of multiorgan failure and mortality from EHS depends upon how fast it is diagnosed and rapid cooling implemented [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11594/abstract/11,27\">",
"     11,27",
"    </a>",
"    ]. With rapid treatment, cardiovascular injury from EHS usually resolves within hours [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11594/abstract/29-32\">",
"     29-32",
"    </a>",
"    ]. Biomarkers of hepatic injury (eg, elevated transaminase concentrations) may remain elevated for 24 to 48 hours before returning to a normal range, which may require weeks to months depending upon the severity of the episode [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11594/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Renal injury may require weeks to resolve [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11594/abstract/4\">",
"     4",
"    </a>",
"    ]. Biomarkers of muscle injury associated with rhabdomyolysis (creatine kinase, myoglobin) may increase for 24 to 96 hours before starting to decline; a return to normal concentrations may require weeks depending upon the severity of the injury [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11594/abstract/35\">",
"     35",
"    </a>",
"    ]. Although cognitive function improves quickly in most survivors of EHS who are rapidly cooled, some evidence suggests that severe episodes can cause permanent neurologic sequelae [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11594/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. In the absence of early and effective intervention in EHS, multiorgan failure can result in permanent residual injury, require organ transplantation, or result in death [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11594/abstract/1,4,33,37-39\">",
"     1,4,33,37-39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12884513\">",
"    <span class=\"h2\">",
"     Disposition and admission criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nearly all patients who develop EHS, including all of those at risk or with signs of complications, are hospitalized for a period of observation and monitoring for complications. Indications for admission include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Difficulty correcting hypotension",
"     </li>",
"     <li>",
"      Seizure",
"     </li>",
"     <li>",
"      Severe encephalopathy",
"     </li>",
"     <li>",
"      Moderate encephalopathy (eg, confusion) that is not clearing rapidly",
"     </li>",
"     <li>",
"      Persistent oliguria",
"     </li>",
"     <li>",
"      Persistent myalgia suggesting evolving rhabdomyolysis",
"     </li>",
"     <li>",
"      Persistent electrolyte abnormalities",
"     </li>",
"     <li>",
"      Persistent creatinine above 2",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (180",
"      <span class=\"nowrap\">",
"       &micro;mol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Evidence of acute kidney injury or myoglobinuria",
"     </li>",
"     <li>",
"      Evidence of disseminated intravascular coagulation",
"     </li>",
"     <li>",
"      Exertional hypoglycemia",
"     </li>",
"     <li>",
"      Persistent substantial diarrhea",
"     </li>",
"     <li>",
"      Significant gastrointestinal bleeding",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, patients should be admitted to a monitored setting if they manifest persistent vital sign abnormalities or alterations in mental status despite appropriate treatment, or appear to be at increased risk for severe complications (eg, rhabdomyolysis, disseminated intravascular coagulation), as determined by clinical signs or laboratory studies. Patients with signs of multiorgan dysfunction are admitted to an intensive care setting.",
"   </p>",
"   <p>",
"    Although it is best to err on the side of caution and hospitalize patients with EHS, some patients may be amenable to discharge after a period of close observation. Common practice at many major endurance events with appropriate on-site medical coverage that includes experienced physicians has been to observe and monitor carefully a minority of athletes who are healthy at baseline (ie, no comorbidities), recover rapidly and completely from EHS with cooling, and have no subsequent symptoms or signs of complications. Such individuals can generally be discharged after an appropriate period of observation with arrangements for proper follow-up. There are no studies on which to base a recommendation, but a six hour period of observation seems reasonable. A thorough reexamination of the patient should be performed prior to discharge. The patient should be admitted if this reexamination reveals any concerning findings or if the patient develops recurrent or new symptoms during the observation period. A responsible adult should remain with the patient for approximately the first 24 hours following discharge in case complications arise and the patient needs medical attention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12884520\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF OTHER TYPES OF EXERTIONAL HEAT ILLNESS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12884528\">",
"    <span class=\"h2\">",
"     \"Heat cramps\"",
"    </span>",
"    &nbsp;&mdash;&nbsp;So-called &ldquo;heat cramps&rdquo; (which do not appear to be caused by increased ambient temperatures) are muscle cramps that occur during exercise. The etiology and diagnosis of heat cramps are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/58/39849?source=see_link&amp;anchor=H25338593#H25338593\">",
"     \"Exertional heat illness in adolescents and adults: Epidemiology, thermoregulation, risk factors, and diagnosis\", section on '\"Heat cramps\" (exercise associated muscle cramps)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12884536\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest the following treatment measures for suspected heat cramps:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hydrate the athlete and replace sodium losses with a sports drink or other source of salt.",
"      <br/>",
"      <br/>",
"      Oral hydration should be encouraged. This approach helps instruct the athlete about their role in preventing heat illness and prevents them from relying upon intravenous (IV) hydration. IV hydration with isotonic saline is faster and can provide large volumes of fluid that are easily tolerated in most patients. However, oral rehydration has consistently been shown to be as effective as IV rehydration when equal amounts of fluids are given.",
"     </li>",
"     <li>",
"      Relax, stretch, and massage the involved muscle to reduce acute discomfort",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Neuroinhibition techniques to relax the muscle and prolonged stretching (30 to 60 seconds at a time) may also help to relieve symptoms. While some clinicians use intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    to treat exertional muscle cramping, there is no evidence to support these interventions [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11594/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Persistent or systemic cramping should prompt an assessment of the serum sodium to evaluate for exertional hyponatremia and raise the possibility of sickle cell crisis due to exertion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12884543\">",
"    <span class=\"h3\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although evidence is limited mainly to expert opinion, muscle cramps are thought to be prevented best through adequate conditioning, acclimatization, hydration, electrolyte replacement, and appropriate dietary practices [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11594/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional sodium may be needed prior to activity to prevent cramps, particularly in those with a history of heat cramps. Extra sodium can be easily administered by diluting about one-half teaspoon of table salt (approximately 1200 mg sodium) in a typical sports drink. Commercial sports drinks generally contain between 25 and 200 mg of sodium per 8 ounces (240 mL).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12884550\">",
"    <span class=\"h2\">",
"     Heat syncope and exercise associated collapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heat syncope is a transient loss or near-loss of consciousness due to the indirect effects of high ambient temperature that generally occurs during the first few days that someone is exposed to high environmental temperatures, before acclimatization is complete.",
"   </p>",
"   <p>",
"    Exercise associated collapse (EAC) occurs when an athlete is unable to stand or walk as a result of lightheadedness or syncope [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11594/abstract/43\">",
"     43",
"    </a>",
"    ]. EAC usually occurs immediately after completing a race or workout and is commonly observed at endurance events (eg, marathon). The clinical presentation and diagnosis of heat syncope and exercise associated collapse are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/58/39849?source=see_link&amp;anchor=H25338600#H25338600\">",
"     \"Exertional heat illness in adolescents and adults: Epidemiology, thermoregulation, risk factors, and diagnosis\", section on 'Heat syncope and exercise associated collapse'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Particularly in older athletes and those with preexisting cardiac disease, heat-related syncope of either type must be distinguished from other causes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9034?source=see_link\">",
"     \"Approach to the adult patient with syncope in the emergency department\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18682?source=see_link\">",
"     \"Evaluation of syncope in adults\"",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    For heat syncope and EAC, we suggest the following treatment:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Move the person to a shaded area",
"     </li>",
"     <li>",
"      Have the person lay supine",
"     </li>",
"     <li>",
"      Elevate the person&rsquo;s feet above the level of their head (ie, raise their legs)",
"     </li>",
"     <li>",
"      Give fluids to drink",
"     </li>",
"     <li>",
"      The person should avoid sudden or prolonged standing until fully recovered",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An athlete should recover within 15 to 20 minutes with these maneuvers; failure to improve should prompt further evaluation, including a rectal temperature. Patients at higher risk for dangerous causes or adverse outcomes and those who do not completely recover within 20 minutes should be evaluated in the emergency department using the approach for any patient with syncope.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12884557\">",
"    <span class=\"h2\">",
"     Heat exhaustion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heat exhaustion is characterized by the inability to maintain adequate cardiac output due to strenuous physical exercise and environmental heat stress. Most often this manifests as physical collapse during exercise. Body temperature elevation is milder than with EHS or heat injury and the central nervous system is not affected. The clinical presentation and diagnosis of heat exhaustion is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/58/39849?source=see_link&amp;anchor=H25338607#H25338607\">",
"     \"Exertional heat illness in adolescents and adults: Epidemiology, thermoregulation, risk factors, and diagnosis\", section on 'Heat exhaustion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest the following treatment for heat exhaustion:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Remove any athlete from play and move them to a shaded or air-conditioned area.",
"     </li>",
"     <li>",
"      Place the patient supine with their feet elevated above the level of their head (ie, raise their legs).",
"     </li>",
"     <li>",
"      Remove excess clothing and equipment.",
"     </li>",
"     <li>",
"      Cool the patient until their rectal temperature is approximately 101&ordm;F (38.3&ordm;C).",
"     </li>",
"     <li>",
"      The mode of cooling is less important for heat exhaustion than heat stroke since the cooling is primarily for comfort rather than life-saving. Any technique used to treat heat stroke may be used, including immersing the athlete in a tub of cool water, running cool water over them using a shower or hose, or using evaporative cooling measures. The time needed to reach the goal temperature will be much shorter than with heat stroke. (See",
"      <a class=\"local\" href=\"#H12884471\">",
"       'Cooling measures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rehydrate the patient with chilled water or a sports drink if they are not nauseated, vomiting, or manifesting a depressed mental status; give IV fluid if the athlete is unable to drink (one reasonable approach is to give a rapid IV bolus of one liter isotonic saline followed by an infusion at a maintenance or 1.5 times maintenance rate, and titrated to response).",
"     </li>",
"     <li>",
"      Continuously observe and frequently monitor heart rate, blood pressure, respiratory rate, rectal temperature, and mental status.",
"     </li>",
"     <li>",
"      Transport the patient to an emergency department if rapid improvement does not occur despite appropriate treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Athletes who recover completely with the treatments described here within one hour or two of presentation and have no other symptom or sign of illness may be discharged with a responsible adult. Patients who fail to improve within a few hours despite these measures may be developing late complications consistent with possible heat injury, such as rhabdomyolysis, acute kidney injury, disseminated intravascular coagulation, or acute liver failure and should be admitted for observation and diagnostic testing [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11594/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12884506\">",
"     'Complications'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H12884485\">",
"     'Laboratory and radiographic assessment'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H12884513\">",
"     'Disposition and admission criteria'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12884564\">",
"    <span class=\"h2\">",
"     Heat injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exertional heat injury is defined as a progressive multisystem disorder with hyperthermia following vigorous activity that is associated with end-organ damage (eg, kidney, liver, muscle) in the absence of significant neurologic injury. Unlike EHS, core body temperature does not have to exceed 104 to 105&deg;F (40 to 40.5&deg;C), and unlike heat exhaustion, there is clear evidence of end-organ injury. The diagnosis and clinical presentation of heat injury are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/58/39849?source=see_link&amp;anchor=H25338614#H25338614\">",
"     \"Exertional heat illness in adolescents and adults: Epidemiology, thermoregulation, risk factors, and diagnosis\", section on 'Heat injury'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If there is",
"    <strong>",
"     any",
"    </strong>",
"    suspicion of exertional heat stroke (EHS), in other words, any suggestion of neurologic abnormality (eg, abnormal behavior or mood), clinicians should assume that EHS is present and appropriate steps, including rapid cooling, should be initiated as soon as possible. (See",
"    <a class=\"local\" href=\"#H737851\">",
"     'Management of exertional heat stroke'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For patients suspected to have heat injury, we recommend immediate rapid cooling using any of the methods used for EHS. Additional resuscitative measures are provided as necessary; initial care is largely supportive. Although the rate of cooling is less critical in the absence of neurologic dysfunction, patients with heat injury should still be cooled quickly and monitored closely. Treatment for EHS is described in detail separately (",
"    <a class=\"graphic graphic_table graphicRef54492 \" href=\"UTD.htm?13/57/14237\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H737851\">",
"     'Management of exertional heat stroke'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The clinical distinction between heat injury and EHS is made based upon a careful assessment of central nervous system dysfunction (eg, seizure, altered mental status, abnormal behavior). In practice, this distinction is often made after the initial treatment of the patient and is based on a careful review of the event with the patient, witnesses, and other treating clinicians.",
"   </p>",
"   <p>",
"    Subsequent treatment of heat injury following cooling requires careful risk stratification based upon the clinical presentation and the results of diagnostic studies. All patients with signs of heat injury are closely followed to insure the resolution of any end-organ damage prior to returning to play or vigorous activity [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11594/abstract/5\">",
"     5",
"    </a>",
"    ]. In addition to vital signs and urine output, monitoring should include the following studies: liver function tests (serum aminotransferases (AST, ALT), prothrombin time), urinalysis including urine myoglobin, BUN and creatinine, and creatine kinase. The indications for hospital admission are identical to those for EHS. (See",
"    <a class=\"local\" href=\"#H12884513\">",
"     'Disposition and admission criteria'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The specific management plan is determined individually on the basis of the patient&rsquo;s presentation. As examples, patients with diffuse myalgias and an elevated creatine kinase at risk for developing rhabdomyolysis or patients with signs and abnormal laboratory values suggestive of acute kidney or liver injury should be admitted and managed appropriately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=see_link\">",
"     \"Clinical manifestations and diagnosis of rhabdomyolysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21847?source=see_link\">",
"     \"Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/45/30425?source=see_link\">",
"     \"Overview of the management of acute kidney injury (acute renal failure)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38538?source=see_link\">",
"     \"Acute liver failure in adults: Management and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Organ damage does not always manifest with laboratory abnormalities early in the course of illness and clinicians should monitor patients with possible heat injury closely. For patients without severe symptoms or signs and no grossly abnormal initial laboratory results, a reasonable approach is to reexamine the patient and recheck the relevant studies on an outpatient basis every 24 to 48 hours to assess organ function. Once symptoms and signs have resolved and two successive sets of normal laboratory values have been obtained, surveillance may be discontinued, and the patient may gradually return to normal activity. (See",
"    <a class=\"local\" href=\"#H12884571\">",
"     'Determining return to play'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12884571\">",
"    <span class=\"h1\">",
"     DETERMINING RETURN TO PLAY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recovery from exertional heat stroke (EHS) and heat injury is related to the duration of core temperature elevation above the critical level (~105&deg;F, 40.5&deg;C): the longer that a patient&rsquo;s core temperature remained above this level, the greater the risk of severe morbidity and mortality, and the longer the period needed for recovery. Any guidelines used to determine the approach and time frame for an athlete&rsquo;s recovery must be modified based upon the severity of illness.",
"   </p>",
"   <p>",
"    Guidelines for return to activity following full recovery from EHS or heat injury differ among experts and institutions [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11594/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. At a minimum, athletes should not begin",
"    <strong>",
"     any",
"    </strong>",
"    significant physical activity until they are asymptomatic and all blood tests have returned to a normal range. Beyond these requirements, guidelines generally consist of &ldquo;common sense&rdquo; recommendations, including a gradual, cautious reintroduction of physical activity to ensure adequate fitness and full acclimatization [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11594/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The recommendations of the American College of Sports Medicine for returning an athlete to training and competition following an episode of EHS represent one reasonable approach [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11594/abstract/47\">",
"     47",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No exercise permitted for at least seven days following release from medical care.",
"     </li>",
"     <li>",
"      Follow-up with the medical team approximately one week after release for physical examination and any necessary laboratory testing and diagnostic imaging based upon the organs affected during the EHS episode.",
"     </li>",
"     <li>",
"      Once cleared for a return to activity, the athlete begins exercise in a cool environment and gradually increases the duration, intensity, and heat exposure over two weeks to demonstrate heat tolerance and initiate acclimatization.",
"     </li>",
"     <li>",
"      Athletes who cannot resume vigorous activity over four weeks because of recurrent symptoms (eg, excessive fatigue) should be reevaluated. Laboratory exercise-heat tolerance testing may be useful in this setting.",
"     </li>",
"     <li>",
"      The athlete may resume full competition once he or she is able to participate in full training in the heat for two to four weeks without adverse effects.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12884578\">",
"    <span class=\"h1\">",
"     HEAT TOLERANCE TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heat tolerance testing is an area of considerable controversy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11594/abstract/45\">",
"     45",
"    </a>",
"    ]. We concur with current ACSM recommendations that heat tolerance testing be considered only for those athletes who are unable to return to vigorous activity after a suitable period (approximately four weeks) of recovery and acclimatization [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11594/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other organizations take a different approach. As an example, the Israeli Defense Force (IDF) uses a heat tolerance test (HTT) to evaluate soldiers following an episode of EHS and guide decision-making about return to duty [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11594/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. The IDF HTT assumes that tolerance to heat stress varies among individuals. Individuals who are unable to tolerate a specific heat challenge, as indicated by increases in body temperature that occur sooner and at a faster rate than normal responders, under identical environmental and exercise conditions, are defined as &ldquo;heat intolerant&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?11/20/11594/abstract/48\">",
"     48",
"    </a>",
"    ]. While the IDF has used this test for over 30 years, it remains unclear whether heat intolerance, as defined by the HTT, predicts who will experience subsequent episodes of EHS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12884585\">",
"    <span class=\"h1\">",
"     PREVENTION OF EXERTIONAL HEAT ILLNESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exertional heat illness (EHI) is often preventable. Important principles for developing a prevention program for exertional heat illness are described in the accompanying table (",
"    <a class=\"graphic graphic_table graphicRef83028 \" href=\"UTD.htm?27/33/28187\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Specific measures that can be taken to reduce the risk of EHI include the following:",
"   </p>",
"   <p>",
"    Long-term institutional measures:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Institute prevention policies, including an emergency action plan",
"     </li>",
"     <li>",
"      Educate staff and athletes about heat illness",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Long-term athlete measures:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acclimatize gradually to exercising in hot",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      humid conditions",
"     </li>",
"     <li>",
"      Maintain a high level of fitness",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     Institutional/coaching",
"    </span>",
"    measures during activity:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Provide frequent breaks for hydration and cooling",
"     </li>",
"     <li>",
"      Avoid activity during severe heat",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      humidity (use WBGT as a guide); practicing when the WBGT is lower (ie, night, early morning) or in a cooler indoor facility may be a reasonable alternative (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/58/39849?source=see_link&amp;anchor=H25338536#H25338536\">",
"       \"Exertional heat illness in adolescents and adults: Epidemiology, thermoregulation, risk factors, and diagnosis\", section on 'The wet bulb globe temperature (WBGT)'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pay careful attention to athletes with large mass to skin surface ratios (eg, obese athletes) during workouts in hot or humid conditions",
"     </li>",
"     <li>",
"      Carefully monitor those athletes with any history suggestive of prior heat illness",
"     </li>",
"     <li>",
"      Minimize equipment and clothing that hinder heat loss in hot or humid conditions",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Athlete measures during activity:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hydrate before activity and keep well hydrated throughout",
"     </li>",
"     <li>",
"      Avoid exercise in severe heat",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      humidity when ill",
"     </li>",
"     <li>",
"      Stop exercising and notify medical staff immediately if severe exhaustion, lightheadedness, or other concerning symptoms develop in yourself or a teammate",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of note, unless an athlete is deficient in sodium and other electrolytes, increased salt intake before and during exercise is unlikely to help prevent exertional heat illness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12884592\">",
"    <span class=\"h1\">",
"     COMMON MISCONCEPTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Misconceptions about the causes and management of exertional heat illness are common among clinicians, athletes, and the population at large. Important misconceptions are described in the accompanying table (",
"    <a class=\"graphic graphic_table graphicRef83041 \" href=\"UTD.htm?19/7/19581\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/15/37105?source=see_link\">",
"       \"Patient information: Heat stroke (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12884606\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two critical observations inform the management of exertional heat stroke (EHS) and all types of severe heat illness:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The severity of a heat illness may not be apparent during the initial presentation.",
"     </li>",
"     <li>",
"      Morbidity and mortality are directly related to the duration of core temperature elevation. (See",
"      <a class=\"local\" href=\"#H12884448\">",
"       'Guiding principles'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Resuscitation of the athlete with possible severe exertional heat illness (including heat stroke and heat injury) begins by evaluating and securing the airway, breathing, and circulation, in accordance with standard life support protocols. Measurements of vital signs, including a rectal temperature, blood (ie, fingerstick) glucose, and serum sodium concentration, should be obtained quickly and appropriate treatment initiated rapidly. Do",
"      <strong>",
"       NOT",
"      </strong>",
"      use alternative methods to determine body temperature (eg, oral, tympanic, axillary, temporal, forehead sticker). If a rectal thermistor or rectal thermometer is not available, one reasonable approach is to cool the patient with a severe heat illness until they begin to shiver. (See",
"      <a class=\"local\" href=\"#H12884464\">",
"       'Initial assessment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12884471\">",
"       'Cooling measures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Elevated core body temperature (above 105&deg;F, 40.5&deg;C) associated with altered mental status following exertion in high heat and humidity is consistent with a diagnosis of EHS. If appropriate medical staff is available on-site (eg, team physician), tools to implement aggressive cooling are readily available, and",
"      <strong>",
"       no other emergency medical treatment is needed",
"      </strong>",
"      other than rapid lowering of the body temperature, it is generally best to follow the &ldquo;cool-first, transport second&rdquo; guideline. Once initial cooling is achieved (eg, 38.9&deg;C, 102&deg;F), the patient with EHS or other severe heat illness is rapidly transported to the closest emergency department.",
"     </li>",
"     <li>",
"      We recommend that adults with EHS be treated as quickly as possible with rapid cooling (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Cold water immersion therapy is highly effective and the authors&rsquo; preferred treatment if appropriate conditions are met and suitable equipment is available. In circumstances when ice water immersion is not feasible, particularly if the patient has complications requiring aggressive medical intervention (eg, compromised airway, seizure), alternative methods of cooling should be used. In the emergency department, one reasonable approach is to apply ice packs to the neck, axillae, and inguinal regions (areas adjacent to large blood vessels), while simultaneously spraying tepid water over the patient&rsquo;s body and using fans to blow air over the moist skin (ie, evaporative cooling). A detailed guide to field-side cooling is provided in the accompanying table (",
"      <a class=\"graphic graphic_table graphicRef54492 \" href=\"UTD.htm?13/57/14237\">",
"       table 1",
"      </a>",
"      ). The goal temperature is 101 to 102&deg;F or 38.3 to 38.9&deg;C. Continuous monitoring of the patient is mandatory. (See",
"      <a class=\"local\" href=\"#H12884471\">",
"       'Cooling measures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once at the hospital, patients with EHS, or other severe heat illness such as heat injury, receive a complete diagnostic evaluation, while rapid cooling and other interventions (eg, fluid resuscitation, correction of electrolyte abnormalities) are performed as needed. Studies to be obtained are listed in the text. Potential complications of EHS include respiratory failure, seizure, rhabdomyolysis, acute kidney injury, electrolyte abnormalities, hepatic injury, coagulopathy, gastrointestinal bleeding, and myocardial injury. (See",
"      <a class=\"local\" href=\"#H12884478\">",
"       'Clinical assessment at the hospital'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12884485\">",
"       'Laboratory and radiographic assessment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12884492\">",
"       'Supportive therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12884506\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Exertional heat injury is similar to EHS, but the patient&rsquo;s central nervous system is not affected. For patients suspected to have heat injury, we recommend immediate treatment with rapid cooling using any of the methods suitable for EHS (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Additional resuscitative measures are provided as necessary and a hospital evaluation similar to that for patients with EHS should be performed. (See",
"      <a class=\"local\" href=\"#H12884564\">",
"       'Heat injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Heat exhaustion is characterized by the inability to maintain adequate cardiac output (usually manifested as physical collapse during exercise) due to strenuous physical activity and environmental heat stress. Elevations in body temperature are less extreme than with EHS or heat injury and the central nervous system is not affected. Treatment of heat exhaustion is conservative and includes moving the patient to a cool environment, with additional cooling methods used as needed, rehydration (this can usually be done with oral fluids), and careful monitoring. Evaluation in an emergency department is necessary if rapid improvement (within one or two hours) does not occur with appropriate management. Similar management is provided to patients with heat-related syncope and exercise-associated collapse. (See",
"      <a class=\"local\" href=\"#H12884557\">",
"       'Heat exhaustion'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12884550\">",
"       'Heat syncope and exercise associated collapse'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of heat cramps consists of hydration, replacement of sodium losses, and stretching and massage of the affected muscles. (See",
"      <a class=\"local\" href=\"#H12884528\">",
"       '\"Heat cramps\"'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11594/abstract/1\">",
"      Maron BJ, Doerer JJ, Haas TS, et al. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006. Circulation 2009; 119:1085.",
"     </a>",
"    </li>",
"    <li>",
"     Mueller FO, Cantu RC. Catastrophic sports injury research: 26th Annual Report Fall 1982-Spring 2008. University of North Carolina, Chapel Hill 2008. file://www.unc.edu/depts/nccsi/AllSport.pdf (Accessed on July 09, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11594/abstract/3\">",
"      Centers for Disease Control and Prevention (CDC). Heat illness among high school athletes --- United States, 2005-2009. MMWR Morb Mortal Wkly Rep 2010; 59:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11594/abstract/4\">",
"      Bouchama A, Knochel JP. Heat stroke. N Engl J Med 2002; 346:1978.",
"     </a>",
"    </li>",
"    <li>",
"     Gardner JW, JA K. Clinical diagnosis, management, and surveillance of exertional heat illness. In: Textbook of Military Medicine, Zajitchuk R.  (Ed), Army Medical Center Borden Institute, Washington, DC 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11594/abstract/6\">",
"      Heled Y, Rav-Acha M, Shani Y, et al. The \"golden hour\" for heatstroke treatment. Mil Med 2004; 169:184.",
"     </a>",
"    </li>",
"    <li>",
"     Stearns RL, O'Connor FG, Casa DJ, Kenny GP. Exertional heat stroke. In: Preventing Sudden Death in Sport and Physical Activity, Casa DJ.  (Ed), Jones &amp; Bartlett Learning, Sudbury 2011. p.53.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11594/abstract/8\">",
"      Casa DJ, Kenny GP, Taylor NA. Immersion treatment for exertional hyperthermia: cold or temperate water? Med Sci Sports Exerc 2010; 42:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11594/abstract/9\">",
"      Casa DJ, McDermott BP, Lee EC, et al. Cold water immersion: the gold standard for exertional heatstroke treatment. Exerc Sport Sci Rev 2007; 35:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11594/abstract/10\">",
"      Proulx CI, Ducharme MB, Kenny GP. Effect of water temperature on cooling efficiency during hyperthermia in humans. J Appl Physiol 2003; 94:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11594/abstract/11\">",
"      Sithinamsuwan P, Piyavechviratana K, Kitthaweesin T, et al. Exertional heatstroke: early recognition and outcome with aggressive combined cooling--a 12-year experience. Mil Med 2009; 174:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11594/abstract/12\">",
"      Bouchama A, Dehbi M, Chaves-Carballo E. Cooling and hemodynamic management in heatstroke: practical recommendations. Crit Care 2007; 11:R54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11594/abstract/13\">",
"      Smith JE. Cooling methods used in the treatment of exertional heat illness. Br J Sports Med 2005; 39:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11594/abstract/14\">",
"      McDermott BP, Casa DJ, Ganio MS, et al. Acute whole-body cooling for exercise-induced hyperthermia: a systematic review. J Athl Train 2009; 44:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11594/abstract/15\">",
"      Newport M, Grayson A. Towards evidence-based emergency medicine: best BETs from the Manchester Royal Infirmary. BET 3: In patients with heatstroke is whole-body ice-water immersion the best cooling method? Emerg Med J 2012; 29:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11594/abstract/16\">",
"      Casa DJ, Becker SM, Ganio MS, et al. Validity of devices that assess body temperature during outdoor exercise in the heat. J Athl Train 2007; 42:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11594/abstract/17\">",
"      Ganio MS, Brown CM, Casa DJ, et al. Validity and reliability of devices that assess body temperature during indoor exercise in the heat. J Athl Train 2009; 44:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11594/abstract/18\">",
"      Mazerolle SM, Scruggs IC, Casa DJ, et al. Current knowledge, attitudes, and practices of certified athletic trainers regarding recognition and treatment of exertional heat stroke. J Athl Train 2010; 45:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11594/abstract/19\">",
"      Ronneberg K, Roberts WO, McBean AD, Center BA. Temporal artery temperature measurements do not detect hyperthermic marathon runners. Med Sci Sports Exerc 2008; 40:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11594/abstract/20\">",
"      Capacchione JF, Muldoon SM. The relationship between exertional heat illness, exertional rhabdomyolysis, and malignant hyperthermia. Anesth Analg 2009; 109:1065.",
"     </a>",
"    </li>",
"    <li>",
"     Moran DS, Gaffin SL. Clinical management of heat-related illnesses. In: Wildnerness Medicine, Auerbach PS.  (Ed), Mosby, St. Louis 2001. p.290.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11594/abstract/22\">",
"      Zeller L, Novack V, Barski L, et al. Exertional heatstroke: clinical characteristics, diagnostic and therapeutic considerations. Eur J Intern Med 2011; 22:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11594/abstract/23\">",
"      Hashim IA. Clinical biochemistry of hyperthermia. Ann Clin Biochem 2010; 47:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11594/abstract/24\">",
"      Marom T, Itskoviz D, Lavon H, Ostfeld I. Acute care for exercise-induced hyperthermia to avoid adverse outcome from exertional heat stroke. J Sport Rehabil 2011; 20:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11594/abstract/25\">",
"      Shahid MS, Hatle L, Mansour H, Mimish L. Echocardiographic and Doppler study of patients with heatstroke and heat exhaustion. Int J Card Imaging 1999; 15:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11594/abstract/26\">",
"      Atar S, Rozner E, Rosenfeld T. Transient cardiac dysfunction and pulmonary edema in exertional heat stroke. Mil Med 2003; 168:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11594/abstract/27\">",
"      Varghese GM, John G, Thomas K, et al. Predictors of multi-organ dysfunction in heatstroke. Emerg Med J 2005; 22:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11594/abstract/28\">",
"      Leon LR, Helwig BG. Heat stroke: role of the systemic inflammatory response. J Appl Physiol 2010; 109:1980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11594/abstract/29\">",
"      Costrini AM, Pitt HA, Gustafson AB, Uddin DE. Cardiovascular and metabolic manifestations of heat stroke and severe heat exhaustion. Am J Med 1979; 66:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11594/abstract/30\">",
"      Kew MC, Tucker RB, Bersohn I, Seftel HC. The heart in heatstroke. Am Heart J 1969; 77:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11594/abstract/31\">",
"      Wilson TE, Crandall CG. Effect of thermal stress on cardiac function. Exerc Sport Sci Rev 2011; 39:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11594/abstract/32\">",
"      Whiticar R, Laba D, Smith S. Exertional heat stroke in a young man with a documented rise in troponin I. Emerg Med J 2008; 25:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11594/abstract/33\">",
"      Bianchi L, Ohnacker H, Beck K, Zimmerli-Ning M. Liver damage in heatstroke and its regression. A biopsy study. Hum Pathol 1972; 3:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11594/abstract/34\">",
"      Shibolet S, Coll R, Gilat T, Sohar E. Heatstroke: its clinical picture and mechanism in 36 cases. Q J Med 1967; 36:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11594/abstract/35\">",
"      McDermott BP, Casa DJ, Yeargin SW, et al. Recovery and return to activity following exertional heat stroke: considerations for the sports medicine staff. J Sport Rehabil 2007; 16:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11594/abstract/36\">",
"      Mehta AC, Baker RN. Persistent neurological deficits in heat stroke. Neurology 1970; 20:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11594/abstract/37\">",
"      Romero JJ, Clement PF, Belden C. Neuropsychological sequelae of heat stroke: report of three cases and discussion. Mil Med 2000; 165:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11594/abstract/38\">",
"      Wallace RF, Kriebel D, Punnett L, et al. Prior heat illness hospitalization and risk of early death. Environ Res 2007; 104:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11594/abstract/39\">",
"      Garcin JM, Bronstein JA, Cremades S, et al. Acute liver failure is frequent during heat stroke. World J Gastroenterol 2008; 14:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11594/abstract/40\">",
"      Maquirriain J, Merello M. The athlete with muscular cramps: clinical approach. J Am Acad Orthop Surg 2007; 15:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11594/abstract/41\">",
"      Schwellnus MP, Drew N, Collins M. Muscle cramping in athletes--risk factors, clinical assessment, and management. Clin Sports Med 2008; 27:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11594/abstract/42\">",
"      Bergeron MF. Exertional heat cramps: recovery and return to play. J Sport Rehabil 2007; 16:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11594/abstract/43\">",
"      Asplund CA, O'Connor FG, Noakes TD. Exercise-associated collapse: an evidence-based review and primer for clinicians. Br J Sports Med 2011; 45:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11594/abstract/44\">",
"      Binkley HM, Beckett J, Casa DJ, et al. National Athletic Trainers' Association Position Statement: Exertional Heat Illnesses. J Athl Train 2002; 37:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11594/abstract/45\">",
"      O'Connor FG, Casa DJ, Bergeron MF, et al. American College of Sports Medicine Roundtable on exertional heat stroke--return to duty/return to play: conference proceedings. Curr Sports Med Rep 2010; 9:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11594/abstract/46\">",
"      O'Connor FG, Williams AD, Blivin S, et al. Guidelines for return to duty (play) after heat illness: a military perspective. J Sport Rehabil 2007; 16:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11594/abstract/47\">",
"      American College of Sports Medicine, Armstrong LE, Casa DJ, et al. American College of Sports Medicine position stand. Exertional heat illness during training and competition. Med Sci Sports Exerc 2007; 39:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11594/abstract/48\">",
"      Moran DS, Erlich T, Epstein Y. The heat tolerance test: an efficient screening tool for evaluating susceptibility to heat. J Sport Rehabil 2007; 16:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/20/11594/abstract/49\">",
"      Moran DS, Heled Y, Still L, et al. Assessment of heat tolerance for post exertional heat stroke individuals. Med Sci Monit 2004; 10:CR252.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17235 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-0AA24E0359-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_20_11594=[""].join("\n");
var outline_f11_20_11594=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12884606\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12885668\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12884448\">",
"      GUIDING PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H737851\">",
"      MANAGEMENT OF EXERTIONAL HEAT STROKE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12884456\">",
"      Prehospital",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12884464\">",
"      - Initial assessment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12884471\">",
"      - Cooling measures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5303831\">",
"      - Measuring temperature",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12884478\">",
"      Clinical assessment at the hospital",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12884485\">",
"      Laboratory and radiographic assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12884492\">",
"      Supportive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12884499\">",
"      Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12884506\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12884513\">",
"      Disposition and admission criteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12884520\">",
"      MANAGEMENT OF OTHER TYPES OF EXERTIONAL HEAT ILLNESS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12884528\">",
"      \"Heat cramps\"",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12884536\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12884543\">",
"      - Prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12884550\">",
"      Heat syncope and exercise associated collapse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12884557\">",
"      Heat exhaustion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12884564\">",
"      Heat injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12884571\">",
"      DETERMINING RETURN TO PLAY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12884578\">",
"      HEAT TOLERANCE TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12884585\">",
"      PREVENTION OF EXERTIONAL HEAT ILLNESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12884592\">",
"      COMMON MISCONCEPTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12884606\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/17235\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/17235|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/57/14237\" title=\"table 1\">",
"      Cold water immersion tx of exertional heat illness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/33/28187\" title=\"table 2\">",
"      Principles of prevention for exertional heat illness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/7/19581\" title=\"table 3\">",
"      Myths about exertional heat illness",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8090?source=related_link\">",
"      Acute compartment syndrome of the extremities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38538?source=related_link\">",
"      Acute liver failure in adults: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=related_link\">",
"      Acute respiratory distress syndrome: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36068?source=related_link\">",
"      Advanced emergency airway management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28538?source=related_link\">",
"      Approach to acute upper gastrointestinal bleeding in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30841?source=related_link\">",
"      Approach to resuscitation and diagnosis of acute lower gastrointestinal bleeding in the adult patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9034?source=related_link\">",
"      Approach to the adult patient with syncope in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23079?source=related_link\">",
"      Basic airway management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/25/36248?source=related_link\">",
"      Basic life support (BLS) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=related_link\">",
"      Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=related_link\">",
"      Clinical manifestations and diagnosis of rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/2/9258?source=related_link\">",
"      Clinical manifestations and treatment of hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36646?source=related_link\">",
"      Clinical manifestations of hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2167?source=related_link\">",
"      Diagnosis and treatment of hypophosphatemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/63/11254?source=related_link\">",
"      Evaluation and treatment of hypomagnesemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18682?source=related_link\">",
"      Evaluation of syncope in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25753?source=related_link\">",
"      Evaluation of the first seizure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/42/1706?source=related_link\">",
"      Exercise-associated hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/58/39849?source=related_link\">",
"      Exertional heat illness in adolescents and adults: Epidemiology, thermoregulation, risk factors, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21878?source=related_link\">",
"      Heat illness (other than heat stroke) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10234?source=related_link\">",
"      Heat stroke in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32984?source=related_link\">",
"      Malignant hyperthermia: Clinical diagnosis and management of acute crisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20553?source=related_link\">",
"      Neuroleptic malignant syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/45/30425?source=related_link\">",
"      Overview of the management of acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18986?source=related_link\">",
"      Overview of the treatment of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/15/37105?source=related_link\">",
"      Patient information: Heat stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21847?source=related_link\">",
"      Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24744?source=related_link\">",
"      Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16007?source=related_link\">",
"      Severe hyperthermia (heat stroke) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19642?source=related_link\">",
"      Status epilepticus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9065?source=related_link\">",
"      Supportive care and oxygenation in acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/12/22726?source=related_link\">",
"      The decision to intubate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17258?source=related_link\">",
"      Treatment and prevention of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44632?source=related_link\">",
"      Treatment of hypocalcemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_20_11595="Benefits transtracheal O2";
var content_f11_20_11595=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F76455&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F76455&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Potential benefits of transtracheal oxygen",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Physiologic benefit",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mechanism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decrease in dead space",
"       </td>",
"       <td>",
"        O2 from catheter enters the trachea lower in the airways, decreasing dead space.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decrease in total inspired minute ventilation",
"       </td>",
"       <td>",
"        Due to flow from the catheter, less gas is inspired at the mouth, reducing work of breathing.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increase in CO2 elimination efficiency",
"       </td>",
"       <td>",
"        Fresh gas flowing from the catheter flushes the area proximal to the catheter tip during expiration, reducing the amount of CO2 that returns to the alveoli with the next inspiratory cycle. In addition, gas exiting the catheter tip at high velocity generates turbulence that enhances gas mixing distal to the catheter tip, increasing CO2 washout. As a consequence, PaCO2 remains unchanged despite a decrease in total inspired minute ventilation.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_20_11595=[""].join("\n");
var outline_f11_20_11595=null;
var title_f11_20_11596="Diagnostic criteria POEMS syndrome";
var content_f11_20_11596=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F64782&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F64782&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Criteria for the diagnosis of POEMS syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Mandatory major criteria (both required)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polyneuropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Monoclonal plasma cell proliferative disorder (almost always lambda)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other major criteria (one required)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sclerotic bone lesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Castleman's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Elevated levels of vascular endothelial growth factor (VEGF)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Minor criteria (one required)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Organomegaly (splenomegaly, hepatomegaly, or lymphadenopathy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Extravascular volume overload (edema, pleural effusion, or ascites)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Endocrinopathy (adrenal, thyroid, pituitary, gonadal, parathyroid, pancreatic)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Skin changes (hyperpigmentation, hypertrichosis, glomeruloid hemangiomata, plethora, acrocyanosis, flushing, white nails)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Papilledema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thrombocytosis/polycythemia",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The diagnosis of POEMS syndrome is confirmed when both of the mandatory major criteria, one of the three other major criteria, and one of the six minor criteria are present.",
"    <div class=\"footnotes\">",
"     * The source data do not define an optimal cut off value for considering elevated VEGF level as a major criterion. We suggest that VEGF measured in the serum or plasma should be at least three- to fourfold higher than the normal reference range for the laboratory that is doing the testing to be considered a major criterion.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      In order to consider endocrinopathy as a minor criterion, an endocrine disorder other than diabetes or hypothyroidism is required since these two disorders are common in the general population.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Original figure modified for this publication. Dispenzieri A. POEMS syndrome. Blood Rev 2007; 21:285. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_20_11596=[""].join("\n");
var outline_f11_20_11596=null;
var title_f11_20_11597="Rehabilitation Act Section 504";
var content_f11_20_11597=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68063&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68063&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Overview of Section 504 of the Rehabilitation Act",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        What is Section 504?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Section 504 of the Rehabilitation Act of 1973 is a national law that protects qualified individuals from discrimination based on their disability.",
"        </strong>",
"        The nondiscrimination requirements of the law apply to employers and organizations that receive financial assistance from any federal department or agency, including the US Department of Health and Human Services (DHHS). These organizations and employers include many hospitals, nursing homes, mental health centers and human service programs.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Section 504 forbids organizations and employers from excluding or denying individuals with disabilities an equal opportunity to receive program benefits and services. It defines the rights of individuals with disabilities to participate in, and have access to, program benefits and services.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Who is protected from discrimination?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Section 504 protects",
"        <strong>",
"         qualified individuals with disabilities",
"        </strong>",
"        . Under this law,",
"        <strong>",
"         individuals with disabilities",
"        </strong>",
"        are defined as persons with a physical or mental impairment which substantially limits one or more major life activities. People who have a history of, or who are regarded as having a physical or mental impairment that substantially limits one or more major life activities, are also covered. Major life activities include caring for oneself, walking, seeing, hearing, speaking, breathing, working, performing manual tasks, and learning. Some examples of impairments which may substantially limit major life activities, even with the help of medication or aids/devices, are: AIDS, alcoholism, blindness or visual impairment, cancer, deafness or hearing impairment, diabetes, drug addiction, heart disease, and mental illness. In addition to meeting the above definition, for purposes of receiving services, education or training,",
"        <strong>",
"         qualified individuals with disabilities",
"        </strong>",
"        are persons who meet normal and essential eligibility requirements.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        For purposes of employment,",
"        <strong>",
"         qualified individuals with disabilities",
"        </strong>",
"        are persons who, with reasonable accommodation, can perform the essential functions of the job for which they have applied or have been hired to perform. (Complaints alleging employment discrimination on the basis of disability against a single individual will be referred to the US Equal Employment Opportunity Commission for processing.)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Reasonable accommodation",
"        </strong>",
"        means an employer is required to take reasonable steps to accommodate your disability unless it would cause the employer undue hardship.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Prohibited discriminatory acts in health care and human services settings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Section 504 prohibitions against discrimination apply to service availability, accessibility, delivery, employment, and the administrative activities and responsibilities of organizations receiving federal financial assistance. A recipient of federal financial assistance may not, on the basis of disability:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Deny qualified individuals the opportunity to participate in or benefit from federally funded programs, services, or other benefits.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Deny access to programs, services, benefits or opportunities to participate as a result of physical barriers.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Deny employment opportunities, including hiring, promotion, training, and fringe benefits, for which they are otherwise entitled or qualified.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        These and other prohibitions against discrimination based on disability can be found in the DHHS Section 504 regulation at 45 CFR Part 84.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        For information on how to file a complaint of discrimination, or to obtain information of a civil rights nature, please contact us. OCR employees will make every effort to provide prompt service.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hotlines: 1-800-368-1019 (Voice) 1-800-537-7697 (TDD)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         E-mail: ocrmail@hhs.gov",
"        </p>",
"        <p>",
"         Web site: file://www.hhs.gov/ocr",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_20_11597=[""].join("\n");
var outline_f11_20_11597=null;
var title_f11_20_11598="Treatment Turner I";
var content_f11_20_11598=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F50455%7EENDO%2F63261%7EENDO%2F73981&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F50455%7EENDO%2F63261%7EENDO%2F73981&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Management of Turner syndrome: Gonadal dysgenesis, growth failure, skeletal dysgenesis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Characteristic",
"       </td>",
"       <td class=\"subtitle1\">",
"        Neonatal period or at diagnosis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Childhood",
"       </td>",
"       <td class=\"subtitle1\">",
"        Adolescence",
"       </td>",
"       <td class=\"subtitle1\">",
"        Adulthood",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gonadal dysgenesis",
"       </td>",
"       <td>",
"        <p>",
"         Look for mosaicism.",
"        </p>",
"        <p>",
"         Look for Y-chromosome material if marker chromosome or virilization is present.",
"        </p>",
"       </td>",
"       <td>",
"        Discuss reproductive options when appropriate.",
"       </td>",
"       <td>",
"        <p>",
"         Check follicle-stimulating hormone and luteinizing hormone before initiating hormone-replacement therapy around 12 years of age.",
"        </p>",
"        <p>",
"         Begin therapy with low doses of estradiol, and gradually increase during the next two to four years.",
"        </p>",
"       </td>",
"       <td>",
"        Continue hormone replacement.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Growth failure",
"       </td>",
"       <td>",
"        Plot growth on growth curve specific for those with Turner syndrome.",
"       </td>",
"       <td>",
"        <p>",
"         Continue to monitor growth.",
"        </p>",
"        <p>",
"         Check thyroxine and thyrotropin levels. Check for obesity.",
"        </p>",
"        <p>",
"         Institute dietary counseling.",
"        </p>",
"        <p>",
"         Start growth horomone therapy with or without anabolic steroid when growth velocity declines.",
"        </p>",
"       </td>",
"       <td>",
"        Stop growth hormone when bone age exceeds 15 years or growth velocity drops below 2 cm/year.",
"       </td>",
"       <td>",
"        <p>",
"         Check thyroxine and thyrotropin levels.",
"        </p>",
"        <p>",
"         Check thyroid antibodies every&nbsp;three to&nbsp;five years.",
"        </p>",
"        <p>",
"         Continue dietary counseling.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Skeletal dysgenesis",
"       </td>",
"       <td>",
"        Check for dislocated hips.",
"       </td>",
"       <td>",
"        <p>",
"         Watch for scoliosis.",
"        </p>",
"        <p>",
"         Watch knee for tibial problems.",
"        </p>",
"       </td>",
"       <td>",
"        Watch for scoliosis, lordosis, and kyphosis.",
"       </td>",
"       <td>",
"        <p>",
"         Ensure adequate calcium intake (1.2 g/day).",
"        </p>",
"        <p>",
"         Encourage weight-bearing exercise.",
"        </p>",
"        <p>",
"         Check bone mineral density every&nbsp;three to&nbsp;five years.",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Management of Turner syndrome: Craniofacial malformation, abnormal carbohydrate metabolism, cardiovascular abnormalities",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Characteristic",
"       </td>",
"       <td class=\"subtitle1\">",
"        Neonatal period or at diagnosis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Childhood",
"       </td>",
"       <td class=\"subtitle1\">",
"        Adolescence",
"       </td>",
"       <td class=\"subtitle1\">",
"        Adulthood",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Craniofacial malformation",
"       </td>",
"       <td>",
"        Otitis and high arched palate are common.",
"        <br/>",
"        Review results of newborn hearing screen.",
"       </td>",
"       <td>",
"        Otitis is common and should be treated aggressively.",
"        <br/>",
"        Orthodontic work may be necessary.",
"        <br/>",
"        Speech evaluation and/or therapy may be necessary.",
"       </td>",
"       <td>",
"        Continue to monitor hearing.",
"       </td>",
"       <td>",
"        Continue to monitor hearing.",
"        <br/>",
"        Andiogram every&nbsp;three to&nbsp;five years.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abnormal carbohydrate metabolism",
"       </td>",
"       <td>",
"        &mdash;",
"       </td>",
"       <td>",
"        Glucose-tolerance test may be abnormal.",
"        <br/>",
"        Insulin resistance is common.",
"       </td>",
"       <td>",
"        Glucose-tolerance test may be abnormal.",
"        <br/>",
"        Insulin resistance is common.",
"        <br/>",
"        Insulin levels increase with growth hormone therapy.",
"       </td>",
"       <td>",
"        Annual fasting glucose and lipid profile.",
"        <br/>",
"        Glucose-tolerance test may be abnormal.",
"        <br/>",
"        Insulin resistance is common.",
"        <br/>",
"        Insulin levels decline after growth hormone therapy is stopped.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Management of Turner syndrome: Genitourinary abnormalities, skin problems, central nervous system abnormalities, and other problems",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Characteristic",
"       </td>",
"       <td class=\"subtitle1\">",
"        Neonatal period or at diagnosis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Childhood",
"       </td>",
"       <td class=\"subtitle1\">",
"        Adolescence",
"       </td>",
"       <td class=\"subtitle1\">",
"        Adulthood",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Genitourinary abnormalities",
"       </td>",
"       <td>",
"        <p>",
"         Perform renal ultrasonography to rule out structural anomalies.",
"        </p>",
"        <p>",
"         If present, screen yearly for urinary tract infection.",
"        </p>",
"       </td>",
"       <td>",
"        Continue to monitor for urinary tract infection, if necessary.",
"       </td>",
"       <td>",
"        Continue to monitor for urinary tract infection, if necessary.",
"       </td>",
"       <td>",
"        <p>",
"         Continue to monitor for urinary tract infection, if necessary.",
"        </p>",
"        <p>",
"         Perform urinalysis annually.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Skin problems",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        <p>",
"         Remove multiple nevi only if in area where rubbed by clothing.",
"        </p>",
"        <p>",
"         Warn patients to avoid unnecessary surgery because of keloid formation.",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Remove multiple nevi only if in area where rubbed by clothing.",
"        </p>",
"        <p>",
"         Warn patients to avoid unnecessary surgery because of keloid formation.",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Remove multiple nevi only if in area where rubbed by clothing.",
"        </p>",
"        <p>",
"         Warn patients to avoid unnecessary surgery because of keloid formation.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Central nervous system abnormalities",
"       </td>",
"       <td>",
"        Refer to developmental intervention program if indicated.",
"       </td>",
"       <td>",
"        <p>",
"         Screen for intellectual functioning, visuospatial organization.",
"        </p>",
"        <p>",
"         Attention deficit disorder may be more frequent. IQ is generally normal.",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Screen for intellectual functioning, visuospatial organization.",
"        </p>",
"        <p>",
"         Attention deficit disorder may be more frequent. IQ is generally normal.",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Screen for intellectual functioning, visuospatial organization.",
"        </p>",
"        <p>",
"         Attention deficit disorder may be more frequent. IQ is generally normal.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ophthalmologic abnormalities",
"       </td>",
"       <td>",
"        Perform ophthalmologic evaluation.",
"       </td>",
"       <td>",
"        Continue to monitor ophthalmologic examination.",
"       </td>",
"       <td>",
"        Continue to monitor ophthalmologic examination.",
"       </td>",
"       <td>",
"        Continue to monitor ophthalmologic examination.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other problems",
"       </td>",
"       <td>",
"        <p>",
"         Perform stool guaiac test to check for gastrointestinal bleeding.",
"        </p>",
"        <p>",
"         Monitor for feeding problems.",
"        </p>",
"       </td>",
"       <td>",
"        Perform stool guaiac test to check for gastrointestinal bleeding.",
"       </td>",
"       <td>",
"        Watch for anorexia nervosa and inflammatory bowel disease.",
"       </td>",
"       <td>",
"        <p>",
"         Watch for anorexia nervosa and inflammatory bowel disease.",
"        </p>",
"        <p>",
"         Measure LFT, GGT annually.",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_20_11598=[""].join("\n");
var outline_f11_20_11598=null;
var title_f11_20_11599="Hip internal rotation";
var content_f11_20_11599=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F77932&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F77932&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 484px\">",
"   <div class=\"ttl\">",
"    Evaluation of internal rotation of the hips",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 464px; height: 326px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Evaluation of internal rotation of the hips is performed with the child in the prone position and with the knees flexed; the ankles and feet are then rotated away from the body to compare the amount of internal rotation in the symptomatic versus the asymptomatic hip. The pelvis must be kept flat on the examining table; otherwise, asymmetry of internal rotation may not be appreciated.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_20_11599=[""].join("\n");
var outline_f11_20_11599=null;
